National Institute for Health and Care Excellence

Draft for Consultation

Thyroid Disease: assessment and management

[N] Imaging for Fine Needle Aspiration

NICE guideline

Diagnostic evidence review underpinning recommendations 1.9.1 to 1.9.6 in the guideline. See also evidence review O June 2019

Draft for Consultation

This evidence review was developed by the National Guideline Centre



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© National Institute for Health and Care Excellence, 2019

ISBN

Contents

1	Imag	ging for	Fine Needle Aspiration	5
	1.1	enlarg	v question: Which imaging tests should be requested (for thyroid ement)? Which people with structural abnormalities should have a fine- aspiration?	5
	1.2	Introdu	uction	5
	1.3	PICO 1	able	5
	1.4	Clinica	I evidence	6
		1.4.1	Included studies	6
		1.4.2	Excluded studies	6
		1.4.3	Summary of clinical studies included in the evidence review	7
		1.4.4	Quality assessment of clinical studies included in the evidence review.	19
	1.5	Econo	mic evidence	23
		1.5.1	Included studies	23
		1.5.2	Excluded studies	23
		1.5.3	Health economic modelling	23
		1.5.4	Resource costs	23
	1.6	Eviden	ce statements	23
		1.6.1	Clinical evidence statements	23
		1.6.2	Health economic evidence statements	24
	1.7	The co	ommittee's discussion of the evidence	25
		1.7.1	Interpreting the evidence	25
		1.7.2	Cost effectiveness and resource use	26
		1.7.3	Other factors the committee took into account	27
Re	feren	ces		28
Ap	pendi	ices		55
	App	endix A:	Review protocols	55
	App	endix B:	Literature search strategies	60
	App	endix C:	Clinical evidence selection	69
	Appe	endix D:	Clinical evidence tables	71
	Appe	endix E:	Coupled sensitivity and specificity forest plots and sROC curves	. 158
	Appe	endix F:	Health economic evidence selection	. 162
	Арре	endix G:	Health economic evidence tables	. 164
	Арре	endix H:	Health economic analysis	. 165
	Appe	endix I:	Excluded studies	. 166

1 Imaging for Fine Needle Aspiration

1.1 Review question: Which imaging tests should be requested (for thyroid enlargement)? Which people with structural abnormalities should have a fine-needle aspiration?

5 1.2 Introduction

6 Patients with thyroid enlargement usually present due to mass effect symptoms or cosmetic 7 embarrassment or are identified following incidental imaging findings on investigation of other 8 pathology. With the knowledge that the majority of thyroid disease is benign, imaging of 9 enlargement is usually only performed if there are features of concern – for example vocal 10 cord palsy, prior radiation or risk factors for malignancy. With incidental thyroid enlargement 11 identified on prior cross sectional imaging, ultrasound is recommended where there is extra 12 thyroidal extension, invasion of adjacent structures or abnormal local neck nodes.

The aim of imaging is to assess risk of malignancy, guide percutaneous sampling if it is indicated and assess the extent of glandular enlargement in patients where surgical intervention is considered. Ultrasound, performed by appropriately trained and practiced specialists is readily available, inexpensive and a sensitive modality for gland assessment. Neither CT nor MRI are as sensitive at gland assessment (nor do they allow for real time image guided tissue sampling when desired) although CT may be used to assess mass effect on the trachea and retrosternal extension.

Tissue sampling is routinely performed when malignancy is suspected although there are a number of different assessment criteria to suggest malignant potential on ultrasound.

1.3 PICO table

23 For full details see the review protocol in Appendix A:.

24

Table 1: PICO characteristics of review question

Population	People presenting with euthyroid thyroid enlargement being investigated for possible malignancy.
Target condition	Malignancy
Index tests	Ultrasound scan CT scan MRI scan
Reference standard	Malignant status as confirmed by biopsy/subsequent development of cancer in case of false negatives that do not receive biopsy
Statistical measures [or] Outcomes	Sensitivity Specificity PPV NPV Sensitivity prioritised
Study design	Diagnostic accuracy studies Prospective studies prioritised, retrospective studies included if insufficient prospective studies identified.

1 **1.4 Clinical evidence**

2 1.4.1 Included studies

- Forty two studies were included in the review;<sup>6, 9, 36, 48, 67, 80, 86, 87, 92, 94, 97, 114, 116, 122, 129, 133, 138, 150,
 166, 170, 175, 179, 187, 188, 190, 207, 215, 218, 231, 276, 281, 309, 323, 324, 329, 331, 332, 346, 353, 354, 363, 367. Evidence from
 these studies is summarised in the clinical evidence summary below (Table 3). All studies
 looked at the diagnostic accuracy of ultrasound using different sonographic criteria.
 </sup>
- 7 Thirty-nine studies conducted in adults assessed ultrasound classified according to the 8 British Thyroid Association (BTA, 2 studies), different version of the Kim criteria (10 studies), Society of Radiologists in Ultrasound (SRU, 3 studies), American Association of Clinical 9 10 Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi (AACE/ACE/AME, 5 studies), American Thyroid Association (ATA, 13 studies), Korean 11 12 Society of Thyroid Radiology (KSThR, 3 study), different versions of the Thyroid Imaging Reporting and Data System (TIRADS, 31 studies), TIRADS combined with contrast-13 14 enhanced US (CEUS) parameter ratios (2 studies) and National Comprehensive Cancer 15 Network (NCCN, 1 study). Of those, two studies assessed the diagnostic accuracy of gray-16 scale ultrasound combined with power Doppler ultrasound using the Kim criteria. One study 17 assessed the diagnostic accuracy of ultrasound combined with elastography using the Kim 18 criteria combined with the Rago and Asteria criteria.
- 19Three studies assessed the diagnostic accuracy of ultrasound using Kwak's TIRADS (one20study) and the ATA guidelines (three studies) in children.
- 21 See also the study selection flow chart in Appendix C:, sensitivity and specificity forest plots 22 in Appendix E:, and study evidence tables in Appendix D:

23 1.4.2 Excluded studies

- 24 See the excluded studies list in Appendix I:.
- 25
- 26

.3 Summary of clinical studies included in the evidence review

 Table 2: Summary of studies included in the evidence review

Study	Population	Target condition	Index test	Reference standard	Comments
Ahn 2010 ⁶	Patients: n=1318 mean age 46.3 years; 1398 nodules confirmed with FNAB or surgery South Korea	Thyroid cancer	Ultrasound (that should lead to FNAB) under different criteria: Kim Society of Radiologists in Ultrasound American association of Clinical Endocrinologists	Surgical or cytologic findings if the patient did not undergo surgery (FNAB or surgery) Surgery was performed for 455 nodules	
Alahm 2014 ⁹	Patients: n=100; mean age (SD) 41.77 (12.31) Pakistan	Thyroid cancer	Ultrasound	FNAB	
Chen 2019 ³⁶	Patients: n=1092; mean age (SD): 46.92 (13.59) Mean nodule size (SD): 19.63 (13.90)mm China	Thyroid cancer	Ultrasound Classified using the ACR-TI-RADS	FNAB	
Creo 2018 ⁴⁸	Children: n=112; mean age (SD): 15.5 (3.2) years USA	Thyroid cancer	US+ USD (Gray-scale US with colour Doppler) Classified using the 2015 ATA TIRADS	UG FNA Using the Bethesda System for Reporting Thyroid Cytology	Children

Study	Population	Target condition	Index test	Reference standard	Comments
Grani 2019 ⁸⁰	Patients: n=477; mean age (SD): 55.9 (13.9) years Italy	Thyroid cancer	Ultrasound Classified using the ACR TIRADS, AACE/ACE/AME, ATA, EU-TIRADS, K- TIRADS	UGFNAB Using the Italian Consensus for Thyroid Cytopathology Histological examination for nodules that had undergone surgery. FNA cytology for nodules that had not been managed surgically; using the Bethesda System	
Farihah 2018 ⁶⁷	Patients: n=91 (104 nodules) ; mean age (range): 54.7 (27-80) Malaysia	Thyroid cancer	Ultrasound Classified using the BTA Guidelines (test positive: U4-5; test negative U2-3)	UGFNAC and histopathology (for cases that were inadequate, indeterminate or suspicious of malignancy)	
Ha 2016 ⁸⁶	Patients: n=750 (902 nodules); mean age (range): 49.2 (9-81) Mean nodule size (SD; range): 1.5 cm (1.1; 0.5- 10 cm)	Thyroid cancer	Ultrasound Classified using K- TIRADS	FNA or core needle biopsy (CNB) or surgery Using the Bethesda System for Cytological classification of Thyroid	Multicentre study (4 hospitals) Nodules >5mm

Study	Population	Target condition	Index test	Reference standard	Comments
	South Korea			Nodules for FNA; a six- tier pathology reporting system for CNB	
Ha 2018 ⁸⁷	Patients: n= 750 (902 nodules); mean age (range): 49.2 (9-81) years	Thyroid cancer	Ultrasound Classified using 2015 ATA, 2016 KTA/KSThR, 2017 ACR guidelines	Surgical resection (n=191/266 malignant nodules); surgery (n=36 benign nodules); FNA or core needle biopsy (n=75 malignant nodules) Using the Bethesda system	Multicentre study
Hoang 2018 ⁹²	Patients: n=92 (100 nodules); mean age (SD; range): 52 (14; 19-82) Mean nodule size (SD; range): 2.7cm (1.3; 0.7- 5.9 cm) USA	Thyroid cancer	Ultrasound Classified using ACR- TIRADS, ATA, K- TIRADS, F-TIRADS	FNAB or surgery Using the Bethesda System for Cytological classification of Thyroid Nodules	
Hobbs 2014 ⁹⁴	Patients: n=350 (360 biopsies); mean age (range): 55 (7-91) Mean nodule size (SD): 26 mm (14) USA	Thyroid cancer	Ultrasound Classified using the SRU guidelines	FNA or surgery Using the Bethesda System for Cytological classification of Thyroid Nodules	

Study	Population	Target condition	Index test	Reference standard	Comments
Horvath 2009 97	1097 nodules Nodule size range: 4-60 mm Chile	Thyroid cancer	Ultrasound Classified using TI- RADS (taking BI- RADS as a model)	FNAB Classified as: benign, intermediate/suspiciou s (follicular lesions), or malignant according to standardised criteria (Clark et al 2005)	8 year prospective study. Malignant nodules received surgery; Benign nodules were followed up. Mean follow-up (range): 3.9 years (2.1-5.8)
Kim 2002 ¹¹⁴	Patients: n=132 mean age (range) 48 (22-77); 155 nonpalpable solid nodules South Korea	Thyroid cancer	Sonography Sonographic characteristics used to classify malignancy were based on nonpublished criteria from authors' retrospective study.	Histology: FNAB and follow-up (>24 months) of 83 benign nodules; FNAB+ surgery of 44 malignant and 15 benign nodules; surgery alone on five malignant and 8 benign nodules.	
Kim 2013 ¹¹⁶	Patients: n=686; mean age 49.7 ; 713 nodules South Korea	Thyroid cancer	Ultrasound (US) Need for FNAB determined by US characteristics of the ATA 2009 guidelines	FNAB	Subcentimetre nodules
Kim 2013 ¹²²	Patients: n=925 (1419 nodules); mean age (range): 51.87 (14-85) South Korea	Thyroid cancer	Ultrasound Classified using Kim and modified Kim criteria	UGFNA	Suggests new US-based guideline system.

Study	Deputation	Torret oor dition	Index test	Deference standard	Commonto
Study Koh 2018 ¹²⁹	Population Patients: n=363 (370 nodules); mean age (SD; range): 53.1 (13; 19-86) Nodule mean size (SD; range): 20.8 mm (9.8; 10-44mm) South Korea	Target condition Thyroid cancer	Index test Ultrasound Classified using Kim, K-TIRADS, 2015 ATA	Reference standard UGFNA or surgery (n=57 nodules)	Comments
Koseoglu Atilla ¹³³	Patients n=2614; mean age (SD): 51.01 (13.86) Turkey	Thyroid cancer	Ultrasound Classified using the ACR TI-RADS	FNAB Interpreted using the Bethesda System for Reporting Thyroid Cytopathology	
Lauria Pantano 2018 ¹³⁸	Patients: n=946 (1169 nodules); mean age (SD; range): 56 (13.3; 16-88) Nodule media size (range): 14mm (4-56 mm) Italy	Thyroid Cancer	Ultrasound Classified according to the ATA, AACE/ACE/AME and ACR-TI-RADS by an automated algorithm	FNA Classified based on Italian Reporting System for Thyroid Cytology	
Lim-Dunham 2017 ¹⁵⁰	Children: n=33 (39 nodules); median age (range): benign: 16 years (8-18); malignant: 16.5 years (9-18) Median nodule size: malignant: 25.5 mm;	Thyroid cancer	Ultrasound Classified using the 2015 ATA Guidelines for Children	UGFNA or surgery (n=14 nodules)	

Study	Population	Target condition	Index test	Reference standard	Comments
	benign: 21mm USA				
Macedo 2018 ¹⁶⁶	Patients: n= 178 median age (range) 59 (49-66); 195 nodules Brazil	Thyroid cancer	Ultrasonography (US) Classified using modified TI-RADS (malignancy classified in the categories 4 or 5) and ATA risk assessment systems (malignancy classified in the intermediate or high suspicion risk)	Cytology (UGFNAB) Classified based on the Bethesda System for Cytological classification of Thyroid Nodules Histopathology (available for 45 cases after surgery)	Diagnostic accuracy findings reported separately for TI-RADS and ATA.
Maino 2018 ^{114,} ¹⁷⁰	Patients: 340 (432 nodules), mean age (SD, range): 57 years (14.3, 16-86) Median nodules diameter: 20mm (9 - 83 mm) Italy	Thyroid cancer	Ultrasonography (US) Classified based on the ATA risk assessment and the EU-TIRADS (based on the ETA US)	US-guided FNAC Using the British Thyroid Association criteria	
Martinez-Rios 2018 ¹⁷⁵	Children: n=124 (123 nodules); age mean (SD, range): 13.6 (3.1, 3.3- 17.7) Mean nodules size (SD, range): 27.5 (14.6mm,	Thyroid cancer	Ultrasound Classified using the ATA (high, intermediate suspicion classifications considered as probably	Histopathology/cytolog y or 2-year follow-up of clinical outcome for nonoperative cases	Retrospective

Study	Population	Target condition	Index test	Reference standard	Comments
	10-94 mm) Canada		malignant; low, very low suspicion and benign considered as probably malignant) and TI-RADS (4a, 4b, 4c, 5 considered as probably malignant; 2, 3 as probably benign) risk assessment systems.		
Middleton 2017 ¹⁷⁹	Patients: n=3315 (3822 nodules); mean age (range): 54.4 (18-97) USA	Thyroid cancer	Ultrasound Classified using TIRADS	UGFNA	Patients from six geographically diverse medical centres.
Moon 2010 ¹⁸⁷	Patients: n=1024 (1083 nodules); median age (range): 51 (16-83) 539 nodules ≤10mm; 544 >10mm South Korea	Thyroid cancer	Ultrasound + USD (gray-scale + power Doppler US) Classified using the Kim criteria, Kim+USD, AACE/AME	UGFNA	
Moon 2012 ¹⁸⁸	Patients: n=676 (703 nodules); mean age (range): 49.7 (18-79) 308 nodules > 10mm; 395 were ≤10mm; 577 nodules > 5mm; 126 nodules ≤5mm	Thyroid cancer	Ultrasound + USE (gray-scale US + elastography) Classified using the Kim criteria, Kim+USE Rago, Kim+USE Asteria	UGFNA or Surgery Surgery performed after FNA in 221 nodules (202 patients); UGFNA for two nodules in 27 patients and one nodule in 649 patients.	Solid thyroid nodules

Study	Population	Target condition	Index test	Reference standard	Comments
	South Korea				
Na 2016 ¹⁹⁰	Patients: n=1802 (2000 nodules); mean age (SD): 51.2 (12.2) Mean nodule size (SD, range): 20 mm (11.4, 10- 100 mm) South Korea	Thyroid cancer	Ultrasound Classified using the K- TIRADS	UGFNA (Bethesda System for Reporting Thyroid Cytopathology) or CNB (diagnosed with a six-tier pathology reporting system) or surgery Surgery:690 nodules CNB: 3 nodules Repeated FNA or CNB: 381 nodules FNA or CNB and follow-up US: 926 nodules	Patients enrolled from low and high cancer volume institutions (two primary medical centres, two tertiary hospitals) Final diagnoses were determined by surgical resections in 15.5% of benign nodules, 99.3% of malignant nodules and by CNB in 0.7% of malignant nodules.
Pandya 2018 207	Patients: n=1947 (1947 nodules); mean age (range): 56 (26 to 86 years) Mean nodule diameter (SD): 1.7 cm (0.9cm) USA	Thyroid cancer	Ultrasound Classified based on the 2015 ATA categories of risk	UGFNA Classified according to the Bethesda System for Cytological classification of Thyroid Nodules	
Park 2016 ²¹⁵	Patients: n=592 (622 nodules); mean age (range): 49.8 (14-86) Mean nodules size	Thyroid cancer	Ultrasound Classified using the Korea Society of Thyroid radiology	UG-FNAB Classified based on the Bethesda System for Cytological	Nodules followed up for at least 2 years or that underwent surgery.

Study	Population	Target condition	Index test	Reference standard	Comments
	(range): 1.61 cm (0.6-7 cm) South Korea		(KSThR) guidelines	classification of Thyroid Nodules	
Persichetti 2018 ²¹⁸	Patients: n=789 (1100 nodules); mean age (SD): 55 (14) Mean nodule size (SD; range): 21.2mm (13.4, 6- 75mm) Italy	Thyroid cancer	Ultrasound Classified using the BTA, ATA, AACE/ACE/AME systems.	UGFNA	
Rahal 2016 ²³¹	Patients: n=906 (n=1000 nodules) Brazil	Thyroid cancer	Ultrasound Classified using TI- RADS	UGFNA Using the Bethesda System for Cytological classification of Thyroid Nodules	
Tae 2007 ²⁷⁶	Patients: n=580 (1255 nodules); mean age (SD): 47.8 (13.9) Mean nodule size (SD): 2.1 cm (1) South Korea	Thyroid cancer	Ultrasound Classified using the Kim criteria	FNAB and surgery (n=78 patients)	Palpable or non-palpable thyroid nodules
Tang 2017 ²⁸¹	Patients: n= 199; 206 nodules USA	Thyroid cancer	US Classified using the ATA risk assessment system	FNAB Using the Bethesda System for reporting thyroid cryopathology	

Study	Population	Target condition	Index test	Reference standard	Comments
				(TBSRTC)	
Weiss 2018 309	Patients: n=57 (61 nodules <1cm); mean age (range) 52 (19-81) Mean nodule size (range): 7.8 mm (5-9 mm) USA	Thyroid cancer	US Classified using the ACR TI-RADS risk assessment system	FNAB Using TBSRTC criteria	Subcentimeter nodules (<1 cm)
Xu 2017 ³²³	Patients: n= 734 (962 nodules); mean age (SD): 46.75 (14.09) Mean nodule diameter (SD): 17.7 (12.8)mm China	Thyroid cancer	US Classified using TI- RADS (d<10mm) and 2015 ATA (d=10- 20mm and d>20mm)guidelines	Surgery (n=703 nodules); >1 year follow-up (repeated cytology; n=259)	Multicentre study (eight tertiary hospitals) Diagnostic accuracy stratified by nodule diameter (d>20mm, d=10- 20 mm, d<10mm) and reported separately
Xu 2018 ³²⁴	Patients: n = 2031 (2465 nodules); mean age (SD): 47.7 (13.38) years Mean nodule size (SD): 16.63 (11.78) mm China	Thyroid cancer	US Classified based on patterns and US features of KSThR- TIRADS, ACR- TIRADS, EU-TIRADS	FNAB or surgery	Included lesions undergoing examinations from three tertiary hospitals around JiangSu Province.

Study	Population	Target condition	Index test	Reference standard	Comments
Yoon 2017 ³²⁹	Patients: n= 4585 (4696 nodules); mean age (SD; range): 51 (11.9; 17-94) Mean nodules size (SD, range): 13.3 mm (2.7, 10-19mm) South Korea	Thyroid cancer	US Classification according to six different guidelines: SRU, NCCN, 2015 ATA, F- TI-RADS, Kim, K-TIRADS	Surgery (1072 nodules) or UGFNAB (3624 nodules) Using TBSRTC from December 2009 onwards and the following categories before that: inadequate, benign, intermediate suspected of papillary carcinoma and malignant	Thyroid nodules 1-2 cm
Yoon 2016 ³³¹	Patients: n=1241 (1293 nodules); mean age (SD; range): 50.8 (13.5; 18- 87) Mean nodule size (SD, range): 21.5 mm (11.4, 10-113mm) South Korea	Thyroid cancer	US Classified using TIRADS (Category 3 was considered negative; categories 4a to 5 positive) and ATA (Very-low suspicion were considered negative; low-to-high suspicion positive)	(UG)FNAB (1051 nodules) or surgery (234 nodules) Using TBSRTC criteria	Nodules measured at least 10 mm
Yoon 2015 332	Patients: n=1257 (1309 nodules); mean age (SD; range): 50.1 (12.1; 18- 83)	Thyroid cancer	US US+ vascularity pattern (2-D Doppler US)	UG-FNAB or surgery (347 nodules) Using TBSRTC	
	Mean nodules size (SD;		Classified using Kim		

Study	Population range): 15.1mm (10.3 ; 5-66mm)	Target condition	Index test criteria	Reference standard	Comments
	South Korea				
Zhang 2018 353	Patients: n-162 (243 nodules); mean age (range): 54.7 (21-79) China	Thyroid cancer	US Classified using Russ TI-RADS	FNAB and pathological tests, surgery (n=82 nodules)	Nodules more than 1cm in largest diameter
Zheng 2018 ³⁶³	Patients: n=1013 (1033 nodules); mean age (SD; range): 45.3 (13; 15-81)	Thyroid cancer	US Classified using ACR TI-RADS	FNA (n=506 nodules) or surgery (n=527 nodules)	
Zhang 2017 354	Patients: n=246 (319 nodules); mean age (SD; range): 46.1 (15.2; 19- 74) Mean nodule size (SD; range): 11.9 mm (3.3; 2.5-46 mm) China	Thyroid cancer	US Classified using TI- RADS, TI- RADS+CEUS	FNAB (n=230 nodules) or surgery (n=89 nodules)	
Zhang 2015 ³⁴⁶	Patients: n = 2921 (3980 nodules) Mean nodules diameter (SD; range): 15.7 mm (11 mm; 2.0-70.0mm) China	Thyroid cancer	US Classified using Kwak's TI-RADS	FNA (628 nodules) Surgery (partial or total thyroidectomy) performed in all nodules with benign or suspicious cytology and 55 nodules with inconclusive cytology and 10 benign nodules. Remaining	

Study	Population	Target condition	Index test	Reference standard	Comments
				737 nodules underwent surgery without FNA. Pathological diagnosis by surgery (971 nodules)	
Zhou 2018 ³⁶⁷	Patients: n=161 (167 nodules); mean age (SD): 44.14 (12.01) Mean nodule size (SD):1.31 cm (0.96) China	Thyroid cancer	US Classified using conventional TI-RADS and a novel classification system using TI-RADS+ contrast-enhanced US parameter ratios	FNA or surgery Using TBSRTC	Solitary thyroid nodules

See Appendix D: for full evidence tables.

4 Quality assessment of clinical studies included in the evidence review

Table 3: Clinical evidence summary: ultrasound in adults

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
BTA	2	1091	VERY LOW ^{a,b,c} due to risk of bias, serious inconsistency and serious imprecision	100% (74-100) 90% (85-95)	35% (25-45) 63% (60-67)
Kim	10	11694	VERY LOW ^{a,b,c}	91% (84-96)	67% (47-82)

	Number of studies				
Index Test	Nur stuo	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
			due to risk of bias, serious inconsistency and serious imprecision		
Modified Kim	1	945	LOW ^a due to risk of bias	96% (91-98%)	85% (82-87%)
Kim + Doppler	2	2392	MODERATE ^a due to risk of bias	91% (87-94%) 91% (88-94%)	52% (49-56%) 62% (59-65%)
Kim + USE (Rago)	1	703	MODERATE ^a due to risk of bias	92% (88-95%)	65% (61-69%)
Kim + USE (Asteria)	1	703	MODERATE ^a due to risk of bias	94% (91-97%)	48% (43-52%)
SRU	3	6454	VERY LOW ^{a,b,c} due to risk of bias, very serious inconsistency and very serious imprecision	58% (17-92%)	51% (12-88%)
AACE/ACE/AME	5	5019	VERY LOW ^{b,c} due to very serious inconsistency and very serious imprecision	93% (75-98%)	51% (15-87%)
ΑΤΑ	13	13786	LOW ^{b,c} due to serious inconsistency and serious imprecision	92% (87-95%)	50% (37-63%)
ATA (subcentimetre)	1	713	MODERATE ^a due to risk of bias	97% (94-98%)	27% (22-31%)
KSThR	3	3837	VERY LOW ^{b,c} due to very serious inconsistency and serious imprecision	95% (85 to 99%)	76% (20-97%)
TIRADS (ACR)	10	13249	LOW ^{b,c} due to serious inconsistency and serious imprecision	94% (86 to 98%)	54% (45-62%)
TIRADS (French)	7	8494	VERY LOW ^{a,b,c} due to risk of bias, serious	94% (87 to 98%)	53% (35-70%)

	Number of studies				
Index Test	sti N	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
			inconsistency and serious imprecision		
TIRADS (Kwak)	7	12905	VERY LOW ^{a,b,c}	97% (94 to 99%)	53% (27 to 78%)
			due to risk of bias, very serious inconsistency, very serious imprecision		
TIRADS (Korean)	4	3504	VERY LOW ^{b,c}	91% (74-97%)	38% (10-76%)
			due to very serious inconsistency, very serious imprecision		
TIRADS (Horvath)	2	2028	VERY LOW ^{a,b,c}	88% (85-91%)	49% (45-52%)
			due to risk of bias, serious inconsistency, serious imprecision	83% (79-87%)	73% (69-76%)
TIRADS (Zhang)	1	319	VERY LOW ^{a,c}	87% (77-93%)	91% (87-95%)
			due to risk of bias, serious imprecision		
TIRADS (Zhang + CEUS)	1	319	LOW ^a due to risk of bias	97% (91-100%)	96% (93-98%)
TIRADS (Kwak +	1	161	LOW ^{a,c}	98% (92-100%)	78% (66-87%)
CEUS)			due to risk of bias, serious imprecision		
NCCN	1	4696	MODERATE ^a	93% (91-95%)	40% (38-41%)
			due to risk of bias		

The assessment of the evidence quality was conducted with emphasis on sensitivity as this was identified by the committee as the primary measure in guiding decisionmaking.

(a) Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias, and downgraded by 2 increments if the majority of studies were rated at very high risk of bias.

(b) Inconsistency was assessed by inspection of the sensitivity and specificity plots. Particular attention was placed on the sensitivity threshold set by the committee as an acceptable level to recommend a test. The evidence was

• downgraded by 1 increment if the individual study values varied across 2 areas: where values of individual studies are both above and below 50%, or both above and below the acceptable threshold 90%

• downgraded by 2 increments if the individual study values varied across 3 areas, where values of individual studies are above and below 50%, and also above and below the acceptable threshold 90%

(c) Imprecision was assessed based on inspection of the credible intervals of sensitivity in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies

Table 4: Clinical evidence summary: ultrasound in children

Index Test	Number of studies	n	Quality	Sensitivity % (95% Cl)	Specificity % (95% CI)
ΑΤΑ	3	301	VERY LOW ^{a,b} due to very serious inconsistency and serious imprecision	91% (69-98%)	53% (19-85%)
TIRADS (Kwak)	1	123	HIGH	100% (93-100%)	18% (10-29%)

The assessment of the evidence quality was conducted with emphasis on sensitivity as this was identified by the committee as the primary measure in guiding decisionmaking.

(a) Inconsistency was assessed by inspection of the sensitivity and specificity plots. Particular attention was placed on the sensitivity threshold set by the committee as an acceptable level to recommend a test. The evidence was

- downgraded by 1 increment if the individual study values varied across 2 areas: where values of individual studies are both above and below 50%, or both above and below the acceptable threshold 90%
- downgraded by 2 increments if the individual study values varied across 3 areas, where values of individual studies are above and below 50%, and also above and below the acceptable threshold 90%

(b) Imprecision was assessed based on inspection of the credible intervals of sensitivity in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies

1 **1.5 Economic evidence**

2 1.5.1 Included studies

3 No relevant health economic studies were identified.

4 1.5.2 Excluded studies

- 5 No health economic studies that were relevant to this question were excluded due to 6 assessment of limited applicability or methodological limitations.
- 7 See also the health economic study selection flow chart in Appendix F:.

8 1.5.3 Health economic modelling

9 This area was not prioritised for new cost-effectiveness analysis.

10 1.5.4 Resource costs

13

14

15

16

17

28

29

30

31

11 Relevant unit costs are provided below to aid consideration of cost effectiveness.

12 Table 5: UK costs of imaging tests

Imaging test	Unit costs
Ultrasound scan (USS) (a)	£53.22
Computerised Tomography (CT) (b)	£85.78
Magnetic Resonance Imaging Scan (MRI) (c)	£138.38
Source[s]: NHS reference costs 2016-17, total HRG schedule 54	

Source[s]: NHS reference costs 2016-17, total HRG schedule ⁹⁴.

(a) Ultrasound Scan with duration of less than 20 minutes and over 20 minutes, without contrast, RD40Z, RD42Z

(b) Computerised Tomography Scan of One Area, without contrast, all age groups, RD20A, RD20B and RD20C (c) Magnetic Resonance Imaging Scan of One Area, without contrast, all age groups, RD01A, RD01B and

RD01C

18 **1.6 Evidence statements**

19 1.6.1 Clinical evidence statements

20Thirty-four studies that evaluated ultrasound under different criteria were included in the21review. Of these, two studies were conducted in children. The evidence was of very low to22moderate quality for adults and low to high quality for children.

23 **1.6.1.1** Ultrasound in adults

•	BTA: very low quality evidence from 2 studies with 1091 participants showed that
	ultrasound using the BTA guidelines has a sensitivity range of 90 -100% and a
	specificity of 35-63%

- **Kim:** very low quality evidence from 10 studies with 11694 participants showed that ultrasound using the Kim criteria has a sensitivity of 91% and a specificity of 67%.
- **Modified Kim:** low quality evidence from 1 study with 945 participants showed that ultrasound using modified Kim criteria has a sensitivity of 96% and a specificity of 85%.
- Kim + Doppler: moderate quality evidence from 2 studies with 2392 participants
 showed that ultrasound combined with power Doppler using the Kim criteria has a
 sensitivity of 91% and a specificity of 52%.

1	• Kim + USE (Rago):moderate quality evidence from 1 study with 703 participants
2	showed that ultrasound using the Kim criteria combined with elastography (USE)
3	using the Rago criteria has a sensitivity of 92% and a specificity of 65%
4	 Kim + USE (Asteria): moderate quality evidence from 1 study with 703 participants
5	showed that ultrasound using the Kim criteria combined with elastography (USE)
6	using the Asteria criteria has a sensitivity of 94% and a specificity of 48%
7	 SRU: very low quality evidence from 3 studies with 6454 participants showed that
8	ultrasound using the SRU criteria has a sensitivity of 58% and a specificity of 51%.
9	 AACE/ACE/AME: very low quality evidence from 5 studies showed that ultrasound
10	using the AACE/ACE/AME criteria has a sensitivity of 93% and a specificity of 51%.
11	ATA: low quality evidence from 13 studies with 13786 participants showed that
12	ultrasound using the ATA guidelines has a sensitivity of 92% and a specificity of 50%.
13	• ATA (subcentimeter): moderate quality evidence from 1 study with 713 participants
14	showed that for subcentimeter nodules, ultrasound using the ATA criteria has a
15	sensitivity of 97% and a specificity of 27%.
16	
17	
	ultrasound using the KSThR criteria has a sensitivity of 95% and a specificity of 76%.
18	• TIRADS (ACR): low quality evidence from 10 studies with 13249 participants showed
19	that ultrasound using ACR-TIRADS has a sensitivity of 94% and a specificity of 54%.
20	 TIRADS (French): very low quality evidence from 7 studies with 8494 participants
21	showed that ultrasound using French-TIRADS has a sensitivity of 94% and a
22	specificity of 53%.
23	 TIRADS (Kwak): very low quality evidence from 7 studies with 12905 participants
24	showed that ultrasound using Kwak's TIRADS has a sensitivity of 97% and a
25	specificity of 53%.
26	• TIRADS (Korean): very low quality evidence from 4 studies with 3504 participants
27	showed that ultrasound using the Korean TIRADS has a sensitivity of 91% and a
28	specificity of 38%.
29	 TIRADS (Horvath): very low quality evidence from 2 studies with 2028 participants
30	showed that ultrasound using Horvath's version of the TIRADS has a sensitivity range
31	of 83-88% and a specificity range of 49-73%.
32	• TIRADS (Zhang): very low quality evidence from 1 study with 319 participants
33	showed that ultrasound using Zhang's version of the TIRADS has a sensitivity of 87%
34	and a specificity of 91%.
35	• TIRADS (Zhang + CEUS): low quality evidence from 1 study with 319 participants
36	showed that ultrasound using Zhang's TIRADS and CEUS classification has a
37	sensitivity of 97% and a specificity of 96%.
38	 TIRADS (Kwak + CEUS): low quality evidence from 1 study with 161 participants
39	showed that ultrasound using Kwak's TIRADS combined with CEUS classification
40	has a sensitivity of 98% and a specificity of 78%.
41	NCCN: moderate quality evidence from 1 study with 4696 participants showed that
42	ultrasound using the NCCN criteria has a sensitivity of 93% and a specificity of 40%.
43 1.6.1.2	Ultrasound in children
44	• ATA: very low quality evidence from 3 studies with 301 participants showed that
45	ultrasound using the ATA guidelines has a sensitivity of 91% and a specificity range
46	of 53% in children.
47	 TIRADS (Kwak): high quality evidence from 1 study with 123 participants showed
48	that ultrasound using Kwak's TIRADS has a sensitivity of 100% and a specificity of
49	18% in children.
50 1.6.2	Health economic evidence statements

• No relevant economic evaluations were identified.

1.7 The committee's discussion of the evidence

2 1.7.1 Interpreting the evidence

3 1.7.1.1 The diagnostic measures that matter most

4 The diagnostic measures of sensitivity, specificity, positive and negative predictive value of 5 the ultrasound scan for diagnosing malignancy under different sonographic criteria were 6 considered for this review. Sensitivity was deemed the most important measure by the 7 committee and hence it was prioritised for decision making.

8 1.7.1.2 The quality of the evidence

9 The quality of the evidence for adults ranged from very low to moderate; the majority being of 10 very low quality, and was downgraded due to risk of bias, inconsistency and imprecision. In 11 children, the quality of the evidence ranged from very low to high and was downgraded for 12 inconsistency and imprecision. No evidence was identified for the diagnostic accuracy of CT 13 and MRI scan. Across studies, the diagnostic accuracy of ultrasound was based on 14 histopathological confirmation that was mostly fine-needle aspiration (FNA) and/or surgery.

- 15 The committee noted that the majority of studies excluded participants whose FNA results 16 were not definitive (i.e. included if benign or malignant result but anything else excluded). 17 They agreed that in reality there will be a considerable number of FNA results that fall 18 between these ends of the spectrum, the appropriate management of these results is outside 19 the scope of this guideline. However it is unlikely to have a significant effect on the choice of 20 optimal imaging option and ultrasound criteria.
- The committee agreed that the breadth of evidence for the various ultrasound criteria was dictated by their novelty. The older criteria (for example Kim) have been available since the early 2000s whereas criteria like the BTA and some of the TIRADS have only been available for around 5 years. This inevitably impacts the number of studies available assessing their accuracy.

26 1.7.1.3 Benefits and harms

271.7.1.3.1 Ultrasound scan in adults

28 Evidence suggested that in adults, both measures of sensitivity and specificity were similarly 29 high for the use of ultrasound under the majority of different criteria identified. The only ultrasound criteria for which diagnostic accuracy was considerably lower compared to the 30 31 other criteria were the SRU (58% sensitivity). The committee noted that the reason for this 32 discrepancy is likely to be that the size of nodules is taken into account when assessing the 33 likelihood of malignancy according to the SRU guidelines. They specified that nodule size is 34 irrelevant in predicting malignancy and using size criteria can result in less sensitivity. 35 Evidence suggested that the diagnostic accuracy of ultrasound is increased when a modified version of the Kim criteria is used compared to the conventional version (96 vs 91% 36 sensitivity; 85 vs 67% specificity). However the committee noted that this was shown by only 37 38 one study and as the modified criteria essentially involved a raising of threshold making the benefit in both sensitivity and specificity counter intuitive, that this was not likely to reflect a 39 true difference in diagnostic accuracy. Gray-scale ultrasound combined with power Doppler 40 41 ultrasound under the Kim criteria did not lead to increased diagnostic accuracy compared to conventional gray-scale ultrasound under the Kim criteria alone (both 91% sensitivity). 42

43 Studies using ultrasound imaging based on the TIRADS, showed that diagnostic accuracy 44 was high for all the different versions of the guidelines identified. Evidence also showed that 45 when using the TIRADS criteria, ultrasound combined with contrast-enhanced US parameter 46 ratios (CEUS) may result in higher sensitivity and specificity compared to ultrasound without CEUS. Similarly it was evident that under the Kim criteria, ultrasound had a minor increase in diagnostic accuracy when combined with elastography (USE). The committee noted that combining elastography with ultrasound is not current practice and would require specialised equipment, training and expertise and would thus be likely to have a significant economic impact. Based on the small number of studies for CEUS and USE and the small magnitude of the benefit in diagnostic accuracy introduced, the committee agreed that the current evidence did not justify a change in current practice.

8 There was a lack of evidence for the diagnostic accuracy of CT and MRI. The committee 9 noted that CT is not good at discriminating structures of the thyroid gland and that the MRI 10 has no consistent ability to examine malignancy. There was agreement that ultrasound 11 constitutes the only good existing imaging technique for the first assessment of thyroid 12 enlargement. However the committee emphasised that further imaging may be useful in 13 other circumstances, for example CT scanning in the case of enlargement causing 14 compression symptoms.

15 The committee discussed the role of incidental findings of thyroid enlargement from other 16 imaging. They noted that these are frequent reasons for referral but in their experience, and based on their awareness of other evidence, incidental findings rarely indicate malignancy. 17 Despite this, further investigation is often done due to concerns around medicolegal risk. The 18 19 committee agreed that in some cases incidental findings may need further investigation but 20 that healthcare professionals should consider the overall likelihood of malignancy in a person 21 before continuing on the investigative pathway. The committee also noted that the likelihood of malignancy will be dependent on the imaging modality, incidental findings on CT scans are 22 23 less concerning but rates of malignancy may be higher in incidental findings on FDG-PET 24 scans for example.

251.7.1.3.2 Ultrasound scan in children

1

2 3

4

5

6

7

The imaging evidence identified for children in the review showed that ultrasound had high diagnostic accuracy both when using the ATA guidelines and the TIRADS proposed by Kwak. No evidence for the diagnostic accuracy of the CT and the MRI scan was identified in children. The committee agreed that similarly to adults, this was likely to be due to the fact that ultrasound is the only good existing imaging technique and that the imaging recommendations made for adults would be applicable to children as well.

32 1.7.2 Cost effectiveness and resource use

No health economic evidence was identified for this question. The committee was therefore not able to assess the cost effectiveness of which imaging tests should be requested (for thyroid enlargement) and which people with structural abnormalities should have a fineneedle aspiration biopsy. Unit costs for the US, CT and MRI, obtained from the NHS reference cost 2016-17, were presented to the committee. The cheapest imaging test was the US scan costing £53.22 (RD40Z, RD42Z), CT cost £85.78 (RD20A, RD20B and RD20C), and MRI was £138.38 (RD01A, RD01B and RD01C).

- 40The clinical review found evidence suggesting ultrasound, when used with appropriate41diagnostic criteria's, had good diagnostic accuracy where as evidence was not identified to42support the use of CT or MRI. Ultrasound is also the lowest cost option and so the committee43recommended its use.
- The committee also noted that using an established grading system that did not take into account the nodular size for referring patients to have FNAB, is likely to reduce the number of patients being referred to FNAB and therefore it is likely to be cost saving. In addition, by correctly reporting these findings, repeats could be avoided and money saved.
- 48 Ultrasound to assess likelihood of thyroid malignancy is current practice. The most 49 commonly used ultrasound criteria are those of the British Thyroid Association, which are in

line with the recommendations made above. Therefore, overall these recommendations are
 not expected to have a substantial resource impact to the NHS in England.

3 1.7.3 Other factors the committee took into account

Although not a focus of this evidence review, the committee raised a need for US images to be recorded and stored to enable review in cases such as multi-disciplinary team meetings and referral to secondary care. They raised the importance for US reports to be explicit in terms of the criteria based on which the likelihood of malignancy was determined to facilitate clinicians in cases where re-visiting imaging is warranted.

9

References

1

2

3

4

5

6

7

8 9

10

11 12

13

14

15

16 17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33 34

35

36

37

38

39

- 1. Abdel-Rahman HM, Abowarda MH, Abdel-Aal SM. Diffusion-weighted MRI and apparent diffusion coefficient in differentiation of benign from malignant solitary thyroid nodule. Egyptian Journal of Radiology and Nuclear Medicine. 2016; 47(4):1385-1390
- Afifi AH, Alwafa WAHA, Aly WM, Alhammadi HAB. Diagnostic accuracy of the combined use of conventional sonography and sonoelastography in differentiating benign and malignant solitary thyroid nodules. Alexandria Journal of Medicine. 2017; 53(1):21-30
 - 3. Aggarwal A, Aggarwal J, Awasthi S. Non invasive assessment of malignancy in solitary non palpable thyroid nodules: A comparative and complimentary evaluation of grey scale ultrasound and color doppler parameters -way towards a new scoring system? Acta Medica International. 2017; 4(1):1-6
 - Aghaghazvini L, Sharifian H, Yazdani N, Hosseiny M, Pirouzi P, Ghadiri A et al. Differentiation between benign and malignant thyroid nodules using diffusionweighted imaging, a 3-T MRI study. Indian Journal of Radiology and Imaging. 2018; 28(4):460-464
 - 5. Ahn HS, Lee JB, Seo M, Park SH, Choi BI. Distinguishing benign from malignant thyroid nodules using thyroid ultrasonography: utility of adding superb microvascular imaging and elastography. Radiologia Medica. 2018; 123(4):260-270
 - Ahn SS, Kim EK, Kang DR, Lim SK, Kwak JY, Kim MJ. Biopsy of thyroid nodules: comparison of three sets of guidelines. AJR American Journal of Roentgenology. 2010; 194(1):31-7
 - Akhavan A, Jafari SM, Khosravi MH, Khajehpour H, Karimi-Sari H. Reliability of fineneedle aspiration and ultrasound-based characteristics of thyroid nodules for diagnosing malignancy in Iranian patients. Diagnostic Cytopathology. 2016; 44(4):269-73
 - 8. Al Nofal A, Gionfriddo MR, Javed A, Haydour Q, Brito JP, Prokop LJ et al. Accuracy of thyroid nodule sonography for the detection of thyroid cancer in children: systematic review and meta-analysis. Clinical Endocrinology. 2016; 84(3):423-30
 - 9. Alam T, Khattak YJ, Beg M, Raouf A, Azeemuddin M, Khan AA. Diagnostic accuracy of ultrasonography in differentiating benign and malignant thyroid nodules using fine needle aspiration cytology as the reference standard. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014; 15(22):10039-43
- 10. Albair Ashamallah G, M.A EL-A. Risk for malignancy of thyroid nodules: Comparative study between TIRADS and US based classification system. Egyptian Journal of Radiology and Nuclear Medicine. 2016; 47(4):1373-1384
 - 11. Algin O, Algin E, Gokalp G, Ocakoglu G, Erdogan C, Saraydaroglu O et al. Role of duplex power Doppler ultrasound in differentiation between malignant and benign thyroid nodules. Korean Journal of Radiology. 2010; 11(6):594-602
- 41 12. Appetecchia M, Solivetti FM. The association of colour flow Doppler sonography and 42 conventional ultrasonography improves the diagnosis of thyroid carcinoma. Hormone 43 Research. 2006; 66(5):249-56

- Asteria C, Giovanardi A, Pizzocaro A, Cozzaglio L, Morabito A, Somalvico F et al. US-elastography in the differential diagnosis of benign and malignant thyroid nodules. Thyroid. 2008; 18(5):523-31
 - 14. Azizi G, Keller J, Lewis M, Puett D, Rivenbark K, Malchoff C. Performance of elastography for the evaluation of thyroid nodules: a prospective study. Thyroid. 2013; 23(6):734-40
- 15. Bae JM, Hahn SY, Shin JH, Ko EY. Erratum to "Inter-exam agreement and diagnostic performance of the Korean Thyroid Imaging Reporting and Data System for thyroid nodule assessment: Real-time versus static ultrasonography". European Journal of Radiology. 2018; 101:193
 - 16. Bae JM, Hahn SY, Shin JH, Ko EY. Inter-exam agreement and diagnostic performance of the Korean thyroid imaging reporting and data system for thyroid nodule assessment: Real-time versus static ultrasonography. European Journal of Radiology. 2018; 98:14-19
 - 17. Bhatia KS, Rasalkar DP, Lee YP, Wong KT, King AD, Yuen HY et al. Cystic change in thyroid nodules: a confounding factor for real-time qualitative thyroid ultrasound elastography. Clinical Radiology. 2011; 66(9):799-807
 - 18. Bhatia KS, Tong CS, Cho CC, Yuen EH, Lee YY, Ahuja AT. Shear wave elastography of thyroid nodules in routine clinical practice: preliminary observations and utility for detecting malignancy. European Radiology. 2012; 22(11):2397-406
 - 19. Bojunga J, Herrmann E, Meyer G, Weber S, Zeuzem S, Friedrich-Rust M. Real-time elastography for the differentiation of benign and malignant thyroid nodules: a meta-analysis. Thyroid. 2010; 20(10):1145-50
 - 20. Brito JP, Gionfriddo MR, Al Nofal A, Boehmer KR, Leppin AL, Reading C et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2014; 99(4):1253-63
 - 21. Brophy C, Stewart J, O'Donovan N, McCarthy J, Murphy M, Sheahan P. Impact of microcalcifications on risk of malignancy in thyroid nodules with indeterminate or benign cytology. Otolaryngology Head & Neck Surgery. 2016; 154(1):46-51
 - Cakal E, Sahin M, Unsal IO, Gungunes A, Akkaymak E, Ozkaya EC et al. Elastography in the differential diagnosis of thyroid nodules. Ultrasonic Imaging. 2015; 37(3):251-7
 - 23. Cakir B, Aydin C, Korukluoglu B, Ozdemir D, Sisman IC, Tuzun D et al. Diagnostic value of elastosonographically determined strain index in the differential diagnosis of benign and malignant thyroid nodules. Endocrine. 2011; 39(1):89-98
 - 24. Cam OH, Tekin M, Acar GO, Kilicaslan A. What is the Role of Diffusion Weigh Magnetic Resonance Imaging in Evaluation of Thyroid Nodules? Indian Journal of Otolaryngology & Head & Neck Surgery. 2014; 66(3):336-40
- 25. Camargo RY, Tomimori EK, Knobel M, Medeiros-Neto G. Preoperative assessment of thyroid nodules: role of ultrasonography and fine needle aspiration biopsy followed by cytology. Clinics (Sao Paulo, Brazil). 2007; 62(4):411-8
- 4326.Cantisani V, Grazhdani H, Ricci P, Mortele K, Di Segni M, D'Andrea V et al. Q-44elastosonography of solid thyroid nodules: assessment of diagnostic efficacy and45interobserver variability in a large patient cohort. European Radiology. 2014;4624(1):143-50

27. 1 Cantisani V, Lodise P, Di Rocco G, Grazhdani H, Giannotti D, Patrizi G et al. 2 Diagnostic accuracy and interobserver agreement of guasistatic ultrasound 3 elastography in the diagnosis of thyroid nodules. Ultraschall in der Medizin. 2015; 4 36(2):162-7 5 28. Cappelli C, Castellano M, Pirola I, Cumetti D, Agosti B, Gandossi E et al. The predictive value of ultrasound findings in the management of thyroid nodules. QJM:An 6 International Journal of Medicine. 2007; 100(1):29-35 7 8 29. Cappelli C, Castellano M, Pirola I, Gandossi E, De Martino E, Cumetti D et al. Thyroid nodule shape suggests malignancy. European Journal of Endocrinology. 2006; 9 155(1):27-31 10 30. Cappelli C, Pirola I, Cumetti D, Micheletti L, Tironi A, Gandossi E et al. Is the 11 12 anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a 13 sonographic criteria for recommending fine-needle aspiration cytology? Clinical Endocrinology. 2005; 63(6):689-93 14 15 31. Cavallo A, Johnson DN, White MG, Siddigui S, Antic T, Mathew M et al. Thyroid 16 nodule size at ultrasound as a predictor of malignancy and final pathologic size. Thyroid. 2017; 27(5):641-650 17 18 32. Cetin N, Yucel C, Uyar Gocun P, Aladag Kurt S, Taneri F, Oktar S et al. The efficiency of ultrasound elastography in the differential diagnosis of thyroid nodules. 19 20 Journal of the Belgian Society of Radiology. 2015; 98(1):20-26 Chandramohan A, Khurana A, Pushpa BT, Manipadam MT, Naik D, Thomas N et al. 21 33. 22 Is TIRADS a practical and accurate system for use in daily clinical practice? Indian 23 Journal of Radiology & Imaging. 2016; 26(1):145-52 24 34. Chen BD, Xu HX, Zhang YF, Liu BJ, Guo LH, Li DD et al. The diagnostic 25 performances of conventional strain elastography (SE), acoustic radiation force impulse (ARFI) imaging and point shear-wave speed (pSWS) measurement for non-26 27 calcified thyroid nodules. Clinical Hemorheology and Microcirculation. 2017; 28 65(3):259-273 29 35. Chen L, Xu J, Bao J, Huang X, Hu X, Xia Y et al. Diffusion-weighted MRI in differentiating malignant from benign thyroid nodules: a meta-analysis. BMJ Open. 30 31 2016; 6(1):e008413 32 36. Chen L, Zhang J, Meng L, Lai Y, Huang W. A new ultrasound nomogram for differentiating benign and malignant thyroid nodules. Clinical Endocrinology. 2019; 33 34 90(2):351-359 35 37. Chen M, Zhang KQ, Xu YF, Zhang SM, Cao Y, Sun WQ. Shear wave elastography and contrast-enhanced ultrasonography in the diagnosis of thyroid malignant 36 37 nodules. Molecular & Clinical Oncology. 2016; 5(6):724-730 Chen PY, Chiou SC, Yeh HY, Chen CP, Ho C, Lin JD et al. Correlation of 38 38. 39 ultrasonography with fine needle aspiration cytology and final pathological diagnoses 40 in patients with thyroid nodules. Chinese Journal of Radiology. 2010; 35(1):1-7 41 39. Chen SP, Hu YP, Chen B. Taller-than-wide sign for predicting thyroid 42 microcarcinoma: comparison and combination of two ultrasonographic planes. 43 Ultrasound in Medicine and Biology. 2014; 40(9):2004-11 44 40. Cheng P, Chen ED, Zheng HM, He QX, Li Q. Ultrasound score to select 45 subcentimeter-sized thyroid nodules requiring ultrasound-guided fine needle 46 aspiration biopsy in eastern China. Asian Pacific Journal of Cancer Prevention: Apjcp. 47 2013; 14(8):4689-92

- 41. Cheng SP, Lee JJ, Lin JL, Chuang SM, Chien MN, Liu CL. Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TI-RADS). Head and Neck. 2013; 35(4):541-7
- 42. Chi J, Walia E, Babyn P, Wang J, Groot G, Eramian M. Thyroid Nodule Classification in Ultrasound Images by Fine-Tuning Deep Convolutional Neural Network. Journal of Digital Imaging. 2017; 30(4):477-486
- 43. Chiu WY, Chia NH, Wan SK, Yuen CH, Cheung MT. The investigation and management of thyroid nodules--a retrospective review of 183 cases. Annals of the Academy of Medicine, Singapore. 1998; 27(2):196-9
 - 44. Chng CL, Tan HC, Too CW, Lim WY, Chiam PPS, Zhu L et al. Diagnostic performance of ATA, BTA and TIRADS sonographic patterns in the predication of malignancy in histologically proven thyroid nodules. Singapore Medical Journal. 2018; Epublication
 - 45. Choi YJ, Baek JH, Baek SH, Shim WH, Lee KD, Lee HS et al. Web-based malignancy risk estimation for thyroid nodules using ultrasonography characteristics: Development and validation of a predictive model. Thyroid. 2015; 25(12):1306-12
- 46. Choi YJ, Baek JH, Park HS, Shim WH, Kim TY, Shong YK et al. A computer-aided diagnosis system using artificial intelligence for the diagnosis and characterization of thyroid nodules on ultrasound: Initial clinical assessment. Thyroid. 2017; 27(4):546-552
 - 47. Chong Y, Shin JH, Ko ES, Han BK. Ultrasonographic elastography of thyroid nodules: is adding strain ratio to colour mapping better? Clinical Radiology. 2013; 68(12):1241-6
 - 48. Creo A, Alahdab F, Al Nofal A, Thomas K, Kolbe A, Pittock ST. Ultrasonography and the American Thyroid Association Ultrasound-Based Risk Stratification Tool: Utility in Pediatric and Adolescent Thyroid Nodules. Hormone Research in Paediatrics. 2018; 90(2):93-101
 - 49. D'Souza MM, Marwaha RK, Sharma R, Jaimini A, Thomas S, Singh D et al. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and highresolution ultrasonography. Annals of Nuclear Medicine. 2010; 24(5):345-55
 - 50. Delfim RLC, Veiga L, Vidal APA, Lopes F, Vaisman M, Teixeira P. Likelihood of malignancy in thyroid nodules according to a proposed Thyroid Imaging Reporting and Data System (TI-RADS) classification merging suspicious and benign ultrasound features. Archives of Endocrinology & Metabolism. 2017; 61(3):211-221
 - 51. Deng J, Zhou P, Tian SM, Zhang L, Li JL, Qian Y. Comparison of diagnostic efficacy of contrast-enhanced ultrasound, acoustic radiation force impulse imaging, and their combined use in differentiating focal solid thyroid nodules. PloS One. 2014; 9(3):e90674
- 52. Deng S, Jiang Q, Zhu Y, Zhang Y. An analysis of the clinical value of high-frequency color Doppler ultrasound in the differential diagnosis of benign and malignant thyroid nodules. International Journal of Clinical and Experimental Medicine. 2018; 11(3):2331-2336
- 4353.Deng XH, Tang LN, Liu SQ, Li XL, He YP, Xu HX. A proposal to stratify the44intermediate-risk thyroid nodules according to the AACE/ACE/AME guidelines with45ultrasound features. Scientific Reports. 2017; 7:17901

- 54. Department of Health. NHS reference costs 2016-17. 2017. Available from: https://www.gov.uk/government/collections/nhs-reference-costs Last accessed: 15/02/2019
- 55. Diao X, Zhan J, Chen L, Chen Y, Liu Y. Quantification of solid hypo-echoic thyroid nodule enhancement with contrast-enhanced ultrasound. Translational Cancer Research. 2017; 6(6):1078-1087
- 56. Dighe M, Kim J, Luo S, Kim Y. Utility of the ultrasound elastographic systolic thyroid stiffness index in reducing fine-needle aspirations. Journal of Ultrasound in Medicine. 2010; 29(4):565-74
 - Dighe M, Luo S, Cuevas C, Kim Y. Efficacy of thyroid ultrasound elastography in differential diagnosis of small thyroid nodules. European Journal of Radiology. 2013; 82(6):e274-80
 - 58. Dilli A, Ayaz UY, Cakir E, Cakal E, Gultekin SS, Hekimoglu B. The efficacy of apparent diffusion coefficient value calculation in differentiation between malignant and benign thyroid nodules. Clinical Imaging. 2012; 36(4):316-322
- 59. Ding J, Cheng H, Ning C, Huang J, Zhang Y. Quantitative measurement for thyroid cancer characterization based on elastography. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2011; 30(9):1259-1266
 - 60. Dobruch-Sobczak K, Zalewska EB, Guminska A, Slapa RZ, Mlosek K, Wareluk P et al. Diagnostic performance of shear wave elastography parameters alone and in combination with conventional b-mode ultrasound parameters for the characterization of thyroid nodules: A prospective, dual-center study. Ultrasound in Medicine and Biology. 2016; 42(12):2803-2811
 - 61. Du YR, Ji CL, Wu Y, Gu XG. Combination of ultrasound elastography with TI-RADS in the diagnosis of small thyroid nodules (<=10 mm): A new method to increase the diagnostic performance. European Journal of Radiology. 2018; 109:33-40
 - 62. Duan SB, Yu J, Li X, Han ZY, Zhai HY, Liang P. Diagnostic value of two-dimensional shear wave elastography in papillary thyroid microcarcinoma. OncoTargets and Therapy. 2016; 9:1311-7
 - 63. Dy JGD, Kasala R, Yao C, Ongoco R, Mojica DJ. Thyroid imaging reporting and data system (TIRADS) in stratifying risk of thyroid malignancy at the Medical city. Journal of the ASEAN Federation of Endocrine Societies. 2017; 32(2):108-116
 - 64. Ebeed AE, Romeih MAEH, Refat MM, Salah NM. Role of ultrasound, color doppler, elastography and micropure imaging in differentiation between benign and malignant thyroid nodules. Egyptian Journal of Radiology and Nuclear Medicine. 2017; 48(3):603-610
 - 65. EI-Hariri MA, Taha Ali TF, Tawab MA, Magid AMA, EI-Shiekh AF. The clinical value of ultrasound elastography in predicting malignant thyroid nodules. Egyptian Journal of Radiology and Nuclear Medicine. 2014; 45(2):353-359
 - 66. Elsayed NM, Elkhatib YA. Diagnostic criteria and accuracy of categorizing malignant thyroid nodules by ultrasonography and ultrasound elastography with pathologic correlation. Ultrasonic Imaging. 2016; 38(2):148-58
- 4467.Farihah AG, Nurismah MI, Husyairi H, Shahrun Niza AS, Radhika S. Reliability of the45ultrasound classification system of thyroid nodules in predicting malignancy. Medical46Journal of Malaysia. 2018; 73(1):9-15

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17 18

19

20

21

22

23

24

25

26

27 28

29

30

31

32

33

34

35

36

37

38

- 68. Fukunari N, Nagahama M, Sugino K, Mimura T, Ito K, Ito K. Clinical evaluation of color Doppler imaging for the differential diagnosis of thyroid follicular lesions. World Journal of Surgery. 2004; 28(12):1261-5
- 69. Gamme G, Parrington T, Wiebe E, Ghosh S, Litt B, Williams DC et al. The utility of thyroid ultrasonography in the management of thyroid nodules. Canadian Journal of Surgery. 2017; 60(2):134-139
- 70. Gannon AW, Langer JE, Bellah R, Ratcliffe S, Pizza J, Mostoufi-Moab S et al. Diagnostic Accuracy of Ultrasound With Color Flow Doppler in Children With Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism. 2018; 103(5):1958-1965
 - 71. Gao L, Liu R, Jiang Y, Song W, Wang Y, Liu J et al. Computer-aided system for diagnosing thyroid nodules on ultrasound: A comparison with radiologist-based clinical assessments. Head and Neck. 2018; 40(4):778-783
 - 72. Garcia-Monco Fernandez C, Serrano-Moreno C, Donnay-Candil S, Carrero-Alvaro J. Acorrelation study between histological results and thyroid ultrasound findings. The TI-RADS classification. Endocrinologia Diabetes y Nutricion. 2018; 65(4):206-212
- 73. Gietka-Czernel M, Kochman M, Bujalska K, Stachlewska-Nasfeter E, Zgliczynski W. Real-time ultrasound elastography a new tool for diagnosing thyroid nodules. Endokrynologia Polska. 2010; 61(6):652-7
 - 74. Ginat DT, Butani D, Giampoli EJ, Patel N, Dogra V. Pearls and pitfalls of thyroid nodule sonography and fine-needle aspiration. Ultrasound Quarterly. 2010; 26(3):171-178
 - 75. Giusti M, Orlandi D, Melle G, Massa B, Silvestri E, Minuto F et al. Is there a real diagnostic impact of elastosonography and contrast-enhanced ultrasonography in the management of thyroid nodules? Journal of Zhejiang University SCIENCE B. 2013; 14(3):195-206
 - 76. Glogovsek M, Gaberscek S, Zorman M. A simple graphical quantitative analysis of ultrasonography images to decide when to perform fine needle aspiration biopsy in diagnosing malignancy in solid thyroid nodules? A two centres prospective study. Hellenic Journal of Nuclear Medicine. 2015; 18(1):25-30
 - 77. Goldfarb M, Gondek S, Solorzano C, Lew JI. Surgeon-performed ultrasound can predict benignity in thyroid nodules. Surgery. 2011; 150(3):436-41
 - 78. Goldfarb M, Gondek SS, Sanchez Y, Lew JI. Clinic-based ultrasound can predict malignancy in pediatric thyroid nodules. Thyroid. 2012; 22(8):827-31
- 79. Gotzberger M, Krueger S, Gartner R, Reincke M, Pichler M, Assmann G et al. Comparison of color-Doppler and qualitative and quantitative strain-elastography for differentiation of thyroid nodules in daily practice. Hormones. 2016; 15(2):197-204
 - Brani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L et al. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. Journal of Clinical Endocrinology and Metabolism. 2019; 104(1):95-102
- 41 81. Gu F, Han L, Yang X, Liu H, Li X, Guo K et al. Value of time-intensity curve analysis
 42 of contrast-enhanced ultrasound in the differential diagnosis of thyroid nodules.
 43 European Journal of Radiology. 2018; 105:182-187
- 4482.Gu J, Du L, Bai M, Chen H, Jia X, Zhao J et al. Preliminary study on the diagnostic45value of acoustic radiation force impulse technology for differentiating between

1 benign and malignant thyroid nodules. Journal of Ultrasound in Medicine. 2012; 2 31(5):763-71 3 83. Guazzaroni M, Spinelli A, Coco I, Del Giudice C, Girardi V, Simonetti G. Value of strain-ratio on thyroid real-time sonoelastography. Radiologia Medica. 2014; 4 5 119(3):149-55 Gul K, Ersoy R, Dirikoc A, Korukluoglu B, Ersoy PE, Aydin R et al. Ultrasonographic 6 84. 7 evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and 8 histopathological findings. Endocrine. 2009; 36(3):464-72 Gupta N, Norbu C, Goswami B, Chowdhury V, RaviShankar L, Gulati P et al. Role of 9 85. 10 dynamic MRI in differentiating benign from malignant follicular thyroid nodule. Auris, Nasus, Larynx. 2011; 38(6):718-723 11 12 86. Ha EJ, Moon WJ, Na DG, Lee YH, Choi N, Kim SJ et al. A multicenter prospective validation study for the Korean thyroid imaging reporting and data system in patients 13 14 with thyroid nodules. Korean Journal of Radiology. 2016; 17(5):811-821 15 87. Ha EJ, Na DG, Moon WJ, Lee YH, Choi N. Diagnostic performance of ultrasoundbased risk-stratification systems for thyroid nodules: Comparison of the 2015 16 American thyroid association guidelines with the 2016 Korean thyroid 17 18 association/Korean society of thyroid radiology and 2017 American congress of radiology guidelines. Thyroid. 2018; 28(11):1532-1537 19 20 88. Ha SM, Ahn HS, Baek JH, Ahn HY, Chung YJ, Cho BY et al. Validation of three scoring risk-stratification models for thyroid nodules. Thyroid. 2017; 27(12):1550-1557 21 22 89. Ha SM, Kim JK, Baek JH. Detection of malignancy among suspicious thyroid nodules 23 <1cm on ultrasound with various thyroid image reporting and data systems. Thyroid. 24 2017; 27(10):1307-1315 25 90. Hamidi C, Goya C, Hattapoglu S, Uslukaya O, Teke M, Durmaz MS et al. Acoustic 26 Radiation Force Impulse (ARFI) imaging for the distinction between benign and 27 malignant thyroid nodules. La Radiologia Medica. 2015; 120(6):579-583 He LZ, Zeng TS, Pu L, Pan SX, Xia WF, Chen LL. Thyroid Hormones, 28 91. 29 Autoantibodies, Ultrasonography, and Clinical Parameters for Predicting Thyroid 30 Cancer. International Journal of Endocrinology Print. 2016; 2016:8215834 92. 31 Hoang JK, Middleton WD, Farjat AE, Langer JE, Reading CC, Teefey SA et al. Reduction in thyroid nodule biopsies and improved accuracy with American College 32 33 of Radiology Thyroid Imaging Reporting and Data System. Radiology. 2018; 34 287(1):185-193 35 93. Hoang JK, Middleton WD, Farjat AE, Teefey SA, Abinanti N, Boschini FJ et al. 36 Interobserver variability of sonographic features used in the American college of 37 radiology thyroid imaging reporting and data system. American Journal of 38 Roentgenology. 2018; 211(1):162-167 Hobbs HA, Bahl M, Nelson RC, Eastwood JD, Esclamado RM, Hoang JK. Applying 39 94. 40 the Society of Radiologists in Ultrasound recommendations for fine-needle aspiration of thyroid nodules: effect on workup and malignancy detection. AJR American Journal 41 42 of Roentgenology. 2014; 202(3):602-7 43 95. Hong Y, Liu X, Li Z, Zhang X, Chen M, Luo Z. Real-time ultrasound elastography in 44 the differential diagnosis of benign and malignant thyroid nodules. Journal of 45 Ultrasound in Medicine. 2009; 28(7):861-7

- 96. Hong YR, Wu YL, Luo ZY, Wu NB, Liu XM. Impact of nodular size on the predictive values of gray-scale, color-Doppler ultrasound, and sonoelastography for assessment of thyroid nodules. Journal of Zhejiang University SCIENCE B. 2012; 13(9):707-16
- 97. Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. Journal of Clinical Endocrinology and Metabolism. 2009; 94(5):1748-51
- 98. Hu J, Xia J, Tian W. Diagnosis of thyroid cancer using computed tomography. Journal of Medical Imaging and Health Informatics. 2018; 8(5):969-972
- 99. Huan Q, Wang K, Lou F, Zhang L, Huang QX, Han YF et al. Epidemiological characteristics of thyroid nodules and risk factors for malignant nodules: A retrospective study from 6 304 surgical cases. Chinese Medical Journal. 2014; 127(12):2286-2292
 - 100. Huang X, Guo LH, Xu HX, Gong XH, Liu BJ, Xu JM et al. Acoustic radiation force impulse induced strain elastography and point shear wave elastography for evaluation of thyroid nodules. International Journal of Clinical and Experimental Medicine. 2015; 8(7):10956-63
 - 101. Hughes NM, Nae A, Barry J, Fitzgerald B, Feeley L, Sheahan P. Sonographic differences between conventional and follicular variant papillary thyroid carcinoma. European Archives of Oto-Rhino-Laryngology. 2017; 274(7):2907-2913
 - 102. Ianni F, Campanella P, Rota CA, Prete A, Castellino L, Pontecorvi A et al. A metaanalysis-derived proposal for a clinical, ultrasonographic, and cytological scoring system to evaluate thyroid nodules: the "CUT" score. Endocrine. 2016; 52(2):313-21
 - 103. Ishigaki S, Shimamoto K, Satake H, Sawaki A, Itoh S, Ikeda M et al. Multi-slice CT of thyroid nodules: comparison with ultrasonography. Radiation Medicine. 2004; 22(5):346-53
 - 104. Ito Y, Amino N, Yokozawa T, Ota H, Ohshita M, Murata N et al. Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid. 2007; 17(12):1269-76
 - 105. Jiang J, Shang X, Wang H, Xu YB, Gao Y, Zhou Q. Diagnostic value of contrastenhanced ultrasound in thyroid nodules with calcification. Kaohsiung Journal of Medical Sciences. 2015; 31(3):138-44
 - 106. Jin XZ, Lu WW, Zhang HF, Yan YY, Gu XL. Comparative study on the diagnostic values of different ultrasound technologies for malignant thyroid nodules. Oncology Letters. 2018; 16(1):910-914
 - 107. Jin ZQ, Lin MY, Hu WH, Li WY, Bai SJ. Gray-scale ultrasonography combined with elastography imaging for the evaluation of papillary thyroid microcarcinoma: as a prognostic clinicopathology factor. Ultrasound in Medicine and Biology. 2014; 40(8):1769-77
 - Kagoya R, Monobe H, Tojima H. Utility of elastography for differential diagnosis of benign and malignant thyroid nodules. Otolaryngology - Head & Neck Surgery. 2010; 143(2):230-4
- 42 109. Kakkos SK, Scopa CD, Chalmoukis AK, Karachalios DA, Spiliotis JD, Harkoftakis JG
 43 et al. Relative risk of cancer in sonographically detected thyroid nodules with
 44 calcifications. Journal of Clinical Ultrasound. 2000; 28(7):347-352

- 110. Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H et al. Thyroid nodule size and prediction of cancer. Journal of Clinical Endocrinology and Metabolism. 2013; 98(2):564-70
- 111. Kathuria S, Sen J, Sen R, Singh S, Yadav RK, Sharma JP. The role of Color Doppler sonography in predicting malignacy in thyroid nodules. Ultrasound International. 2003; 9(1):8-14
- 112. Khamis MEM, Ismail AAA, Alaa El-deen AM, Amin MF. Additional value of qualitative strain ultrasound elastography and strain ratio in predicting thyroid malignancy. Egyptian Journal of Radiology and Nuclear Medicine. 2017; 48(4):913-920
 - 113. Kim DW, Jung SJ, Baek HJ. Computed tomography features of benign and malignant solid thyroid nodules. Acta Radiologica. 2015; 56(10):1196-202
 - 114. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR American Journal of Roentgenology. 2002; 178(3):687-91
 - 115. Kim H, Kim JA, Son EJ, Youk JH. Quantitative assessment of shear-wave ultrasound elastography in thyroid nodules: diagnostic performance for predicting malignancy. European Radiology. 2013; 23(9):2532-7
- 116. Kim HG, Moon HJ, Kwak JY, Kim EK. Diagnostic accuracy of the ultrasonographic features for subcentimeter thyroid nodules suggested by the revised American Thyroid Association guidelines. Thyroid. 2013; 23(12):1583-9
 - 117. Kim HJ, Kwak MK, Choi IH, Jin SY, Park HK, Byun DW et al. Utility of shear wave elastography to detect papillary thyroid carcinoma in thyroid nodules: efficacy of the standard deviation elasticity. Korean Journal of Internal Medicine. 2018; Epublication
 - 118. Kim JK, Baek JH, Lee JH, Kim JL, Ha EJ, Kim TY et al. Ultrasound elastography for thyroid nodules: A reliable study? Ultrasound in Medicine and Biology. 2012; 38(9):1508-1513
- 119. Kim JY, Jung SL, Kim MK, Kim TJ, Byun JY. Differentiation of benign and malignant thyroid nodules based on the proportion of sponge-like areas on ultrasonography: Imaging-pathologic correlation. Ultrasonography. 2015; 34(4):304-311
 - Kim JY, Kim SY, Yang KR. Ultrasonographic criteria for fine needle aspiration of nonpalpable thyroid nodules 1-2 cm in diameter. European Journal of Radiology. 2013; 82(2):321-6
 - 121. Kim JY, Lee CH, Kim SY, Jeon WK, Kang JH, An SK et al. Radiologic and pathologic findings of nonpalpable thyroid carcinomas detected by ultrasonography in a medical screening center. Journal of Ultrasound in Medicine. 2008; 27(2):215-23
- 122. Kim KM, Park JB, Kang SJ, Bae KS. Ultrasonographic guideline for thyroid nodules cytology: single institute experience. Journal of the Korean Surgical Society. 2013; 84(2):73-9
- 123. Kim MJ, Kim EK, Kwak JY, Park CS, Chung WY, Nam KH et al. Differentiation of thyroid nodules with macrocalcifications: role of suspicious sonographic findings. Journal of Ultrasound in Medicine. 2008; 27(8):1179-84
- 42 124. Kim SC, Kim JH, Choi SH, Yun TJ, Wi JY, Kim SA et al. Off-site evaluation of three43 dimensional ultrasound for the diagnosis of thyroid nodules: comparison with two44 dimensional ultrasound. European Radiology. 2016; 26(10):3353-60

- 125. Kim SH, Park CS, Jung SL, Kang BJ, Kim JY, Choi JJ et al. Observer variability and the performance between faculties and residents: US criteria for benign and malignant thyroid nodules. Korean Journal of Radiology. 2010; 11(2):149-55
- 126. Kim SY, Kim EK, Moon HJ, Yoon JH, Kwak JY. Application of Texture Analysis in the Differential Diagnosis of Benign and Malignant Thyroid Nodules: Comparison With Gray-Scale Ultrasound and Elastography. AJR American Journal of Roentgenology. 2015; 205(3):W343-51
- 127. Kizilkaya MC, Erozgen F, Akinci M, Kaplan R, Tuzun S, Citlak G. The predictive value of elastography in thyroid nodules and its comparison with fine-needle aspiration biopsy results. Turkish Journal of Surgery. 2014; 30(3):147-52
 - 128. Ko MS, Jeong KS, Shong YK, Gong GY, Baek JH, Lee JH. Collapsing benign cystic nodules of the thyroid gland: sonographic differentiation from papillary thyroid carcinoma. AJNR: American Journal of Neuroradiology. 2012; 33(1):124-7
- 129. Koh J, Kim SY, Lee HS, Kim EK, Kwak JY, Moon HJ et al. Diagnostic performances and interobserver agreement according to observer experience: a comparison study using three guidelines for management of thyroid nodules. Acta Radiologica. 2018; 59(8):917-923
- 130. Koh J, Moon HJ, Park JS, Kim SJ, Kim HY, Kim EK et al. Variability in interpretation of ultrasound elastography and gray-scale ultrasound in assessing thyroid nodules. Ultrasound in Medicine and Biology. 2016; 42(1):51-9
 - 131. Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Kawamoto H et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Archives of Surgery. 2001; 136(3):334-7
 - 132. Koltin D, O'Gorman CS, Murphy A, Ngan B, Daneman A, Navarro OM et al. Pediatric thyroid nodules: ultrasonographic characteristics and inter-observer variability in prediction of malignancy. Journal of Pediatric Endocrinology and Metabolism. 2016; 29(7):789-94
 - 133. Koseoglu Atilla FD, Ozgen Saydam B, Erarslan NA, Diniz Unlu AG, Yilmaz Yasar H, Ozer M et al. Does the ACR TI-RADS scoring allow us to safely avoid unnecessary thyroid biopsy? single center analysis in a large cohort. Endocrine. 2018; 61(3):398-402
 - 134. Kunz W, Mismar A, Wille G, Ahmad R, Materazzi G, Miccoli P. Preoperative prediction of the risk of malignancy in thyroid nodules. Acta Medica Mediterranea. 2014; 30(2):329-334
 - 135. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011; 260(3):892-9
 - 136. Kwak JY, Jung I, Baek JH, Baek SM, Choi N, Choi YJ et al. Image reporting and characterization system for ultrasound features of thyroid nodules: multicentric Korean retrospective study. Korean Journal of Radiology. 2013; 14(1):110-7
- 137. Lai X, Zhang B, Jiang Y, Li J, Zhao R, Yang X et al. Sonographic and clinical features of papillary thyroid microcarcinoma less than or equal to five millimeters: A retrospective study. PloS One. 2016; 11(2):e0148567
- Lauria Pantano A, Maddaloni E, Briganti SI, Beretta Anguissola G, Perrella E, Taffon
 C et al. Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound
 classifications performance in identifying cytological high-risk thyroid nodules.
 European Journal of Endocrinology. 2018; 178(6):595-603

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17 18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

- 139. Lee YH, Kim DW, In HS, Park JS, Kim SH, Eom JW et al. Differentiation between benign and malignant solid thyroid nodules using an US classification system. Korean Journal of Radiology. 2011; 12(5):559-67
- 140. Li F, Wang Y, Bai B, Wang S, Liu S. Advantages of routine ultrasound combined with contrast-enhanced ultrasound in diagnosing papillary thyroid carcinoma. Ultrasound Quarterly. 2017; 33(3):213-218
- 141. Li F, Zhang J, Wang Y, Liu L. Clinical value of elasticity imaging and contrastenhanced ultrasound in the diagnosis of papillary thyroid microcarcinoma. Oncology Letters. 2015; 10(3):1371-1377
 - 142. Li HW, Wu XW, Liu B, Liu WD, Gao N. Clinical values of of gemstone spectral CT in diagnosing thyroid disease. Journal of X-Ray Science & Technology. 2015; 23(1):45-56
 - 143. Li J, Zhang M, Sheng L. The clinical value of real-time tissue elastography in diagnosing thyroid malignancy. International Journal of Clinical and Experimental Medicine. 2018; 11(2):824-829
- 144. Li JW, Chang C, Chen M, Zeng W, Gao Y, Zhou SC et al. Is Ultrasonography More Sensitive Than Computed Tomography for Identifying Calcifications in Thyroid Nodules? Journal of Ultrasound in Medicine. 2016; 35(10):2183-90
 - 145. Li L, Wang Y, Luo DH, Zhao YF, Lin M, Guo W et al. Diagnostic value of singlesource dual-energy spectral computed tomography for papillary thyroid microcarcinomas. Journal of X-Ray Science & Technology. 2017; 25(5):793-802
 - 146. Li L, Wang Y, Zhao Y, Zou S, Lin M, Yu X et al. Evaluation with low-dose dual-phase helical computed tomography of patients with thyroid lesions. Chinese Medical Journal. 2014; 127(22):3937-43
 - 147. Li T, Zhou P, Zhang X, Ding M, Yuchi M, Li Y. Diagnosis of thyroid nodules using virtual touch tissue quantification value and anteroposterior/transverse diameter ratio. Ultrasound in Medicine and Biology. 2015; 41(2):384-92
 - 148. Li WB, Zhang B, Zhu QL, Jiang YX, Sun J, Yang M et al. Comparison between thinslice 3-D volumetric ultrasound and conventional ultrasound in the differentiation of benign and malignant thyroid lesions. Ultrasound in Medicine and Biology. 2015; 41(12):3096-101
 - 149. Liang JY, Huang XW, Hu HT, Liu YH, Zhou Q, Cao QH et al. Predicting malignancy in thyroid nodules: Radiomics Score versus 2017 American College of Radiology (ACR) Thyroid Imaging, Reporting and Data System (TI-RADS). Thyroid. 2018; 28(8):1024-1033
- 150. Lim-Dunham JE, Erdem Toslak I, Alsabban K, Aziz A, Martin B, Okur G et al. Ultrasound risk stratification for malignancy using the 2015 American Thyroid Association Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Pediatric Radiology. 2017; 47(4):429-436
- 40151.Lim KJ, Choi CS, Yoon DY, Chang SK, Kim KK, Han H et al. Computer-aided41diagnosis for the differentiation of malignant from benign thyroid nodules on42ultrasonography. Academic Radiology. 2008; 15(7):853-8
- 43 152. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the
 44 thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology.
 45 Thyroid. 2005; 15(7):708-17

- 153. Lingam RK, Qarib MH, Tolley NS. Evaluating thyroid nodules: predicting and selecting malignant nodules for fine-needle aspiration (FNA) cytology. Insights Into Imaging. 2013; 4(5):617-24
- 154. Lippolis PV, Tognini S, Materazzi G, Polini A, Mancini R, Ambrosini CE et al. Is elastography actually useful in the presurgical selection of thyroid nodules with indeterminate cytology? Journal of Clinical Endocrinology and Metabolism. 2011; 96(11):E1826-30
- 155. Liu BJ, Zhao CK, Xu HX, Zhang YF, Xu JM, Li DD et al. Quality measurement on shear wave speed imaging: diagnostic value in differentiation of thyroid malignancy and the associated factors. Oncotarget. 2017; 8(3):4848-4959
 - 156. Liu BX, Xie XY, Liang JY, Zheng YL, Huang GL, Zhou LY et al. Shear wave elastography versus real-time elastography on evaluation thyroid nodules: a preliminary study. European Journal of Radiology. 2014; 83(7):1135-1143
- 157. Liu J, Zheng D, Li Q, Tang X, Luo Z, Yuan Z et al. A predictive model of thyroid malignancy using clinical, biochemical and sonographic parameters for patients in a multi-center setting. BMC Endocrine Disorders. 2018; 18(1):17
- 158. Liu MJ, Men YM, Zhang YL, Zhang YX, Liu H. Improvement of diagnostic efficiency in distinguishing the benign and malignant thyroid nodules via conventional ultrasound combined with ultrasound contrast and elastography. Oncology Letters. 2017; 14(1):867-871
 - 159. Liu YI, Kamaya A, Desser TS, Rubin DL. A bayesian network for differentiating benign from malignant thyroid nodules using sonographic and demographic features. AJR American Journal of Roentgenology. 2011; 196(5):W598-605
 - 160. Lu C, Chang TC, Hsiao YL, Kuo MS. Ultrasonographic findings of papillary thyroid carcinoma and their relation to pathologic changes. Journal of the Formosan Medical Association. 1994; 93(11-12):933-8
 - Lu Z, Mu Y, Zhu H, Luo Y, Kong Q, Dou J et al. Clinical value of using ultrasound to assess calcification patterns in thyroid nodules. World Journal of Surgery. 2011; 35(1):122-7
 - 162. Luo S, Kim EH, Dighe M, Kim Y. Thyroid nodule classification using ultrasound elastography via linear discriminant analysis. Ultrasonics. 2011; 51(4):425-31
- 163. Luo S, Lim DJ, Kim Y. Objective ultrasound elastography scoring of thyroid nodules using spatiotemporal strain information. Medical Physics. 2012; 39(3):1182-9
- 164. Lyshchik A, Drozd V, Demidchik Y, Reiners C. Diagnosis of thyroid cancer in children: value of gray-scale and power doppler US. Radiology. 2005; 235(2):604-13
- 165. Ma JJ, Ding H, Xu BH, Xu C, Song LJ, Huang BJ et al. Diagnostic performances of various gray-scale, color Doppler, and contrast-enhanced ultrasonography findings in predicting malignant thyroid nodules. Thyroid. 2014; 24(2):355-63
- 166. Macedo BM, Izquierdo RF, Golbert L, Meyer ELS. Reliability of Thyroid Imaging Reporting and Data System (TI-RADS), and ultrasonographic classification of the American Thyroid Association (ATA) in differentiating benign from malignant thyroid nodules. Archives of Endocrinology & Metabolism. 2018; 62(2):131-138
- 43167.Maia FF, Matos PS, Pavin EJ, Vassallo J, Zantut-Wittmann DE. Value of ultrasound44and cytological classification system to predict the malignancy of thyroid nodules with45indeterminate cytology. Endocrine Pathology. 2011; 22(2):66-73

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 33

34

35

36

37

38

39

40

- 168. Maia FFR, Matos PS, Silva BP, Pallone AT, Pavin EJ, Vassallo J et al. Role of ultrasound, clinical and scintigraphyc parameters to predict malignancy in thyroid nodule. Head and Neck Oncology. 2011; 3:17
- 169. Maimaiti Y, Sun S, Liu Z, Zeng W, Liu CP, Wang S et al. Diagnostic accuracy of ultrasonographic features for benign and malignant thyroid nodules smaller than 10 mm. International Journal of Clinical and Experimental Medicine. 2016; 9(3):6476-6482
- 170. Maino F, Forleo R, Martinelli M, Fralassi N, Barbato F, Pilli T et al. Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism. 2018; 103(6):2362-2368
 - 171. Majstorov V. Ultrasonographic findings in patients with benign and malignant thyroid nodules who underwent ultrasound guided fine needle aspiration cytology. Open Access Macedonian Journal of Medical Sciences. 2015; 3(4):689-93
- 172. Mallikarjunappa B, Ashish SR. Ultrasound evaluation of thyroid nodules and its pathological correlation. Journal International Medical Sciences Academy. 2014; 27(1):9-11
- 173. Mansor M, Okasha H, Esmat S, Hashem AM, Attia KA, El-din Hussein H. Role of ultrasound elastography in prediction of malignancy in thyroid nodules. Endocrine Research. 2012; 37(2):67-77
 - 174. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Annals of Internal Medicine. 2000; 133(9):696-700
 - 175. Martinez-Rios C, Daneman A, Bajno L, van der Kaay DCM, Moineddin R, Wasserman JD. Utility of adult-based ultrasound malignancy risk stratifications in pediatric thyroid nodules. Pediatric Radiology. 2018; 48(1):74-84
 - 176. Mehrotra P, McQueen A, Kolla S, Johnson SJ, Richardson DL. Does elastography reduce the need for thyroid FNAs? Clinical Endocrinology. 2013; 78(6):942-9
 - 177. Memon I, Talpur MKB, Shaikh ZI, Talpur MO. Evaluation of ultrasonography and fine needle aspiration cytology in diagnosing thyroid nodules. Medical Forum Monthly. 2017; 28(5):69-73
 - 178. Merino S, Arrazola J, Cardenas A, Mendoza M, De Miguel P, Fernandez C et al. Utility and interobserver agreement of ultrasound elastography in the detection of malignant thyroid nodules in clinical care. AJNR: American Journal of Neuroradiology. 2011; 32(11):2142-8
- 179. Middleton WD, Teefey SA, Reading CC, Langer JE, Beland MD, Szabunio MM et al. Multiinstitutional Analysis of Thyroid Nodule Risk Stratification Using the American College of Radiology Thyroid Imaging Reporting and Data System. AJR American Journal of Roentgenology. 2017; 208(6):1331-1341
- 180. Migda B, Migda M, Migda AM, Bierca J, Slowinska-Srzednicka J, Jakubowski W et al. Evaluation of four variants of the thyroid imaging reporting and data system (TIRADS) classification in patients with multinodular goitre - initial study. Endokrynologia Polska. 2018; 69(2):156-162
- 43181.Migda B, Migda M, Migda MS, Slapa RZ. Use of the Kwak Thyroid Image Reporting44and Data System (K-TIRADS) in differential diagnosis of thyroid nodules: systematic45review and meta-analysis. European Radiology. 2018; 28(6):2380-2388

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24 25

26

27

28

29

30

31

32

33

34

35

36

37

38

39 40

- 182. Mohamed RE, Abodewan KA. Diagnostic utility of real-time ultrasound elastography for prediction of malignancy in solid thyroid nodules. Egyptian Journal of Radiology and Nuclear Medicine. 2013; 44(1):33-43
- 183. Mohammadi A, Hajizadeh T. Evaluation of diagnostic efficacy of ultrasound scoring system to select thyroid nodules requiring fine needle aspiration biopsy. International Journal of Clinical and Experimental Medicine. 2013; 6(8):641-8
- 184. Mohey N, Hassan TA, Abdel-Baki S. Role of combined grey scale US and US tissue elastography in differentiating solid thyroid nodules. Egyptian Journal of Radiology and Nuclear Medicine. 2013; 44(3):505-512
 - 185. Moon HG, Jung EJ, Park ST, Ha WS, Choi SK, Hong SC et al. Role of ultrasonography in predicting malignancy in patients with thyroid nodules. World Journal of Surgery. 2007; 31(7):1410-6
 - 186. Moon HJ, Kwak JY, Kim EK, Kim MJ. A taller-than-wide shape in thyroid nodules in transverse and longitudinal ultrasonographic planes and the prediction of malignancy. Thyroid. 2011; 21(11):1249-53
- 187. Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology. 2010; 255(1):260-9
 - 188. Moon HJ, Sung JM, Kim EK, Yoon JH, Youk JH, Kwak JY. Diagnostic performance of gray-scale US and elastography in solid thyroid nodules. Radiology. 2012; 262(3):1002-13
 - Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH et al. Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology. 2008; 247(3):762-70
 - 190. Na DG, Baek JH, Sung JY, Kim JH, Kim JK, Choi YJ et al. Thyroid imaging reporting and data system risk stratification of thyroid nodules: Categorization based on solidity and echogenicity. Thyroid. 2016; 26(4):562-72
 - 191. Nachiappan M, Poornima V, Kumar A, Prabhu SD, Chouhan RRS. Role of ultrasonography and ultrasound elastography in the evaluation of thyroid nodules. Journal of Clinical and Diagnostic Research. 2018; 12(12):TC13-TC17
 - 192. Nam SJ, Yoo J, Lee HS, Kim EK, Moon HJ, Yoon JH et al. Quantitative Evaluation for Differentiating Malignant and Benign Thyroid Nodules Using Histogram Analysis of Grayscale Sonograms. Journal of Ultrasound in Medicine. 2016; 35(4):775-82
 - 193. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview
 - 194. Nemec U, Nemec SF, Novotny C, Weber M, Czerny C, Krestan CR. Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. European Radiology. 2012; 22(6):1357-65
- 42 195. Nixon IJ, Ganly I, Hann LE, Lin O, Yu C, Brandt S et al. Nomogram for predicting
 43 malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and
 44 cytologic features. Surgery. 2010; 148(6):1120-7; discussion 1127-8

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17 18

19

20

21

22 23

24

25

26

27

28

29

30

31 32

33

34

35

36

37

38

39

40

41

42

- 196. Nixon IJ, Ganly I, Hann LE, Yu C, Palmer FL, Whitcher MM et al. Nomogram for selecting thyroid nodules for ultrasound-guided fine-needle aspiration biopsy based on a quantification of risk of malignancy. Head and Neck. 2013; 35(7):1022-5
 - 197. Nobrega LH, Paiva FJ, Nobrega ML, Mello LE, Fonseca HA, Costa SO et al. Predicting malignant involvement in a thyroid nodule: role of ultrasonography. Endocrine Practice. 2007; 13(3):219-24
- 198. Noda Y, Kanematsu M, Goshima S, Kondo H, Watanabe H, Kawada H et al. MRI of the thyroid for differential diagnosis of benign thyroid nodules and papillary carcinomas. AJR American Journal of Roentgenology. 2015; 204(3):W332-5
 - 199. Nonchev BI, Danev VH, Argatska AV, Miteva MJ, Mateva NG, Orbetzova MM. Prognostic model for ultrasound assessment of malignancy risk of thyroid nodules. Endokrinologya. 2017; 22(3):160-165
 - 200. Okamoto T. Erratum: Test performances of three diagnostic procedures in evaluating thyroid nodules: Physical examination, ultrasonography and fine needle aspiration cytology. Endocrine Journal. 1995; 42(4):x
- 201. Okamoto T, Yamashita T, Harasawa A, Kanamuro T, Aiba M, Kawakami M et al. Test performances of three diagnostic procedures in evaluating thyroid nodules: physical examination, ultrasonography and fine needle aspiration cytology. Endocrine Journal. 1994; 41(3):243-7
 - 202. Okasha H, Elkholy S, Sayed M, El-Sherbiny M, El-Hussieny R, El-Gemeie E et al. Ultrasound, endoscopic ultrasound elastography, and the strain ratio in differentiating benign from malignant lymph nodes. Arab Journal of Gastroenterology. 2018; 19(1):7-15
 - 203. Oliveira CM, Costa RA, Patricio M, Estevao A, Graca B, Caseiro-Alves F. Sonographic Criteria Predictive of Malignant Thyroid Nodules: Which Lesions Should be Biopsied? Academic Radiology. 2018; 25(2):213-218
 - 204. Ozel A, Erturk SM, Ercan A, Yilmaz B, Basak T, Cantisani V et al. The diagnostic efficiency of ultrasound in characterization for thyroid nodules: how many criteria are required to predict malignancy? Medical Ultrasonography. 2012; 14(1):24-8
 - 205. Palaniappan MK, Aiyappan SK, Ranga U. Role of gray scale, color doppler and spectral doppler in differentiation between malignant and benign thyroid nodules. Journal of Clinical and Diagnostic Research. 2016; 10(8):TC01-TC06
 - 206. Pandey NN, Pradhan GS, Manchanda A, Garg A. Diagnostic value of acoustic radiation force impulse quantification in the differentiation of benign and malignant thyroid nodules. Ultrasonic Imaging. 2017; 39(5):326-336
- 207. Pandya A, Caoili EM, Jawad-Makki F, Wasnik AP, Shankar PR, Bude R et al. Limitations of the 2015 ATA Guidelines for Prediction of Thyroid Cancer: A Review of 1947 Consecutive Aspirations. Journal of Clinical Endocrinology and Metabolism. 2018; 103(9):3496-3502
- 208. Pang T, Huang L, Deng Y, Wang T, Chen S, Gong X et al. Logistic regression analysis of conventional ultrasonography, strain elastosonography, and contrastenhanced ultrasound characteristics for the differentiation of benign and malignant thyroid nodules. PloS One. 2017; 12(12):e0188987
- 209. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F et al. Risk of
 malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and colorDoppler features. Journal of Clinical Endocrinology and Metabolism. 2002;
 87(5):1941-6

2

3

4 5

6

7

8

9

10

11 12

13

14

15

16

17 18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

38

39

40

- 210. Park AY, Son EJ, Han K, Youk JH, Kim JA, Park CS. Shear wave elastography of thyroid nodules for the prediction of malignancy in a large scale study. European Journal of Radiology. 2015; 84(3):407-412
- 211. Park JW, Kim DW, Kim D, Baek JW, Lee YJ, Baek HJ. Korean thyroid imaging reporting and data system features of follicular thyroid adenoma and carcinoma: A single-center study. Ultrasonography. 2017; 36(4):349-354
- 212. Park JY, Lee HJ, Jang HW, Kim HK, Yi JH, Lee W et al. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid. 2009; 19(11):1257-1264
 - 213. Park M, Shin JH, Han BK, Ko EY, Hwang HS, Kang SS et al. Sonography of thyroid nodules with peripheral calcifications. Journal of Clinical Ultrasound. 2009; 37(6):324-8
 - 214. Park SJ, Park SH, Choi YJ, Kim DW, Son EJ, Lee HS et al. Interobserver variability and diagnostic performance in US assessment of thyroid nodule according to size. Ultraschall in der Medizin. 2012; 33(7):E186-190
- 215. Park SY, Hahn SY, Shin JH, Ko EY, Oh YL. The diagnostic performance of thyroid us in each category of the bethesda system for reporting thyroid cytopathology. PloS One. 2016; 11(6):e0155898
 - 216. Pathirana AA, Bandara KG, Faleel MA, Kuruppumullage SD, Solangarachchi N, Rupasinghe RD et al. A sonographic scoring system to assess the risk of thyroid malignancy. Ceylon Medical Journal. 2016; 61(1):32-4
 - 217. Peccin S, de Castsro JA, Furlanetto TW, Furtado AP, Brasil BA, Czepielewski MA. Ultrasonography: is it useful in the diagnosis of cancer in thyroid nodules? Journal of Endocrinological Investigation. 2002; 25(1):39-43
 - 218. Persichetti A, Di Stasio E, Guglielmi R, Bizzarri G, Taccogna S, Misischi I et al. Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems: A Prospective Study. Journal of Clinical Endocrinology and Metabolism. 2018; 103(4):1359-1368
 - 219. Petrone L, Mannucci E, De Feo ML, Parenti G, Biagini C, Panconesi R et al. A simple ultrasound score for the identification of candidates to fine needle aspiration of thyroid nodules. Journal of Endocrinological Investigation. 2012; 35(8):720-4
 - 220. Phuttharak W, Somboonporn C, Hongdomnern G. Diagnostic performance of grayscale versus combined gray-scale with colour doppler ultrasonography in the diagnosis of malignancy in thyroid nodules. Asian Pacific Journal of Cancer Prevention: Apjcp. 2009; 10(5):759-64
- 221. Pompili GG, Tresoldi S, Ravelli A, Primolevo A, Leo GD, Carrafiello G. Use of the ultrasound-based total malignancy score in the management of thyroid nodules. Ultrasonography. 2018; 37(4):315-322
 - 222. Popli MB, Rastogi A, Bhalla P, Solanki Y. Utility of gray-scale ultrasound to differentiate benign from malignant thyroid nodules. Indian Journal of Radiology & Imaging. 2012; 22(1):63-8
- 42223.Popowicz B, Klencki M, Lewinski A, Slowinska-Klencka D. The usefulness of43sonographic features in selection of thyroid nodules for biopsy in relation to the44nodule's size. European Journal of Endocrinology. 2009; 161(1):103-11
- 45 224. Ragazzoni F, Deandrea M, Mormile A, Ramunni MJ, Garino F, Magliona G et al. High
 46 diagnostic accuracy and interobserver reliability of real-time elastography in the

1 evaluation of thyroid nodules. Ultrasound in Medicine and Biology. 2012; 38(7):1154-2 62 3 225. Raggiunti B, Capone F, Franchi A, Fiore G, Filipponi S, Colagrande V et al. Ultrasoundelastography: Can it provide valid information for differentiation of benign 4 and malignant thyroid nodules? Journal of Ultrasound. 2011; 14(3):136-41 5 Raghavendra U, Rajendra Acharya U, Gudigar A, Hong Tan J, Fujita H, Hagiwara Y 6 226. 7 et al. Fusion of spatial gray level dependency and fractal texture features for the 8 characterization of thyroid lesions. Ultrasonics. 2017; 77:110-120 Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P et al. Combined clinical, 9 227. thyroid ultrasound and cytological features help to predict thyroid malignancy in 10 follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 11 12 consecutive patients. Clinical Endocrinology. 2007; 66(1):13-20 13 228. Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in 14 ultrasound for predicting malignancy in thyroid nodules. Journal of Clinical 15 Endocrinology and Metabolism. 2007; 92(8):2917-22 229. Rago T, Scutari M, Loiacono V, Santini F, Tonacchera M, Torregrossa L et al. Low 16 elasticity of thyroid nodules on ultrasound elastography is correlated with malignancy. 17 18 degree of fibrosis, and high expression of Galectin-3 and Fibronectin-1. Thyroid. 2017; 27(1):103-110 19 20 230. Rago T, Vitti P, Chiovato L, Mazzeo S, De Liperi A, Miccoli P et al. Role of conventional ultrasonography and color flow-doppler sonography in predicting 21 malignancy in 'cold' thyroid nodules. European Journal of Endocrinology. 1998; 22 23 138(1):41-6 24 231. Rahal AJ, Falsarella PM, Rocha RD, Lima JP, Iani MJ, Vieira FA et al. Correlation of 25 Thyroid Imaging Reporting and Data System [TI-RADS] and fine needle aspiration: 26 experience in 1,000 nodules. Einstein. 2016; 14(2):119-23 27 232. Ram N, Hafeez S, Qamar S, Hussain SZ, Asghar A, Anwar Z et al. Diagnostic validity 28 of ultrasonography in thyroid nodules. JPMA - Journal of the Pakistan Medical 29 Association. 2015; 65(8):875-8 30 233. Rao G, Rao S, Varma R, Bhagwat NM, Chadha MD, Joshi AS et al. Predicting 31 malignancy in a solitary thyroid nodule: A prospective study on the role of color 32 Doppler ultrasonography. Otorhinolaryngology Clinics. 2014; 6(1):9-14 33 234. Razavi SA, Hadduck TA, Sadigh G, Dwamena BA. Comparative effectiveness of elastographic and B-mode ultrasound criteria for diagnostic discrimination of thyroid 34 35 nodules: a meta-analysis (Provisional abstract). AJR American Journal of 36 Roentgenology. 2013; 200(6):1317-1326 37 235. Razek AA, Sadek AG, Kombar OR, Elmahdy TE, Nada N. Role of apparent diffusion 38 coefficient values in differentiation between malignant and benign solitary thyroid 39 nodules. AJNR: American Journal of Neuroradiology. 2008; 29(3):563-8 40 236. Refaat R, Kamel A, Elganzory M, Awad NM. Can real-time ultrasound elastography 41 using the color score and strain ratio differentiate between benign and malignant 42 solitary thyroid nodules? Egyptian Journal of Radiology and Nuclear Medicine. 2014; 43 45(1):75-87 44 237. Reginelli A, Urraro F, di Grezia G, Napolitano G, Maggialetti N, Cappabianca S et al. Conventional ultrasound integrated with elastosonography and B-flow imaging in the 45 46 diagnosis of thyroid nodular lesions. International Journal of Surgery. 2014; 12(Suppl 47 1):S117-22

Rios A, Rodriguez JM, Torregrosa NM, Torregrosa B, Cepero A, Abellan MD et al. 1 238. 2 Evaluation of the thyroid nodule with high-resolution ultrasonography and 3 elastography without fine needle aspiration biopsy. Medicina Clínica. 2018; 4 151(3):89-96 5 239. Rios A, Torregrosa B, Rodriguez JM, Rodriguez D, Cepero A, Abellan MD et al. Ultrasonographic risk factors of malignancy in thyroid nodules. Langenbeck's 6 7 Archives of Surgery. 2016; 401(6):839-849 8 240. Rivo-Vazquez A, Rodriguez-Lorenzo A, Rivo-Vazquez JE, Paramo-Fernandez C, Garcia-Lorenzo F, Pardellas-Rivera H et al. The use of ultrasound elastography in the 9 assessment of malignancy risk in thyroid nodules and multinodular goitres. Clinical 10 11 Endocrinology. 2013; 79(6):887-91 12 241. Rosario PW, Da Silva AL, Nunes MB, Borges MAR. Risk of Malignancy in Thyroid 13 Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System in the NIFTP Era. Hormone and Metabolic Research. 2018; 50(10):735-14 15 737 16 242. Rosario PW, Silva AL, Borges MA, Calsolari MR. Is Doppler ultrasound of additional value to gray-scale ultrasound in differentiating malignant and benign thyroid 17 18 nodules? Archives of Endocrinology & Metabolism. 2015; 59(1):79-83 19 243. Russ G, Bienvenu-Perrard M, Rouxel A, Royer B, Bigorgne C. Ti-RADS score: Clinical efficiency evaluated with the Bethesda system in a one-year prospective 20 study on 2480 nodules. European Thyroid Journal. 2011; Conference Publication:96 21 Russ G, Rouxel A, Bienvenu-Perrard M, Bigorgne C, Royer B. Do ultrasound and 22 244. 23 elastographic patterns of thyroid carcinomas vary with their size? European Thyroid 24 Journal. 2011; Conference Publication:157 25 245. Sagazio A, Bucci I, Olivieri M, Di Dalmazi G, Carpenito A, Giuliani C et al. Real time 26 elastosonography versus cytology: Diagnostic role in thyroid lesions. Endocrine 27 Reviews Conference: 96th Annual Meeting and Expo of the Endocrine Society, 28 ENDO. 2014; 35(SUPPL. 3) 29 246. Sahbaz NA, Dural AC, Akarsu C, Akbulut S, Turkay R, Baytekin HF et al. Feasibility of thyroid imaging reporting and data system (TIRADS) classification in predicting 30 31 thyroid malignancy. Langenbeck's Archives of Surgery. 2017; 402(2):360-361 32 247. Saito OC, Chammas MC, Tochetto S, Cerri GG. Elastography of thyroid nodules: 33 Which elastography index can predict malignancy? Ultrasound in Medicine and 34 Biology. 2015; 41(4 Suppl):S37-S38 35 248. Sajjadieh HR, Sajjadieh V, Aminorroaya A, Amini M, Oveisgharan S, Reisifar M et al. Value of sonography in determining the nature of thyroid nodules: Evaluation of the 36 37 sonographic characteristics. Journal of Diagnostic Medical Sonography. 2005; 38 21(1):38-44 39 249. Salehi M, Nalaini F, Izadi B, Setayeshi K, Rezaei M, Naseri SN. Gray-scale vs. color doppler ultrasound in cold thyroid nodules. Global Journal of Health Science. 2014; 40 41 7(3):147-52 42 250. Salmaslioglu A, Erbil Y, Dural C, Issever H, Kapran Y, Ozarmagan S et al. Predictive 43 value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World Journal of Surgery. 2008; 32(9):1948-54 44 Samulski TD, Shutty C, LiVolsi VA, Montone K, Baloch Z. The reliability of thyroid 45 251. 46 nodule ultrasound features and size to predict malignancy in fine needle aspiration

2

3

4

5 6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 27

28

29

30 31

32

33

34

35

36 37

38

39

40

41

42

43

44

specimens: Practical utility for the evaluating pathologist. Diagnostic Cytopathology. 2015; 43(6):471-7

- 252. Sands NB, Karls S, Amir A, Tamilia M, Gologan O, Rochon L et al. McGill Thyroid Nodule Score (MTNS): "Rating the risk," a novel predictive scheme for cancer risk determination. Journal of Otolaryngology - Head and Neck Surgery. 2011; 40(SUPPL. 1):S1-S13
- 253. Sarabia JJU, Agno MN, Fabile JL, Delos Santos NC. Role of ultrasound in evaluation and differentiation of benign from malignant thyroid nodules using thyroid imaging reporting and data system in a tertiary government hospital. Journal of the American College of Surgeons. 2017; 225(Supplement 2):e94-e95
 - 254. Schenke S, Rink T, Zimny M. TIRADS for sonographic assessment of hypofunctioning and indifferent thyroid nodules. Nuklearmedizin. 2015; 54(3):144-50
 - 255. Schenke S, Seifert P, Zimny M, Winkens T, Binse I, Gorges R. Risk Stratification of Thyroid Nodules Using the Thyroid Imaging Reporting and Data System (TIRADS): The Omission of Thyroid Scintigraphy Increases the Rate of Falsely Suspected Lesions. Journal of Nuclear Medicine. 2019; 60(3):342-347
- 256. Schueller-Weidekamm C, Kaserer K, Schueller G, Scheuba C, Ringl H, Weber M et al. Can quantitative diffusion-weighted MR imaging differentiate benign and malignant cold thyroid nodules? Initial results in 25 patients. AJNR: American Journal of Neuroradiology. 2009; 30(2):417-22
 - 257. Sebag F, Vaillant-Lombard J, Berbis J, Griset V, Henry JF, Petit P et al. Shear wave elastography: a new ultrasound imaging mode for the differential diagnosis of benign and malignant thyroid nodules. Journal of Clinical Endocrinology and Metabolism. 2010; 95(12):5281-8
 - 258. Seo H, Na DG, Kim JH, Kim KW, Yoon JW. Ultrasound-Based Risk Stratification for Malignancy in Thyroid Nodules: A Four-Tier Categorization System. European Radiology. 2015; 25(7):2153-62
 - 259. Seo JK, Kim YJ, Kim KG, Shin I, Shin JH, Kwak JY. Differentiation of the Follicular Neoplasm on the Gray-Scale US by Image Selection Subsampling along with the Marginal Outline Using Convolutional Neural Network. BioMed Research International. 2017; 2017:3098293
 - 260. Seo YL, Yoon DY, Yoon SJ, Lim KJ, Yun EJ, Choi CS et al. Compressibility of thyroid masses: a sonographic sign differentiating benign from malignant lesions? AJR American Journal of Roentgenology. 2012; 198(2):434-8
- 261. Shankar K, Kumar MV, Kumar MVV, S K. Ultrasound of the thyroid: A preoperative tool to assess the risk of malignancy. European Journal of Cancer. 2015; 51(Suppl 3):S574
- 262. Shao J, Shen Y, Lu J, Wang J. Ultrasound scoring in combination with ultrasound elastography for differentiating benign and malignant thyroid nodules. Clinical Endocrinology. 2015; 83(2):254-60
- 263. Shi HF, Feng Q, Qiang JW, Li RK, Wang L, Yu JP. Utility of diffusion-weighted imaging in differentiating malignant from benign thyroid nodules with magnetic resonance imaging and pathologic correlation. Journal of Computer Assisted Tomography. 2013; 37(4):505-10
- 45 264. Shimura H, Haraguchi K, Hiejima Y, Fukunari N, Fujimoto Y, Katagiri M et al. Distinct
 46 diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a
 47 multicenter study. Thyroid. 2005; 15(3):251-8

- 265. Shrestha M, Crothers BA, Burch HB. The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution. Thyroid. 2012; 22(12):1251-6
- Shuzhen C. Comparison analysis between conventional ultrasonography and ultrasound elastography of thyroid nodules. European Journal of Radiology. 2012; 81(8):1806-11
- 267. Siderova MV, Hristozov K, Krasnaliev I. Differential diagnosis of thyroid nodules using strain ultrasound elastography. European Thyroid Journal. 2016; 5 (Suppl 1):159-160
- 268. Simon D, Hetkamp P, Farahati J, Hautzel H, Gorges R. Diagnostic assessment of dignity of thyroid nodules: The role of scintigraphy and FNAB with application of TIRADS. Langenbeck's Archives of Surgery. 2017; 402(7):1139
 - 269. Singaporewalla RM, Hwee J, Lang TU, Desai V. Clinico-pathological correlation of thyroid nodule ultrasound and cytology using the TIRADS and Bethesda classifications. World Journal of Surgery. 2017; 41(7):1807-1811
 - 270. Stacul F, Bertolotto M, De Gobbis F, Calderan L, Cioffi V, Romano A et al. US, colour-Doppler US and fine-needle aspiration biopsy in the diagnosis of thyroid nodules. Radiologia Medica. 2007; 112(5):751-62
 - 271. Stoian D, Timar B, Derban M, Pantea S, Varcus F, Craina M et al. Thyroid Imaging Reporting and Data System (TI-RADS): the impact of quantitative strain elastography for better stratification of cancer risks. Medical Ultrasonography. 2015; 17(3):327-32
 - 272. Sui X, Liu HJ, Jia HL, Fang QM. Contrast-enhanced ultrasound and real-time elastography in the differential diagnosis of malignant and benign thyroid nodules. Experimental and Therapeutic Medicine. 2016; 12(2):783-791
 - 273. Sun J, Cai J, Wang X. Real-time ultrasound elastography for differentiation of benign and malignant thyroid nodules: a meta-analysis (Provisional abstract). Journal of Ultrasound in Medicine. 2014; 33(3):495-502
 - 274. Swan KZ, Nielsen VE, Bibby BM, Bonnema SJ. Is the reproducibility of shear wave elastography of thyroid nodules high enough for clinical use? A methodological study. Clinical Endocrinology. 2017; 86(4):606-613
 - 275. Szczepanek-Parulska E, Wolinski K, Stangierski A, Gurgul E, Biczysko M, Majewski P et al. Comparison of diagnostic value of conventional ultrasonography and shear wave elastography in the prediction of thyroid lesions malignancy. PloS One. 2013; 8(11):e81532
- 276. Tae HJ, Lim DJ, Baek KH, Park WC, Lee YS, Choi JE et al. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid. 2007; 17(5):461-6
 - 277. Taghipour Zahir S, Binesh F, Mirouliaei M, Khajeh E, Noshad S. Malignancy risk assessment in patients with thyroid nodules using classification and regression trees. Journal of Thyroid Research. 2013; 2013:983953
- 278. Taha Ali TF. Solitary thyroid nodule: Diagnostic yield of combined diffusion weighted imaging and magnetic resonance spectroscopy. Egyptian Journal of Radiology and Nuclear Medicine. 2017; 48(3):593-601
- 43 279. Tahmasebi M, Dezfouli MRB, Gharibvand MM, Jahanshahi A, Nikpour N, Rahim F.
 44 Diagnostic accuracy of sonography in assessment of thyroid masses in comparison 45 with pathology. Russian Open Medical Journal. 2016; 5(1):e0103

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 27

28

29

30 31

32

33

34

35

36

37

38

39

40

41

42

- 280. Tamsel S, Demirpolat G, Erdogan M, Nart D, Karadeniz M, Uluer H et al. Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules. Clinical Radiology. 2007; 62(3):245-51
- 281. Tang AL, Falciglia M, Yang H, Mark JR, Steward DL. Validation of american thyroid association ultrasound risk assessment of thyroid nodules selected for ultrasound fine-needle aspiration. Thyroid. 2017; 27(8):1077-1082
- 282. Tatar IG, Kurt A, Yilmaz KB, Akinci M, Kulacoglu H, Hekimoglu B. The learning curve of real time elastosonography: a preliminary study conducted for the assessment of malignancy risk in thyroid nodules. Medical Ultrasonography. 2013; 15(4):278-84
 - 283. Tatar IG, Kurt A, Yilmaz KB, Dogan M, Hekimoglu B, Hucumenoglu S. The role of elastosonography, gray-scale and colour flow Doppler sonography in prediction of malignancy in thyroid nodules. Radiology & Oncology. 2014; 48(4):348-53
 - 284. Tezelman S, Giles Y, Tunca F, Gok K, Poyanli A, Salmaslioglu A et al. Diagnostic value of dynamic contrast medium enhanced magnetic resonance imaging in preoperative detection of thyroid carcinoma. Archives of Surgery. 2007; 142(11):1036-41
- 285. Trimboli P, Guglielmi R, Monti S, Misischi I, Graziano F, Nasrollah N et al. Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism. 2012; 97(12):4524-30
 - 286. Tugendsam C, Petz V, Buchinger W, Schmoll-Hauer B, Schenk IP, Rudolph K et al. Ultrasound criteria for risk stratification of thyroid nodules in the previously iodine deficient area of Austria a single centre, retrospective analysis. Thyroid research. 2018; 11:3
 - 287. Tunca F, Giles Y, Salmaslioglu A, Poyanli A, Yilmazbayhan D, Terzioglu T et al. The preoperative exclusion of thyroid carcinoma in multinodular goiter: Dynamic contrastenhanced magnetic resonance imaging versus ultrasonography-guided fine-needle aspiration biopsy. Surgery. 2007; 142(6):992-1002; discussion 1002.e1-2
 - 288. Tuzun D, Ersoy R, Kilicyazgan A, Kiyak G, Yalcin S, Cakir B. Elastosonography scoring and strain index of thyroid nodules with Hurthle cells. Minerva Endocrinologica. 2016; 41(2):157-65
 - Unluturk U, Erdogan MF, Demir O, Gullu S, Baskal N. Ultrasound elastography is not superior to grayscale ultrasound in predicting malignancy in thyroid nodules. Thyroid. 2012; 22(10):1031-8
- 290. Vargas-Uricoechea H, Meza-Cabrera I, Herrera-Chaparro J. Concordance between the TIRADS ultrasound criteria and the BETHESDA cytology criteria on the nontoxic thyroid nodule. Thyroid research. 2017; 10:1
- 291. Varverakis E, Neonakis E. Contribution of high-resolution ultrasonography in the differential diagnosis of benign from malignant thyroid nodules. Hormones. 2002; 1(1):51-6
- 292. Veyrieres JB, Albarel F, Lombard JV, Berbis J, Sebag F, Oliver C et al. A threshold value in Shear Wave elastography to rule out malignant thyroid nodules: a reality? European Journal of Radiology. 2012; 81(12):3965-72
- 44293.Vidal-Casariego A, Lopez-Gonzalez L, Jimenez-Perez A, Ballesteros-Pomar MD,45Kyriakos G, Urioste-Fondo A et al. Accuracy of ultrasound elastography in the46diagnosis of thyroid cancer in a low-risk population. Experimental and clinical47endocrinology & diabetes. 2012; 120(10):635-638

- 294. Vorlander C, Wolff J, Saalabian S, Lienenluke RH, Wahl RA. Real-time ultrasound elastography--a noninvasive diagnostic procedure for evaluating dominant thyroid nodules. Langenbeck's Archives of Surgery. 2010; 395(7):865-71
- 295. Wang D, He YP, Zhang YF, Liu BJ, Zhao CK, Fu HJ et al. The diagnostic performance of shear wave speed (SWS) imaging for thyroid nodules with elasticity modulus and SWS measurement. Oncotarget. 2017; 8(8):13387-13399
- 296. Wang F, Chang C, Chen M, Gao Y, Chen YL, Zhou SC et al. Does Lesion Size Affect the Value of Shear Wave Elastography for Differentiating Between Benign and Malignant Thyroid Nodules? Journal of Ultrasound in Medicine. 2018; 37(3):601-609
- 297. Wang H, Brylka D, Sun LN, Lin YQ, Sui GQ, Gao J. Comparison of strain ratio with elastography score system in differentiating malignant from benign thyroid nodules. Clinical Imaging. 2013; 37(1):50-5
 - 298. Wang H, Zhao L, Xin X, Wei X, Zhang S, Li Y et al. Diagnostic value of elastosonography for thyroid microcarcinoma. Ultrasonics. 2014; 54(7):1945-9
- 299. Wang HL, Zhang S, Xin XJ, Zhao LH, Li CX, Mu JL et al. Application of Real-time Ultrasound Elastography in Diagnosing Benign and Malignant Thyroid Solid Nodules. Cancer Biology & Medicine. 2012; 9(2):124-7
- 300. Wang M, Wu WD, Chen GM, Chou SL, Dai XM, Xu JM et al. Could Tumor Size Be A Predictor for Papillary Thyroid Microcarcinoma: a Retrospective Cohort Study. Asian Pacific Journal of Cancer Prevention: Apjcp. 2015; 16(18):8625-8
 - 301. Wang N, Xu Y, Ge C, Guo R, Guo K. Association of sonographically detected calcification with thyroid carcinoma. Head and Neck. 2006; 28(12):1077-83
 - 302. Wang Y, Lei KR, He YP, Li XL, Ren WW, Zhao CK et al. Malignancy risk stratification of thyroid nodules: comparisons of four ultrasound Thyroid Imaging Reporting and Data Systems in surgically resected nodules. Scientific Reports. 2017; 7:11560
 - 303. Wang Y, Nie F, Liu T, Yang D, Li Q, Li J et al. Revised value of contrast-enhanced ultrasound for solid hypo-echoic thyroid nodules graded with the thyroid imaging reporting and data system. Ultrasound in Medicine and Biology. 2018; 44(5):930-940
 - 304. Wang Z, Zhang H, Zhang P, He L, Dong W. Diagnostic value of ultrasound-detected calcification in thyroid nodules. Annals of the Academy of Medicine, Singapore. 2014; 43(2):102-6
 - 305. Watters DA, Ahuja AT, Evans RM, Chick W, King WW, Metreweli C et al. Role of ultrasound in the management of thyroid nodules. American Journal of Surgery. 1992; 164(6):654-7
 - 306. Wei X, Li Y, Zhang S, Gao M. Thyroid imaging reporting and data system (TI-RADS) in the diagnostic value of thyroid nodules: a systematic review. Tumour Biology. 2014; 35(7):6769-6776
- 307. Wei X, Li Y, Zhang S, Gao M. Meta-analysis of thyroid imaging reporting and data system in the ultrasonographic diagnosis of 10,437 thyroid nodules. Head and Neck. 2016; 38(2):309-15
- 41308.Wei Y, Zhou X, Liu S, Wang H, Liu L, Liu R et al. Novel and practical scoring systems42for the diagnosis of thyroid nodules. PloS One. 2016; 11(9):e0163039
- 43309.Weiss VL, Andreotti RF, Ely KA. Use of the Thyroid Imaging, Reporting, and Data44System (TI-RADS) scoring system for the evaluation of subcentimeter thyroid45nodules. Cancer Cytopathology. 2018; 126(8):518-524

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16 17

18

19

20

21

22 23

24

25

26

27

28

29

30

31

32 33

34

35

36

37

38

39

40

41

- 310. Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME et al. Thyroid nodules (>=4 cm): can ultrasound and cytology reliably exclude cancer? World Journal of Surgery. 2014; 38(3):614-21
- 311. Witczak J, Taylor P, Chai J, Amphlett B, Soukias JM, Das G et al. Predicting malignancy in thyroid nodules: feasibility of a predictive model integrating clinical, biochemical, and ultrasound characteristics. Thyroid research. 2016; 9:4
- 312. Wu Q, Li J, Wu J, Li X, Chen C, Jiang N et al. Risk for malignancy of thyroid nodules based on ultrasound imaging characteristics. International Journal of Clinical and Experimental Medicine. 2016; 9(6):11817-11823
 - 313. Wu Q, Qu Y, Zang X, Li Y, Yi X, Wang Y et al. Preliminary study of confounding factors of elastography and the application of fine-needle aspiration in thyroid nodules with indeterminate elastography. Scientific Reports. 2017; 7:18005
 - 314. Wu Q, Wang Y, Li Y, Hu B, He ZY. Diagnostic value of contrast-enhanced ultrasound in solid thyroid nodules with and without enhancement. Endocrine. 2016; 53(2):480-8
- 315. Wu R, Zhu L, Li W, Tang Q, Pan F, Wu W et al. External validation of a nomogram that predicts the pathological diagnosis of thyroid nodules in a Chinese population. PloS One. 2013; 8(6):e65162
- 316. Xia J, Chen H, Li Q, Zhou M, Chen L, Cai Z et al. Ultrasound-based differentiation of malignant and benign thyroid Nodules: An extreme learning machine approach. Computer Methods and Programs in Biomedicine. 2017; 147:37-49
 - 317. Xing P, Chen Q, Yang ZW, Liu CB, Wu CJ. Combination of conventional ultrasound and tissue quantification using acoustic radiation force impulse technology for differential diagnosis of small thyroid nodules. International Journal of Clinical and Experimental Medicine. 2016; 9(5):8288-8295
 - 318. Xing P, Wu L, Zhang C, Li S, Liu C, Wu C. Differentiation of benign from malignant thyroid lesions: calculation of the strain ratio on thyroid sonoelastography. Journal of Ultrasound in Medicine. 2011; 30(5):663-9
 - 319. Xu JM, Xu HX, Xu XH, Liu C, Zhang YF, Guo LH et al. Solid hypo-echoic thyroid nodules on ultrasound: the diagnostic value of acoustic radiation force impulse elastography. Ultrasound in Medicine and Biology. 2014; 40(9):2020-30
 - 320. Xu JM, Xu HX, Zhang YF, Guo LH, Liu LN, Bo XW et al. Virtual Touch Tissue Imaging for Differential Diagnosis of Thyroid Nodules: Additional Value of the Area Ratio. Journal of Ultrasound in Medicine. 2016; 35(5):917-26
- 321. Xu JM, Xu XH, Xu HX, Zhang YF, Zhang J, Guo LH et al. Conventional US, US elasticity imaging, and acoustic radiation force impulse imaging for prediction of malignancy in thyroid nodules. Radiology. 2014; 272(2):577-86
 - 322. Xu SY, Zhan WW, Wang WH. Evaluation of Thyroid Nodules by a Scoring and Categorizing Method Based on Sonographic Features. Journal of Ultrasound in Medicine. 2015; 34(12):2179-85
 - 323. Xu T, Gu JY, Ye XH, Xu SH, Wu Y, Shao XY et al. Thyroid nodule sizes influence the diagnostic performance of TIRADS and ultrasound patterns of 2015 ATA guidelines: a multicenter retrospective study. Scientific Reports. 2017; 7:43183
- 324. Xu T, Wu Y, Wu RX, Zhang YZ, Gu JY, Ye XH et al. Validation and comparison of
 three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk
 determination. Endocrine. 2018; Epublication

2

3

4 5

6

7

8

9

10

11

12

13 14

15

16

17 18

19

20

21

22 23

24

25

26

27

28

29

30

31 32

33

34

35

36

37

38

- 325. Xue E, Zheng M, Zhang S, Huang L, Qian Q, Huang Y. Ultrasonography-Based Classification and Reporting System for the Malignant Risk of Thyroid Nodules. Journal of Nippon Medical School. 2017; 84(3):118-124
- 326. Xue J, Cao XL, Shi L, Lin CH, Wang J, Wang L. The diagnostic value of combination of TI-RADS and ultrasound elastography in the differentiation of benign and malignant thyroid nodules. Clinical Imaging. 2016; 40(5):913-6
- 327. Yang J, Song Y, Wei W, Ruan L, Ai H. Comparison of the effectiveness of ultrasound elastography with that of conventional ultrasound for differential diagnosis of thyroid lesions with suspicious ultrasound features. Oncology Letters. 2017; 14(3):3515-3521
 - 328. Yerli H, Yilmaz T. Diastolic sonoelastographic strain index for the management of thyroid nodules. Erciyes Medical Journal. 2017; 39(2):48-53
 - 329. Yoon JH, Han K, Kim EK, Moon HJ, Kwak JY. Diagnosis and management of small thyroid nodules: A comparative study with six guidelines for thyroid nodules. Radiology. 2017; 283(2):560-569
- 330. Yoon JH, Kim EK, Kwak JY, Park VY, Moon HJ. Application of various additional imaging techniques for thyroid ultrasound: Direct comparison of combined various elastography and Doppler parameters to gray-scale ultrasound in differential diagnosis of thyroid nodules. Ultrasound in Medicine and Biology. 2018; 44(8):1679-1686
- 331. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Malignancy risk stratification of thyroid nodules: Comparison between the thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association management guidelines. Radiology. 2016; 278(3):917-924
- 332. Yoon JH, Shin HJ, Kim EK, Moon HJ, Roh YH, Kwak JY. Quantitative evaluation of vascularity using 2-d power doppler ultrasonography may not identify malignancy of the thyroid. Ultrasound in Medicine and Biology. 2015; 41(11):2873-83
- 333. Yoon JH, Yoo J, Kim EK, Moon HJ, Lee HS, Seo JY et al. Real-time elastography in the evaluation of diffuse thyroid disease: a study based on elastography histogram parameters. Ultrasound in Medicine and Biology. 2014; 40(9):2012-9
 - 334. Yu Q, Jiang T, Zhou A, Zhang L, Zhang C, Xu P. Computer-aided diagnosis of malignant or benign thyroid nodes based on ultrasound images. European Archives of Oto-Rhino-Laryngology. 2017; 274(7):2891-2897
 - 335. Yuan Y, Yue XH, Tao XF. The diagnostic value of dynamic contrast-enhanced MRI for thyroid tumors. European Journal of Radiology. 2012; 81(11):3313-8
- 336. Yuan Z, Quan J, Yunxiao Z, Jian C, Zhu H. Contrast-enhanced ultrasound in the diagnosis of solitary thyroid nodules. Journal of Cancer Research and Therapeutics. 2015; 11(1):41-5
- 337. Yunus M, Ahmed Z. Significance of ultrasound features in predicting malignant solid thyroid nodules: need for fine-needle aspiration. JPMA - Journal of the Pakistan Medical Association. 2010; 60(10):848-53
- 338. Zayadeen AR, Abu-Yousef M, Berbaum K. Retrospective evaluation of ultrasound
 features of thyroid nodules to assess malignancy risk: A step toward tirads. American
 Journal of Roentgenology. 2016; 207(3):460-469
- 339. Zhan J, Diao XH, Chen L, Jin JM, Chen Y. Role of contrast-enhanced ultrasound in diagnosis of thyroid nodules in acoustic radiation force impulse "gray zone".
 Ultrasound in Medicine and Biology. 2017; 43(6):1179-1186

2

3

4

5

6

7

8

9

10

11

12

13 14

15

16

17 18

19

20

21

22 23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

- 340. Zhang B, Jiang YX, Liu JB, Yang M, Dai Q, Zhu QL et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid. 2010; 20(1):51-7
- 341. Zhang F, Zhao X, Han R, Du M, Li P, Ji X. Comparison of Acoustic Radiation Force Impulse Imaging and Strain Elastography in Differentiating Malignant From Benign Thyroid Nodules. Journal of Ultrasound in Medicine. 2017; 36(12):2533-2543
- 342. Zhang FJ, Han RL. The value of acoustic radiation force impulse (ARFI) in the differential diagnosis of thyroid nodules. European Journal of Radiology. 2013; 82(11):e686-90
- 343. Zhang FJ, Han RL, Zhao XM. The value of virtual touch tissue image (VTI) and virtual touch tissue quantification (VTQ) in the differential diagnosis of thyroid nodules. European Journal of Radiology. 2014; 83(11):2033-40
 - 344. Zhang H, Gu J, Xing J, Bai M, Gao F, Du L. Nodule size is a key factor for differentiating benign and malignant thyroid nodules using virtual touch tissue quantification and conventional sonography. International Journal of Clinical and Experimental Medicine. 2017; 10(5):7825-7833
- 345. Zhang H, Shi Q, Gu J, Jiang L, Bai M, Liu L et al. Combined value of Virtual Touch tissue quantification and conventional sonographic features for differentiating benign and malignant thyroid nodules smaller than 10 mm. Journal of Ultrasound in Medicine. 2014; 33(2):257-64
 - 346. Zhang J, Liu BJ, Xu HX, Xu JM, Zhang YF, Liu C et al. Prospective validation of an ultrasound-based thyroid imaging reporting and data system (TI-RADS) on 3980 thyroid nodules. International Journal of Clinical and Experimental Medicine. 2015; 8(4):5911-7
 - 347. Zhang S, Zheng XQ, Wei X, Zhao J, Zhang Y, Gao M. Evaluation of ultrasound application in diagnosis and clinical staging of thyroid cancers. Indian Journal of Cancer. 2014; 51(3):193-199
- 348. Zhang T, Li F, Mu J, Liu J, Zhang S. Multivariate evaluation of Thyroid Imaging Reporting and Data System (TI-RADS) in diagnosis malignant thyroid nodule: application to PCA and PLS-DA analysis. International Journal of Clinical Oncology. 2017; 22(3):448-454
 - 349. Zhang XL, Qian LX. Ultrasonic features of papillary thyroid microcarcinoma and nonmicrocarcinoma. Experimental and Therapeutic Medicine. 2014; 8(4):1335-1339
 - 350. Zhang XY, Zhang B, Jiang YX, Yang X, Zhao RN, Lai XJ. Diagnostic Value of Elastography for Thyroid Nodules in Hashimoto's Thyroiditis. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae. 2018; 40(1):59-66
- 351. Zhang Y, Luo YK, Tang J, Li M, Wang ZL, Wen Q. Clinical Value of Ultrasonography in Diagnosing Diffuse Thyroid Diseases Accompanied with Suspicious Nodules. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae. 2015; 37(3):290-3
- 40352.Zhang Y, Luo YK, Zhang MB, Li J, Li J, Tang J. Diagnostic accuracy of contrast-
enhanced ultrasound enhancement patterns for thyroid nodules. Medical Science41Monitor. 2016; 22:4755-4764
- 43 353. Zhang Y, Meng F, Hong L, Chu L. A Risk Score Model for Evaluation and
 44 Management of Patients with Thyroid Nodules. Hormone and Metabolic Research.
 45 2018; 50(7):543-550

- 354. Zhang Y, Zhou P, Tian SM, Zhao YF, Li JL, Li L. Usefulness of combined use of contrast-enhanced ultrasound and TI-RADS classification for the differentiation of benign from malignant lesions of thyroid nodules. European Radiology. 2017; 27(4):1527-1536
 - 355. Zhang YF, He Y, Xu HX, Xu XH, Liu C, Guo LH et al. Virtual touch tissue imaging on acoustic radiation force impulse elastography: a new technique for differential diagnosis between benign and malignant thyroid nodules. Journal of Ultrasound in Medicine. 2014; 33(4):585-95
- 356. Zhang YF, Xu HX, He Y, Liu C, Guo LH, Liu LN et al. Virtual touch tissue quantification of acoustic radiation force impulse: a new ultrasound elastic imaging in the diagnosis of thyroid nodules. PloS One. 2012; 7(11):e49094
 - 357. Zhang YF, Xu HX, Xu JM, Liu C, Guo LH, Liu LN et al. Acoustic radiation force impulse elastography in the diagnosis of thyroid nodules: Useful or not useful? Ultrasound in Medicine and Biology. 2015; 41(10):2581-93
- 358. Zhang YZ, Xu T, Cui D, Li X, Yao Q, Gong HY et al. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. Scientific Reports. 2015; 5:16927
- 359. Zhang YZ, Xu T, Gong HY, Li CY, Ye XH, Lin HJ et al. Application of high-resolution ultrasound, real-time elastography, and contrast-enhanced ultrasound in differentiating solid thyroid nodules. Medicine. 2016; 95(45):e5329
 - 360. Zhao CK, Chen SG, Alizad A, He YP, Wang Q, Wang D et al. Three-Dimensional Shear Wave Elastography for Differentiating Benign From Malignant Thyroid Nodules. Journal of Ultrasound in Medicine. 2018; 37(7):1777-1788
 - 361. Zhao H, Liu X, Lei B, Cheng P, Li J, Wu Y et al. Diagnostic performance of thyroid imaging reporting and data system (TI-RADS) alone and in combination with contrastenhanced ultrasonography for the characterization of thyroid nodules. Clinical Hemorheology and Microcirculation. 2018; Epublication
- 362. Zheng B, Tublin ME, Klym AH, Gur D. Classification of thyroid nodules using a resonance-frequency-based electrical impedance spectroscopy: a preliminary assessment. Thyroid. 2013; 23(7):854-62
- 363. Zheng Y, Xu S, Kang H, Zhan W. A single-center retrospective validation study of the american college of radiology thyroid imaging reporting and data system. Ultrasound Quarterly. 2018; 34(2):77-83
- 364. Zhou H, Yue WW, Du LY, Xu JM, Liu BJ, Li XL et al. A modified thyroid imaging reporting and data system (mti-rads) for thyroid nodules in coexisting Hashimoto's thyroiditis. Scientific Reports. 2016; 6:26410
- 365. Zhou H, Zhou XL, Xu HX, Li DD, Liu BJ, Zhang YF et al. Virtual Touch Tissue Imaging and Quantification in the Evaluation of Thyroid Nodules. Journal of Ultrasound in Medicine. 2017; 36(2):251-260
- 366. Zhou JQ, Zhou C, Zhan WW, Zhou W, Dong YJ. Maximal, minimal, and mean pulsed Doppler parameters: which should be utilized in the diagnosis of thyroid nodules? Clinical Radiology. 2014; 69(12):e477-84
- 43 367. Zhou X, Zhou P, Hu Z, Tian SM, Zhao Y, Liu W et al. Diagnostic Efficiency of
 44 Quantitative Contrast-Enhanced Ultrasound Indicators for Discriminating Benign
 45 From Malignant Solid Thyroid Nodules. Journal of Ultrasound in Medicine. 2018;
 46 37(2):425-437

- 368. Zhu LC, Ye YL, Luo WH, Su M, Wei HP, Zhang XB et al. A model to discriminate malignant from benign thyroid nodules using artificial neural network. PloS One. 2013; 8(12):e82211
- 2 3

- 4
- 5

Appendices

1

2

3

Appendix A: Review protocols

Table	9 6:	
ID	Field	Content
I	Review question	Which imaging tests should be requested (for thyroid enlargement)?
		Which people with structural thyroid abnormalities should have a fine- needle aspiration biopsy?
П	Type of review question	Diagnostic accuracy
		A review of health economic evidence related to the same review question was conducted in parallel with this review. For details see the health economic review protocol for this NICE guideline.
III	Objective of the review	Determine which imaging tests are most accurate and therefore appropriate for people with thyroid enlargement
IV	Eligibility criteria – population / disease / condition / issue / domain	 People presenting with euthyroid thyroid enlargement being investigated for possible malignancy
V	Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	Ultrasound scanCT scanMRI scan
VI	Eligibility criteria – comparator(s) / control or reference (gold) standard	 Reference standard will be malignant status as confirmed by biopsy/subsequent development of cancer in case of false negatives that do not receive biopsy
VII	Outcomes and prioritisation	• Sensitivity, specificity, PPV, NPV of tests for diagnosing thyroid cancer
		Sensitivity prioritised
VIII	Eligibility criteria – study design	 Diagnostic accuracy studies Prospective studies prioritised, retrospective studies included if insufficient prospective studies identified
IX	Other inclusion exclusion criteria	 Excluding two gate study design Excluding studies that only assess results of those who go on to have surgery as not a representative population Studies assessing ultrasound only included if full criteria used (as opposed to accuracy of single feature) Studies assessing variants of ultrasound (for example elastography) only included if combined with conventional criteria
Х	Proposed sensitivity / subgroup analysis, or	 Stratifications Criteria used (for example Kim, TIRADS, AACE, ATA, BTA for US) CT with contrast vs CT without contrast

	meta- regression	
XI	Selection process – duplicate screening / selection / analysis	• A sample of at least 10% of the abstract lists were double-sifted by a senior research fellow and discrepancies rectified, with committee input where consensus could not be reached, for more information please see the separate Methods report for this guideline.
XII	Data management (software)	 EndNote was used for reference management, sifting, citations and bibliographies. Pair forest plots were constructed using Cochrane Review Manager (RevMan5). WinBUGS was used for diagnostic meta-analysis
XIII	Information sources – databases and dates	• Medline, Embase and the Cochrane library
XIV	ldentify if an update	Not an update
XV	Author contacts	https://www.nice.org.uk/guidance/indevelopment/gid-ng10074
XVI	Highlight if amendment to previous protocol	Not an amendment
XVI I	Search strategy – for one database	For details please see Appendix B:
XVI II	Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as Appendix D: of the evidence report.
XIX	Data items – define all variables to be collected	For details please see evidence tables in Appendix D: (clinical evidence tables) or Appendix G: (health economic evidence tables).
XX	Methods for assessing bias at outcome / study level	QUADAS-2 checklists were used to critically appraise individual studies. The risk of bias across all available evidence was evaluated for each index test using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/
XXI	Criteria for quantitative synthesis	For details please see section 6.4 of Developing NICE guidelines: the manual.
XXI I	Methods for quantitative analysis – combining studies and exploring (in)consistency	For details please see the separate Methods report for this guideline.
XXI II	Meta-bias assessment – publication bias, selective	For details please see section 6.2 of Developing NICE guidelines: the manual.

	reporting bias	
XXI V	Confidence in cumulative evidence	For details please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual.
XX V	Rationale / context – what is known	For details please see the introduction to the evidence review.
XX VI	Describe contributions of authors and guarantor	A multidisciplinary committee [to add link to history page of the guideline after publication] developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired bySarah Fishburn in line with section 3 of Developing NICE guidelines: the manual. Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details please see Developing NICE guidelines: the manual.
XX VII	Sources of funding / support	NGC is funded by NICE and hosted by the Royal College of Physicians.
XX VIII	Name of sponsor	NGC is funded by NICE and hosted by the Royal College of Physicians.
XXI X	Roles of sponsor	NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.
XX X	PROSPERO registration number	Not registered

Table 7: He	ealth economic review protocol
Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	 Populations, interventions and comparators must be as specified in the clinical review protocol above.
	 Studies must be of a relevant health economic study design (cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis, cost-consequences analysis, comparative cost analysis).
	• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)
	 Unpublished reports will not be considered unless submitted as part of a call for evidence.
	Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see Appendix B: below.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.
	Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014). ¹⁹³
	Inclusion and exclusion criteria
	 If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.
	• If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
	 If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.
	Where there is discretion
	The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.
	The health economist will be guided by the following hierarchies. <i>Setting:</i>
	 UK NHS (most applicable). OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
	• OECD countries with predominantly private health insurance systems (for example, Switzerland).

 Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost-utility analysis (most applicable).
- Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.
 Year of analysis:
- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

• The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018 https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869

For more detailed information, please see the Methodology Review. [Add cross reference
after publication]

8 B.1 Clinical search literature search strategy

9 Searches were constructed using a PICO framework where population (P) terms were
10 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are
11 rarely used in search strategies for interventions as these concepts may not be well
12 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were
13 applied to the search where appropriate.

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 07 January 2019	Exclusions Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies
Embase (OVID)	1974 – 07 January 2019	Exclusions Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2019 Issue 1 or 12 CENTRAL to 2019 Issue 1 or 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 2 of 4	None

Table 8: Database date parameters and filters used

1

2

3

4

5

14

Medline (Ovid) search terms

1.	exp thyroid diseases/
2.	hyperthyroid*.ti,ab.
3.	hypothyroid*.ti,ab.
4.	thyrotoxicosis.ti,ab.
5.	(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/

12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	Ultrasonography/
27.	Magnetic Resonance Imaging/
28.	Tomography, X-Ray Computed/
29.	(ultrasonograph* or ultrasound* or ultra sound or sonograph* or sonogram* or echograph* or echotomograph* or doppler).ti,ab.
30.	magnetic resonance.ti,ab.
31.	(MR or MRI).ti,ab.
32.	(diffusion weighted imag* or DWI).ti,ab.
33.	(computed adj3 tomography).ti,ab.
34.	(CT or CAT).ti,ab.
35.	or/26-34
36.	25 and 35
37.	limit 36 to English language
38.	randomized controlled trial.pt.
39.	controlled clinical trial.pt.
40.	randomi#ed.ti,ab.
41.	placebo.ab.
42.	randomly.ti,ab.
43.	Clinical Trials as topic.sh.
44.	trial.ti.
45.	or/38-44
46.	exp "sensitivity and specificity"/
47.	(sensitivity or specificity).ti,ab.
48.	((pre test or pretest or post test) adj probability).ti,ab.
49.	(predictive value* or PPV or NPV).ti,ab.
50.	likelihood ratio*.ti,ab.
51.	likelihood function/
52.	((area under adj4 curve) or AUC).ti,ab.
53.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
54.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
55.	gold standard.ab.

56.	or/46-55
57.	Epidemiologic studies/
58.	Observational study/
59.	exp Cohort studies/
60.	(cohort adj (study or studies or analys* or data)).ti,ab.
61.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
62.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
63.	Controlled Before-After Studies/
64.	Historically Controlled Study/
65.	Interrupted Time Series Analysis/
66.	(before adj2 after adj2 (study or studies or data)).ti,ab.
67.	or/57-66
68.	exp case control study/
69.	case control*.ti,ab.
70.	or/68-69
71.	67 or 70
72.	Cross-sectional studies/
73.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
74.	or/72-73
75.	67 or 74
76.	67 or 70 or 74
77.	Meta-Analysis/
78.	exp Meta-Analysis as Topic/
79.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
80.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
81.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
82.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
83.	(search* adj4 literature).ab.
84.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
85.	cochrane.jw.
86.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
87.	or/77-86
88.	37 and (45 or 56 or 87 or 76)

Embase (Ovid) search terms

1.	exp thyroid disease/
2.	hyperthyroid*.ti,ab.
3.	hypothyroid*.ti,ab.
4.	thyrotoxicosis.ti,ab.
5.	(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.
6.	or/1-5

7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	limit 23 to English language
25.	echography/
26.	nuclear magnetic resonance imaging/
27.	computer assisted tomography/
28.	(ultrasonograph* or ultrasound* or ultra sound or sonograph* or sonogram* or echograph* or echotomograph* or doppler).ti,ab.
29.	magnetic resonance.ti,ab.
30.	(MR or MRI).ti,ab.
31.	(diffusion weighted imag* or DWI).ti,ab.
32.	(computed adj3 tomography).ti,ab.
33.	(CT or CAT).ti,ab.
34.	or/25-33
35.	24 and 34
36.	exp "sensitivity and specificity"/
37.	(sensitivity or specificity).ti,ab.
38.	((pre test or pretest or post test) adj probability).ti,ab.
39.	(predictive value* or PPV or NPV).ti,ab.
40.	likelihood ratio*.ti,ab.
41.	((area under adj4 curve) or AUC).ti,ab.
42.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
43.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
44.	diagnostic accuracy/
45.	diagnostic test accuracy study/
46.	gold standard.ab.
47.	or/36-46
48.	random*.ti,ab.
49.	factorial*.ti,ab.
50.	(crossover* or cross over*).ti,ab.

F1	(/doubl* or cingl*) odi blind*) ti ob
51.	((doubl* or singl*) adj blind*).ti,ab.
52.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
53.	crossover procedure/
54.	single blind procedure/
55.	randomized controlled trial/
56.	double blind procedure/
57.	or/48-56
58.	systematic review/
59.	meta-analysis/
60.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
61.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
62.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
63.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
64.	(search* adj4 literature).ab.
65.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
66.	cochrane.jw.
67.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
68.	or/58-67
69.	Clinical study/
70.	Observational study/
71.	family study/
72.	longitudinal study/
73.	retrospective study/
74.	prospective study/
75.	cohort analysis/
76.	follow-up/
77.	cohort*.ti,ab.
78.	76 and 77
79.	(cohort adj (study or studies or analys* or data)).ti,ab.
80.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
81.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
82.	(before adj2 after adj2 (study or studies or data)).ti,ab.
83.	or/69-75,78-82
84.	exp case control study/
85.	case control*.ti,ab.
86.	or/84-85
87.	83 or 86
88.	cross-sectional study/
89.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
90.	or/88-89
91.	83 or 90

3

4

5

6

7

8

9

10

93.	35 and (47 or 57 or 68 or 92)
Cochra	ne Library (Wiley) search terms
#1.	MeSH descriptor: [Thyroid Diseases] explode all trees
#2.	hyperthyroid*:ti,ab
#3.	hypothyroid*:ti,ab
#4.	thyrotoxicosis:ti,ab
#5.	(thyroid near/3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)):ti,ab
#6.	(or #1-#5)
#7.	MeSH descriptor: [Ultrasonography] explode all trees
#8.	MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#9.	MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#10.	(ultrasonograph* or ultrasound* or ultra sound or sonograph* or sonogram* or echograph* or echotomograph* or doppler):ti,ab
#11.	magnetic resonance:ti,ab
#12.	(MR or MRI):ti,ab
#13.	(diffusion weighted imag* or DWI):ti,ab
#14.	(computed near/3 tomography):ti,ab
#15.	(CT or CAT):ti,ab
#16.	(or #7-#15)
#17.	#6 and #16

Health Economics literature search strategy **B.2** 2

Health economic evidence was identified by conducting a broad search relating to a thyroid disease population in NHS Economic Evaluation Database (NHS EED - this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics, economic modelling and quality of life studies.

Table 9: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 07 January 2019	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	2014 – 07 January 2019	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 07 January 2019 NHSEED - Inception to March 2015	None

Medline (Ovid) search terms

1.	exp thyroid diseases/		
2.	hyperthyroid*.ti,ab.		
3.	hypothyroid*.ti,ab.		
4.	thyrotoxicosis.ti,ab.		
5.	(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.		
6.	or/1-5		
7.	letter/		
8.	editorial/		
9.	news/		
10.	exp historical article/		
11.	Anecdotes as Topic/		
12.	comment/		
13.	case report/		
14.	(letter or comment*).ti.		
15.	or/7-14		
16.	randomized controlled trial/ or random*.ti,ab.		
17.	15 not 16		
18.	animals/ not humans/		
19.	exp Animals, Laboratory/		
20.	exp Animal Experimentation/		
21.	exp Models, Animal/		
22.	exp Rodentia/		
23.	(rat or rats or mouse or mice).ti.		
24.	or/17-23		
25.	6 not 24		
26.	limit 25 to English language		
27.	Economics/		
28.	Value of life/		
29.	exp "Costs and Cost Analysis"/		
30.	exp Economics, Hospital/		
31.	exp Economics, Medical/		
32.	Economics, Nursing/		
33.	Economics, Pharmaceutical/		
34.	exp "Fees and Charges"/		
35.	exp Budgets/		
36.	budget*.ti,ab.		
37.	cost*.ti.		
38.	(economic* or pharmaco?economic*).ti.		
39.	(price* or pricing*).ti,ab.		
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.		
41.	(financ* or fee or fees).ti,ab.		
42.	(value adj2 (money or monetary)).ti,ab.		
43.	or/27-42		

44.	exp models, economic/		
45.	*Models, Theoretical/		
46.	*Models, Organizational/		
47.	markov chains/		
48.	monte carlo method/		
49.	exp Decision Theory/		
50.	(markov* or monte carlo).ti,ab.		
51.	econom* model*.ti,ab.		
52.	(decision* adj2 (tree* or analy* or model*)).ti,ab.		
53.	or/44-52		
54.	quality-adjusted life years/		
55.	sickness impact profile/		
56.	(quality adj2 (wellbeing or well being)).ti,ab.		
57.	sickness impact profile.ti,ab.		
58.	disability adjusted life.ti,ab.		
59.	(qal* or qtime* or qwb* or daly*).ti,ab.		
60.	(euroqol* or eq5d* or eq 5*).ti,ab.		
61.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.		
62.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.		
63.	(hui or hui1 or hui2 or hui3).ti,ab.		
64.	(health* year* equivalent* or hye or hyes).ti,ab.		
65.	discrete choice*.ti,ab.		
66.	rosser.ti,ab.		
67.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.		
68.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.		
69.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.		
70.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.		
71.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.		
72.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.		
73.	or/54-72		
74.	26 and (43 or 53 or 73)		

Embase (Ovid) search terms

1.	exp thyroid diseases/
2.	hyperthyroid*.ti,ab.
3.	hypothyroid*.ti,ab.
4.	thyrotoxicosis*.ti,ab.
5.	(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.

© National Institute for Health and Care Excellence, 2019

12.	or/7-11			
13.	randomized controlled trial/ or random*.ti,ab.			
14.	12 not 13			
15.	animal/ not human/			
16.				
17.	nonhuman/			
18.	exp Animal Experiment/			
19.	exp Experimental Animal/ animal model/			
20.	exp Rodent/			
21.	(rat or rats or mouse or mice).ti.			
22.	or/14-21			
23.	6 not 22			
24.	limit 23 to English language			
25.	health economics/			
26.	exp economic evaluation/			
27.	exp health care cost/			
28.	exp fee/			
29.	· ·			
30.	budget/			
31.	funding/			
32.	budget*.ti,ab.			
33.	(economic* or pharmaco?economic*).ti.			
34.	(price* or pricing*).ti,ab.			
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or			
	variable*)).ab.			
36.	(financ* or fee or fees).ti,ab.			
37.	(value adj2 (money or monetary)).ti,ab.			
38.	or/25-37			
39.	statistical model/			
40.	exp economic aspect/			
41.	39 and 40			
42.	*theoretical model/			
43.	*nonbiological model/			
44.	stochastic model/			
45.	decision theory/			
46.	decision tree/			
47.	monte carlo method/			
48.	(markov* or monte carlo).ti,ab.			
49.	econom* model*.ti,ab.			
50.	(decision* adj2 (tree* or analy* or model*)).ti,ab.			
51.	or/41-50			

52.	quality adjusted life year/		
53.	"quality of life index"/		
54.	short form 12/ or short form 20/ or short form 36/ or short form 8/		
55.	sickness impact profile/		
56.	(quality adj2 (wellbeing or well being)).ti,ab.		
57.	sickness impact profile.ti,ab.		
58.	disability adjusted life.ti,ab.		
59.	(qal* or qtime* or qwb* or daly*).ti,ab.		
60.	(euroqol* or eq5d* or eq 5*).ti,ab.		
61.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.		
62.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.		
63.	(hui or hui1 or hui2 or hui3).ti,ab.		
64.	(health* year* equivalent* or hye or hyes).ti,ab.		
65.	discrete choice*.ti,ab.		
66.	rosser.ti,ab.		
67.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.		
68.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.		
69.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.		
70.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.		
71.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.		
72.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.		
73.	or/52-72		
74.	24 and (38 or 51 or 73)		

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Thyroid Diseases EXPLODE ALL TREES
#2.	hyperthyroid*
#3.	hypothyroid*
#4.	thyrotoxicosis*
#5.	(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*))
#6.	#1 OR #2 OR #3 OR #4 or #5

2

2

4

Appendix C: Clinical evidence selection




Figure 1: Flow chart of clinical study selection for the review of imaging and who to FNAB

Appendix D: Clinical evidence tables

...

Reference	Ahn 2010 ⁶
Study type	Retrospective review
Study methodology	Data source: patients biopsied under ultrasound guidance from September 2002 through July 2004 at the Institute of Radiological Science at Yosnei University
	Recruitment: unclear
Number of patients	n = 1318 (1398 nodules)
Patient characteristics	Age, mean (range): 46.3 (9-82)
	Gender (male to female ratio): 101:1217
	Ethnicity: not specified
	Setting: Department of radiology and Research Institute of Radiological Science, Yosnei University, College of Medicine.
	Country: South Korea
	Inclusion criteria: Ultrasound was performed on the largest of nodules with similar ultrasound features but on each nodule when multiple nodules had several different ultrasound features. Nodules with benign (n=1016) or malignant (n=244) cytologic findings were included.
	Exclusion criteria: 128 of 161 nodules with nondiagnostic cytology, 25 of 52 nodules with cytologic findings of follicular neoplasm and 32 of 110 nodules suspicious for papillary carcinoma were excluded.
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound Ultrasound was performed with a 7-to 12- MHz transducer prospectively by one experienced radiologist who described the sonographic characteristics of thyroid nodules with respect to size, multiplicity, composition, echogenicity, margin, calcification, shape, and abnormal cervical lymph nodes. All images were sent to the local PACS for review. Size was measured at the maximum dimension. Substantial growth was retrospectively assessed in 287 nodules examined with ultrasound at least 6 months before FNAB.

Reference	Ahn 2010 ⁶				
	Reference standard: Surgery or cytology if no surgery Surgery was performed for 455 nodules (of 1583), including 33 with nondiagnostic cytologic findings, 111 benign nodules, 27 follicular neoplasms, 78 nodules suspicious for papillary carcinoma and 206 malignant nodules.				
		Ultrasound-guided FNAB was performed by one experienced radiologist using a 23-gauge needle attached to a 20-mL disposable plastic syringe and aspirator. Each lesion was aspirated at least twice. The cytopathologist was not on site during the biopsy.			
	Time between measurement of index test and reference standard: unclear, FNAB was performed after surgery.				
2×2 table	Kim	Reference standard +	Reference standard -	Total	Notes: Final diagnosis was based on surgical
	Index test +	303	205	508	pathologic findings or on cytologic findings if the
	Index test -	24	866	890	patient did not undergo surgery
	Total	327	1071	1398	
2×2 table	SRU	Reference standard +	Reference standard -	Total	Notes: Final diagnosis was based on surgical
	Index test +	116	489	605	pathologic findings or on cytologic findings if the
	Index test -	211	582	793	patient did not undergo surgery
	Total	327	1071	1398	
2×2 table	AACE	Reference standard +	Reference standard -	Total	Notes: Final diagnosis was based on surgical
	Index test +	259	98	357	pathologic findings or on cytologic findings if the
	Index test -	68	973	1041	patient did not undergo surgery
	Total	327	1071	1398	
Statistical measures	Sensitivity: 92. Specificity: 80. PPV: 59.6% NPV: 97.3% AUC: 0.868	9% <u>asound (Society of radiolog</u> 5%	gists in ultrasound criteria	<u>a)</u>	

© National Institute for Health and Care Excellence. 2019 72

Reference	Ahn 2010 ⁶
	AUC: 0.551 <u>Index text Ultrasound (AACE)</u> Sensitivity: 79.2% Specificity: 90.8% PPV: 72.3% NPV: 93.5% AUC: 0.850
Source of funding	Not stated
Limitations	Risk of bias: serious; high risk of bias in patient selection; flow and timing Indirectness: none
Comments	

Reference	Alam 2014 ⁹						
Study type	Cross-sectional prospective						
Study methodology	Data source: patients referred to radiology department for thyroid ultrasound followed by FNAB from December 2010 to December 2012						
	Recruitment: non-probability consecutive sampling						
Number of patients	n = 100						
Patient characteristics	Age, mean (SD): 41.77 (12.31)						
••••••	Gender (male to female ratio): 24:76						
	Ethnicity: not specified						
	Setting: Department of Radiology, Aga Khan University Hospital, Karachi (AKUH)						
	Country: Pakistan						
	Inclusion criteria: patients with palpable thyroid nodules diagnosed by primary physician in clinical examination, referred to radiology department of AKUH for thyroid ultrasound followed by fine-needle aspiration cytology of thyroid nodules						

Reference	Alam 2014 ⁹						
	Exclusion criteria: proven thyroid malignancy, US or FNAC conducted outside the study institution.						
Target condition(s)	Thyroid cancer						
Index test(s)	Index test: Ultrasound						
and reference standard	All ultrasounds were performed by a single radiologist on Nemio XG ultrasound machine equipped with 3.5-5 MHz Curvilinear and 7.5-15 MHz Linear probe. Transverse and longitudinal images were taken and send to the Picture and Archiving System (PACS) for later review						
	A nodule was considered positive or malignant if one or more than one of the following sonographic features were found: micro calcification defined as punctuate (less than 2mm) hyper echoic foci either with or without acoustic shadows; micro-lobulation was characterized as presence of many small lobules on surface of a nodule or irregular margins; marked hypo echogenicity demarcated as decreased echogenicity compared with surrounding neck muscle; shape characterised as taller than wider.						
	A nodule was	categorised as negative (n	nalignancy not found) if n	one of the above featu	ure was seen.		
	Reference standard: Fine-needle aspiration cytology FNAC followed all ultrasounds; conducted by a single consultant radiologist with more than 5 years of experience in performing the procedure. FNAC specimen was analysed by cryopathologist with 5 years of experience who was blinded to US diagnosis. FNAC diagnosis of malignancy was acquired from medical record system. Time between measurement of index test and reference standard:						
2×2 table		Reference standard +	Reference standard -	Total			
	Index test +	22	16	38			
	Index test -	2	60	62			
	Total	24	76	100			
Statistical measures	Index text Ultrasound Sensitivity : 91.7% Specificity: 78.94% PPV: 57.9% NPV: 96.8% Overall accuracy: 82%						
Source of funding	Not stated						

Reference	Alam 2014 ⁹
Limitations	Risk of bias: none
	Indirectness: none
Comments	

Reference	Chen 2019 ³⁶					
Study type	Retrospective					
Study type Study methodology	Data source: patients with thyroid nodules seen at Guangdong Province Hospital of Chinese Medicine from January 2014 to September 2012					
	Recruitment: not specified					
Number of patients	n = 1092					
Patient characteristics	Age, mean (SD): 46.92 (13.59)					
	Gender (male to female ratio): 240:825					
	Ethnicity: Chinese					
	Setting: Guangdong Province Hospital of Chinese Medicine					
	Country: China					
	Inclusion criteria: a single round or oval nodule with a diameter of 3-93 mm on ultrasound; complete clinical data and thyroid ultrasound imaging data; pathological confirmation of the status of all nodules					
	Exclusion criteria: multiple enlarged neck lymph nodes on ultrasound; findings of inflammation on imaging and distant metastasis identified on auxiliary examination					
Target condition(s)	Thyroid cancer					
Index test(s) and reference standard	Index test: Ultrasound A GE LOGIQ E9 ultrasound system with a linear array probe was used to acquire ultrasound images in the frequency range of 6-15 MHz. Thyroid glands and the surrounding area were scanned while patients were in the supine position with the neck fully exposed. The size, shape, internal structure, echogenicity, features of the border and presence of calcifications were carefully observed and recorded.					

Chen 2019 ³⁶					
ACR-TIRADS classification, ba and focal echogenicity of the n and the sum of scores for each independently reviewed by two					
Reference standard: Fine-nee Pathology of all thyroid cases malignant thyroid nodules grou Time between measurement o					
ACR-TIRADS Index test + Index test - Total	Reference st 385 10 395				
Index text Ultrasound (ACR-TI Sensitivity : 96% Specificity: 53 %					
Department development foun					

measures	Sensitivity : 96% Specificity: 53 %
Source of funding	Department development foundation of Guangdong Province Hospital of Chinese Medicine, Grant/Award number; 2017-01
Limitations	Risk of bias: serious risk due to potential bias in the interpretation of index test and reference standard results Indirectness: none
Comments	Diagnostic accuracy of ACR-TIRADS

76

 \bigcirc

Reference

2×2 table

Statistical

on, based on ultrasound indicators including the internal structure, echogenicity, morphology, boundary features the nodules was applied. Scored for each indicator were determined according to the ACR TI-RADS guidelines, each nodule was calculated to determine the TI-RADS level for the respective nodule. Ultrasound images were y two doctors. When doctors' opinions differed, the decision was made by senior doctors. <u>-needle aspiration cytology (and occasionally Surgery)</u> ises included in the study was confirmed by fine-needle aspiration biopsy. Patients were divided into benign and groups according to cytological results. Surgery was performed in these patients according to the ATA guideline ent of index test and reference standard: not specified							
ce standard +	Reference standard -	Total					
	313	698					
	384	394					
697 1092							
<u>R-TIRADS)</u>							

Reference	Creo 2018 ⁴⁸
Study type	Retrospective
Study methodology	Data source: Paediatric patients (≤21 years old) presenting at tertiary centre with a thyroid nodule between 1996 and 2015
	Recruitment: not specified

	Reference	Creo 2018 ⁴⁸			
	Number of	n = 112 (145 thyroid nodules)			
	patients				
	Patient	Age, mean (SD): 15.5 (3.2)			
	characteristics	Gender (male to female ratio): 16:96			
		Ethnicity: not specified			
		Setting: Division of Paediatric Endocrinology and Metabolism			
		Country: USA			
Inclusion criteria: patients <21 years of age, initial US performed at Mayo Clinic followed by either: 1) histopathology results thyroidectomy, 2) FNA biopsy cytology results with a follow-up FNA performed at the institution ≥1 year after initial biopsy biopsy cytology results with a stable follow-up US performed at the institution ≥1 year after initial biopsy at the institution ≥1 year after initial US; 2 largest nodules in patients with more than 1 nodule.					
		Exclusion criteria: patients with a genetic syndrome known to increase thyroid cancer risk, patients with history of radiation exposure.			
	Target condition(s)	Thyroid cancer			
	Index test(s) and reference standard	Index test: Ultrasound + USD Diagnostic gray-scale US with colour Doppler was obtained using high-frequency linear array transducers. Both cine and still imaging were recorded using longitudinal and transverse views. All images were reviewed on the same imaging system by 2 paediatric radiologists with a combined experience of 27 years after paediatric radiology fellowship training. The radiologists described specific nodule features based upon the TIRADS description for reporting thyroid nodule features. After radiologists recorded the features, an independent reviewer assigned each nodule a level of suspicion for malignancy based on the 2015 ATA Adult risk Classification Guidelines. Radiologists were simply asked to provide their overall impression and were given the descriptive choices of benign, indeterminate, or malignant, which was informed by the presence of absence of calcifications, the type of margins, as well as the size and composition of nodules.			
		Reference standard: Cytology and Histology FNA was performed by institutional radiologists by free-hand technique with US guidance. Cytology results were reported using the Bethesda System for Reporting Thyroid Cytology. This includes (I) nondiagnostic,(II) benign, (III) atypia of undetermined significance, (IV) suspicious for follicular neoplasm, (V) suspicious for malignancy, and (VI) malignant categories. In a child with concerning cytology results who underwent thyroidectomy, appropriate follow-up with repeat FNA or repeat US≥ 1 year was used to ensure the nodule was accurately			

classified as benign.

Reference	Creo 2018 ⁴⁸						
	Time between measurement of index test and reference standard: not specified						
2×2 table	2015 ATA	Reference standard +	Reference standard -	Total			
	Index test +	46	63	109			
	Index test -	4	32	36			
	Total	50	95	145			
Statistical	Index text Ultras	ound (2015 ATA)					
measures	Sensitivity: 92%						
	Specificity: 32%						
Source of	Not specified						
funding Limitations	Risk of bias: nor						
Linitations	Indirectness: no						
Comments	Diagnostic accuracy of 2015 ATA TIRADS						
Reference	Grani 2019 ⁸⁰						
Study type	Retrospective						
Study	Data source: patients referred for FNA cytology of a thyroid nodule at the Thyroid cancer Unit of a large academic referral centre between						
methodology	1 November 2015 and 30 May 2018						
	Recruitment: pro	ospective					
	Reclatifient. pro	ospective					
Number of	n = 477 (502 thy	roid nodules)					
patients							
Patient	Age, mean (SD): 55.9 (13.9) tics						
characteristics							
	Gender (male to female ratio): 119:358						
	Ethnioity, not on	opified					
	Ethnicity: not specified						
	Setting: Thyroid Cancer Unit of academic referral centre (Sapienza, University of Rome)						

Reference	Grani 2019 ⁸⁰						
	Country: Italy						
	Inclusion criteria: all patients consecutively referred to the unit for FNA cytology of a thyroid nodule between 1 November 2015 and 30 May 2018						
	Exclusion criteria: su	bcentimeter nodules, nodu	les with an inconclusive re	eference stand	dard disanosis were excluded		
Target condition(s)	Exclusion criteria: subcentimeter nodules, nodules with an inconclusive reference standard disgnosis were excluded Thyroid cancer						
Index test(s)	Index test: Ultrasoun	Index test: Ultrasound					
and reference					<u>13-MHz linear-array transducer. Two clinicians</u>		
standard					hic features of each nodule on a standardized		
					nodule diameter, margin, structure/composition,		
					as well as location of the solid component for		
					ure were used to classify the risk of malignancy		
	according to the follo	owing risk stratification criter	ria: AACE/ACE/AME, the	ACR-TIRADS	s, the ATA, the EU-TIRADS, and the K-TIRADS.		
	Reference standard:	UCENAR/ Histology					
			lance by clinicians (endoc	rinologists tra	ined in thyroid sonography using 23- to 25-gauge		
	Biopsies were conducted under ultrasound-guidance by clinicians (endocrinologists trained in thyroid sonography using 23- to 25-gauge needles, using the nonaspiration technique in most cases. Direct smears of each specimen were analysed by experienced thyroid						
	cytopathologists and classified according to criteria published in the Italian Consensus for Thyroid Cytopathology.						
	When surgery had been performed, the reference standard diagnosis was based on histological examinations of the respected nodule.						
	When the nodule had been managed non-surgically the reference standard was FNA cytology: nodules were considered malignant when						
					ponding to the Bethesda classes V and VI) and		
	benign when they ha	d been classified as TIR 2,	corresponding to Bethese	da class II.			
	Time between meas	urement of index test and re	eference standard: not sp	ecified			
2×2 table	ACR TIRADS	Reference standard +	Reference standard -	Total	In 34 malignant cases, the diagnosis was		
	Index test +	30	204	234	based on histological findings while the		
	Index test -	6	262	268	remaining 2 were classified cytologically as		
	Total				TIR4/ Bethesda V.		
		36	466	502			
2×2 table	AACE/ACE/AME	Reference standard +	Reference standard -	Total	In 34 malignant cases, the diagnosis was		
	Index test +	31	296	327	based on histological findings while the		

Reference	Grani 2019 ⁸⁰					
	Index test -	5	170	175	remaining 2 were classified cytologically as	
	Total				TIR4/ Bethesda V.	
		36	466	502		
2×2 table	ATA	Reference standard +	Reference standard -	Total	In 34 malignant cases, the diagnosis was	
	Index test +	27	255	282	based on histological findings while the	
	Index test -	9	211	220	remaining 2 were classified cytologically as TIR4/ Bethesda V.	
	Total				TIN4/ Dettiesua V.	
		36	466	502	Excluding 90 not classifiable nodules.	
2×2 table	EU-TIRADS	Reference standard +	Reference standard -	Total	In 34 malignant cases, the diagnosis was	
	Index test +	31	317	348	based on histological findings while the	
	Index test -	5	149	154	remaining 2 were classified cytologically as	
	Total				TIR4/ Bethesda V.	
		36	466	502		
2×2 table	K-TIRADS	Reference standard +	Reference standard -	Total	In 34 malignant cases, the diagnosis was	
	Index test +	33	383	416	based on histological findings while the	
	Index test -	3	83	86	remaining 2 were classified cytologically as	
	Total	36	466	502	TIR4/ Bethesda V.	
Statistical measures	Index text UltrasouSensitivity : 83.3 %Specificity: 56.2%Index text UltrasouSensitivity : 86.1 %Specificity: 36.5 %Index text UltrasouSensitivity : 75 %Specificity: 45.3%Index text UltrasouSensitivity : 86.1 %Specificity: 32%Index text UltrasouSensitivity : 32%Index text Ultrasou	ind (AACE/ACE/AME)				

Reference	Grani 2019 ⁸⁰
	Sensitivity : 91.7 %
	Specificity: 17.8%
Source of	Not specified
funding	
Limitations	Risk of bias: serious due to potential risk of bias in the interpretation of the reference standard; flow and timing.
	Indirectness: none
Comments	Diagnostic accuracy of the ACR TIRADS, AACE/ACE/AME, ATA, EU-TIRADS, K-TIRADS

Reference	Farihah 2018 ⁶⁷
Study type	Cross-sectional retrospective
Study methodology	Data source: patients who underwent US-guided FNAC for US-detected focal thyroid nodules from January 2014 to May 2016, with available pathology results
	Recruitment: not specified
Number of patients	n = 91 (104 nodules)
Patient characteristics	Age, mean (range): 54.7 (27-80)
	Gender (male to female ratio): 21:83
	Ethnicity: 51(49%) Malay, 25 (33.7%) Chinese, 13 (12.5%) Indian, 5 (4.8%) other races.
	Setting: Radiology Department of Universiti Kebangsaan Malaysia Medical Centre (UKMMC)
	Country: Malaysia
	Inclusion criteria: nodules with benign or malignant results at cytology or histology examination; patients who underwent thyroid surgery after specimens from cytology examination were classified as suspicious for thyroid carcinoma, indeterminate, or inadequate.
	Exclusion criteria: patients who had nodules cytologically diagnosed as suspicious for thyroid carcinoma, indeterminate or inadequate but

Reference	Farihah 2018 67				
	did not undergo surgery; patients with previous history of total or partial thyroidectomy, with or without radioiodine ablation.				
Target condition(s)	Thyroid cancer				
Index test(s) and reference standard	Index test: Ultrasound All available US scans of the thyroid gland and neck areas were performed using a linear-array transducer (5-12 MHz) on ultrasound scanners HD11/ HD11 XE/ iU22 Phillips Medical Systems or Toshiba Xario200 using an optimized gain. The radiologist, using Osirix workstation or Medweb, reviewed all images. All thyroid nodules were characterised according to the relevant nodule size, composition, cystic component, echogenicity, margins, evidence of calcifications, taller than wide, halo, colour flow and lymphadenopathy. Nodules were given a U1-U5 score based on the features described by the BTA Guidelines i.e. normal (U1), benign (U2), equivocal/indeterminate (U3), suspicious (U4) and malignant (U5) U2 and U3 were classified as negative; U4 and U5 as positive Reference standard: US-guided Fine-needle aspiration cytology and histopathology US-guided FNAC was performed in either the thyroid nodule with suspicious US features or the largest thyroid nodule if no suspicious US features were detected. US-guided FNAC was performed with a 23-gauge needle attached to a 10 ml disposable plastic syringe. Cytopathology reports were classified as benign, indeterminate, suspicious of malignancy, malignant or inadequate. Histopathology reports were obtained for cases that were cytologically reported as inadequate, indeterminate or suspicious of malignancy. Time between measurement of index test and reference standard: not specified				
2×2 table	Index test +	Reference standard + 12	Reference standard – 60	Total 72	Using BTA recommendations to biopsy U3 upwards
	Index test -	0	32	32	
	Total	12	92	104	
Statistical measures	Index text Ultrasound Sensitivity : 100% Specificity: 35%				
Source of funding	Not stated				

Reference	Farihah 2018 ⁶⁷
Limitations	Risk of bias: very serious due to patient selection; risk of bias in the interpretation of the index test and reference standard
	Indirectness: none
Comments	Diagnostic accuracy of BTA guidelines

Reference	Ha 2016 ⁸⁶
Study type	Prospective multicentre
Study methodology	Data source: patient data collected from four different hospitals from June 2013 to May 2015
	Recruitment: consecutive
Number of patients	n = 750 (902 nodules)
Patient characteristics	Age, mean (range): 49.2 (9-81)
	Gender (male to female ratio): 156:594
	Ethnicity: not specified
	Setting: four different hospitals
	Country: South Korea
	Inclusion criteria: nodules >5mm in patients from four different hospitals who had undergone thyroid US from June 2013 to May 2015
	Exclusion criteria: nodules with no final diagnosis obtained (n=198); entirely calcified nodules with US characteristics that could not be analysed (n=9)
Target condition(s)	Thyroid cancer
Index test(s)	Index test: Ultrasound
and reference standard	All US examinations were performed with a 10-16 MHz linear probe and a real-time US system, by five board-certified radiologists, in four different hospitals specialising in thyroid imaging. Nodules were classified according to K-TIRADS.
	Malignancy risk was stratified into the 5 categories of K-TIRADS according to US patterns by combining solidity, echogenicity, and suspicious US features as follows: 1=normal; 2=benign; 3= low suspicion; 4=intermediate suspicion; 5=high suspicion

biopsies (CNBs) to performed the echniques. CNB w ormed for thyroid m nodules that us f >2cm in case of ns on surgical pla tting thyroid cytop	thyro /as p nodu sually spoi nning
specified	
al	FN
	ma
•	CN on
	OII

	Reference standard: US-guided Fine-needle aspiration or Core needle biopsies (CNBs) or surgery US-guided FNAs or CNBs were performed by the same radiologists who performed the thyroid US. US-guided FNAs were performed with 23-gauge needles and a combination of capillary and aspiration FNA techniques. CNB was performed using a disposable 18-gauge, single -or double-action spring-activated needle. FNA was usually performed for thyroid nodules > 1 cm, with exception of pure cystic nodules, partially cystic nodules with comet-tail artifacts, and spongiform nodules that usually underwent FNA for therapeutic cyst aspiration, ethanol or radiofrequency ablation therapy, or nodule size of >2cm in case of spongiform nodule. FNA was performed for thyroid nodules <1 cm in case of suspicious US features, or for decisions on surgical planning. The interpretation of FNA was based on the Bethesda system for reporting thyroid cytopathology and CNB results were diagnosed with a six-tier pathology reporting system Time between measurement of index test and reference standard: not specified				
	Index test + Index test – Total	Reference standard + 254 12 266		Total 517 385 902	FNA or CNB biopsy on 409 nodules (n=75 malignant, n=334 benign) ; repeated FNA or CNB biopsy on 256 nodules (benign); Surgery on 237 nodules (n=191 malignant, n=46 benign)
	Index text Ultrasound Sensitivity : 95.5% Specificity: 58.6% PPV: 44.5% NPV: 96.9% Overall accuracy: 69.5%				
	Not stated				
6	Risk of bias: none Indirectness: none				
;	Diagnostic accuracy of K-TIRADS guidelines				

Reference	Ha 2018 ⁸⁷
Study type	Retrospective multicentre
Study	Data source: patient data collected from four different hospitals from June 2013 to May 2015

Reference

2×2 table

Statistical measures

Source of funding Limitations

Comments

Ha 2016 86

Re	eference	Ha 2018 ⁸⁷
m	ethodology	Recruitment: consecutive
	umber of atients	n = 750 (902 nodules)
	atient aracteristics	Age, mean (range): 49.2 (9-81) Gender (male to female ratio): 156:594 Ethnicity: not specified
		Setting: four different hospitals (one primary medical centre and three tertiary hospitals) Country: South Korea Inclusion criteria: nodules >5mm in patients from four different hospitals who had undergone thyroid US from June 2013 to May 2015 Exclusion criteria: nodules with no final diagnosis obtained (n=198); entirely calcified nodules with US characteristics that could not be analysed (n=9)
	arget ondition(s)	Thyroid cancer
In an	dex test(s) ad reference andard	Index test: Ultrasound All US examinations were performed with a 10-16 MHz linear probe and a real-time US system, by five board-certified radiologists, in four different hospitals specialising in thyroid imaging (with 8-20 years of clinical experience with thyroid US). Nodules were classified according to
		Malignancy risk was stratified into different categories for the different criteria used based on US patterns by combining solidity, echogenicity, calcification as follows: high, intermediate, low, very low suspicion, benign or not specified for the ATA 2015 guidelines; highly, moderately, mildly, not suspicious or benign for the ACR 2017 guidelines; high, intermediate, low suspicion or benign for the KTA/KAThR 2016 guidelines
		<u>Reference standard:</u> Final diagnoses were determined via surgical resection in 191 of 266 malignant nodules, 36 benign nodules were confirmed by surgery, 75 malignant nodules were diagnosed via FNA or core-needle biopsy.

Final diagnosis was determined by the cytopathologic results of on the Bethesda system and surgical findings.

Reference	Ha 2018 ⁸⁷				
	Time between measurement of index test and reference standard: not specified				
2×2 table		Reference standard +	Reference standard –	Total	Calculated considering ATA 2015 categories of
	Index test +	247	202	449	high, intermediate as malignant; low suspicion,
	Index test -	12	372	384	very low suspicion, benign as benign and
	Total	259	574	833	excluding 'not specified' nodules not meeting criteria for any pattern of malignancy
	ACR	Reference standard +	Reference standard -	Total	Calculated considering ACR 2017 categories of
	Index test +	255	297	552	highly, moderately suspicious as malignant;
	Index test -	11	339	350	mildly not suspicious and benign as benign.
	Total	266	636	902	
	KTA/KSThR	Reference standard +	Reference standard -	Total	Calculated considering KTA/KSThR 2016
	Index test +	254	263	517	categories of high and intermediate suspicion as
	Index test -	12	373	385	malignant; low suspicion and benign as benign.
	Total	266	636	902	
Statistical measures	Index text Ultrasound (ATA) 1 Sensitivity : 95.4% Specificity: 64.8% Index text Ultrasound (ACR) Sensitivity : 95.8% Specificity: 53.3% Index text Ultrasound (KTA/KSThR) Sensitivity : 95.5% Specificity: 58.6%				
Source of funding					
Limitations	Risk of bias: none Indirectness: none				
Comments	Diagnostic acc	uracy of ATA, KTA/KSThF	R, ACR guidelines		

1

Hoang 2018 ⁹²
Retrospective
Data source: patients undergoing FNAB with definitive cytology results or surgical resection from April 2009 to May 2010 Recruitment: consecutive
n = 92 (100 nodules)
Age, mean (SD; range): 52 (14; 19-82) Gender (male to female ratio): Ethnicity: not specified Setting: unspecified institution Country: USA Inclusion criteria: patients undergoing FNAB with definitive cytology results or surgical resection from April 2009 to May 2010 at a single institution Exclusion criteria: absence of a dedicated video clip of the biopsied nodule
Thyroid cancer
Index test: Ultrasound The US examinations were performed by using a variety of commercially available units equipped with 5-15-MHz linear array transducers. In all cases, images of the biopsied nodules were obtained in transverse and longitudinal planes. Video clips of the biopsies nodules were obtained in at least one plane. 11 radiologists from nine different institutions evaluated the nodules on the ACR portal. Readers were blinded to the pathology results. Three expert readers, that were on the ACR TI-RADS committee and had between 26 and 34 years of post-training experience, interpreted the sonograms independently and their consensus was used as the truth for the nodule imaging features. The other eight radiologists were test readers who had no knowledge of ACR TIRADS. All reported thyroid US in their clinical practice. All radiologists assessed the nodules for the five feature categories in the ACR TI-RADS lexicon (composition, echogenicity, shape, margin, and echogenic foci) after reviewing two to four static US images and one or two video images of the same nodule. Test readers also assigned a malignancy risk that matched the five risk stratification levels used in the ACR TI-RADS guidelines (highly suspicious, moderately suspicious, mildly suspicious, not suspicious or benign). Expert and test readers' feature assignments for nodules and maximum nodules size were then used to retrospectively assign an ACR TI-RADS risk stratification level and biopsy

Reference	Hoang 2018 ⁹²						
	recommendation. ATA and Korean and French TI-RADS guidelines were retrospectively applied.						
	Reference stand	dard: Cytology and Patho	blogy				
	Time between r	neasurement of index tes	and reference standard	: not specified			
2×2 table	ACR-TIRADS	Reference standard +	Reference standard -	Total			
	Index test +	14	48	62			
	Index test -	1	37	38			
	Total	15	85		100		
2×2 table	ΑΤΑ	Reference standard +	Reference standard -	To	otal		
	Index test +	13	70		83		
	Index test -	2	15		17		
	Total	15	85	1	100		
2×2 table	F-TIRADS	Reference standard +	Reference standard -	Тс	otal		
	Index test +	13	57		70		
	Index test -	2	28		30		
	Total	15	85	1	100		
2×2 table	K-TIRADS	Reference standard +	Reference standard -	Тс	otal		
	Index test +	13	71		84		
	Index test -	2	14		16		
	Total	15	85	1	100		
Statistical		sound (ACR-TIRADS)					
measures	Sensitivity: 92%						
	Specificity: 44%						
	Accuracy: 52%	0					
	Index text Ultras						
	Sensitivity: 87%						
	Specificity: 18%						

Reference	Hoang 2018 ⁹²
	Accuracy: 28%
	Index text Ultrasound (F-TIRADS)
	Sensitivity: 87%
	Specificity: 33%
	Accuracy: 41%
	Index text Ultrasound (K-TIRADS)
	Sensitivity: 87%
	Specificity: 16%
	Accuracy: 27%
Source of	Not specified
funding	Not specified
Limitations	Risk of bias: serious risk due to reference standard; flow and timing
Linitationo	Indirectness: none
Comments	Diagnostic performance of ATA, ACR-TIRADS, K-TIRADS, F-TIRADS
Reference	Hobbs 2014 ⁹⁴
Study type	Retrospective
Study	Data source: 400 consecutive records of US-guided FNA encounters through the department of radiology from July 2010 to June 2011
methodology	Recruitment: consecutive
Number of	n = 350 (360 biopsy encounters)
patients	
Patient	Age, mean (range): 55 (7-91)
characteristics	
	Gender (male to female ratio): 60:290
	Ethnicity: not specified
	Setting: Department of Rediclegy, Division of Neuroradialogy, Duke University Medical Centre, Durham
	Setting: Department of Radiology, Division of Neuroradiology, Duke University Medical Centre, Durham
	Country: USA

Thyroid Disease: DRAFT FOR CONSULTATION Imaging for Fine Needle Aspiration

Reference	Hobbs 2014 94							
	Inclusion criteria on a given date		hyroid nodules during a		ined as presentation to the department of radiology July 2010 to June 2011.			
Target	Thyroid cancer		ive pairology results					
condition(s)	,							
Index test(s) and reference standard	Index test: Ultrasound Diagnostic ultrasound images of the thyroid nodules were obtained before the biopsy using a 12 MHz transducer. Thyroid nodules were measured on the ultrasound unit by the technologist or radiologist at the time of imaging and were documented in the examination report. These sizes were used and nodules were not measured retrospectively. A board-certified radiologist (7 years of experience) reviewed ultrasound images on PACS workstation for findings according to the SRU recommendations which were met if the biopsied nodule had any of the following characteristics: size 10 mm or larger with microcalcifications, size 15 mm or larger with solid composition or coarse calcifications, size 20 mm or larger with mixed solid-cystic composition, or substantial growth since the prior ultrasound. Biopsy encounters were categorised on the basis of sonographic findings as meeting the SRU recommendations for biopsy, referred to as 'SRU- positive' or not ('SRU-negative'). <u>Reference standard: US-guided Fine-needle aspiration cytopathology (n=253 patients) or surgery (n=87 patients)</u> FNA cytopathology was characterised by the Bethesda class categories. FNAs included Bethesda class II or VI cytopathologic results or final surgical pathology (n=360 biopsy encounters). 40 patients were excluded because FNA cytopathologic results revealed Bethesda class I, III, IV or V without repeat FNA or surgery for definitive pathology results. Time between measurement of index test and reference standard: one day for almost all patients							
2×2 table		Reference standard +	Reference standard -	Total				
	Index test +	24	250	274				
	Index test -	5	81	86				
	Total	29	331	360				
Statistical measures	Index text Ultrasound Sensitivity : 83% Specificity: 25% PPV: 8.76% NPV: 94.2%							
Source of	Not stated							

Reference	Hobbs 2014 ⁹⁴
funding	
Limitations	Risk of bias: Serious due to risk of bias in the interpretation of the index test results. Indirectness: none
Comments	Diagnostic accuracy of SRU guidelines
Reference	Horvath 2009 97
Study type	Prospective
Study	Data source: 1959 thyroid nodules submitted for FNAB
methodology	Recruitment: not specified
Number of patients	n = 1097 nodules
Patient	Age, mean (range): not specified
characteristics	
	Gender (male to female ratio): not specified
	Ethnicity: not specified
	Setting: not specified
	Country: Chile
	Inclusion criteria: not specified
	Exclusion criteria: not specified
Target	Thyroid cancer
condition(s)	
Index test(s)	Index test: Ultrasound
and reference	Us equipment used was the ATL HDI 5000 and the Philips IU22 with a 5-12 and 5 to 17-MHz probe and colour Doppler. Nodules were
standard	classified based on the TI-RADS categories as follows: TIRADS 2: benign findings; TIRADS 3: probably benign; TIRADS 4A:
	undetermined; TIRADS 4B: suspicious; TIRADS 5: consistent with malignancy; TIRADS 6: malignant
	Defense atendered. Fine needle conjustion history
	Reference standard: Fine-needle aspiration biopsy
	FNAB was performed by five specialising radiologists, under US guidance using a 19 or 21-gauge needle attached to a 10-cc syringe.
	Two experience pathologists read all the samples. The histological result of the FNAB was classified as either benign,

Horvath 2009	97			
groups were con	nsidered: benign and nor malignant FNAB results	ns) or malignant, accordir n-benign (including malign were submitted to surger at and reference standard	nant and follicular lesiony. Benign lesions were	
	Reference standard +	Reference standard -	Total	
Index test +	349	360	709	
Index test -	46	342	389	
Total	394	703	1097	
Index text Ultras Sensitivity : 88% Specificity: 49% PPV: 49% NPV: 88% Accuracy: 94%	0			
Not stated				

Thyroid Disease: DRAFT FOR Imaging for Fine Needle Aspiration

DRAFT FOR CONSULTATION

	© National Inst		
	titute for He		
	alth and Ca		
92	© National Institute for Health and Care Excellence. 2019		
	2019		

Reference

2×2 table

Statistical

measures

Source of

Limitations

Comments

funding

Indirectness: none

7 and May 1998

Risk of bias: Very serious due to patient selection; flow and timing

Diagnostic accuracy of TI-RADS guidelines, using BI-RADS as a model

ИНz. irregular	Thyroid Disease: DRAFT FOR CONSULTATION Imaging for Fine Needle Aspiration

Reference	Kim 2002 ¹¹⁴						
Patient	Age, mean (range): 48 (20-77)						
characteristics	Gender (male to female ratio): 12:120						
	Ethnicity: Not a	specified					
	Setting: Depar	tment of Diagnostic radiolc	ogy, Severance Hospital,	Yosnei University Co	ollege of Medicine		
	Country: Korea	a					
	Inclusion criter	ia: solid nonpalpable thyro	id nodules				
	Exclusion crite	Exclusion criteria: not specified; excluded cystic nodules, nodules with mixed cystic and solid portions.					
Target condition(s)	Thyroid cancer						
Index test(s) and reference standard	Index test: Sonography Performed by one radiologist with an HDI 3000 scanner using electronically focused near-field probes with a bandwidth of 7-12 MHz.						
	Nodules were classified as positive (malignant) if one of the following sonographic features was present: micro calcifications, an irregular or microlobulated margin, marked hypoechogenicity, a shape that is more tall than it is wide. If a nodule had no suspicious features was classified as negative (benign).						
	Reference standard: Fine-needle aspiration biopsy (with or without surgery or surgery alone)						
	All solid nodules were aspirated in patients with two or more solid nodules. Further details of the FNAB were not specified.						
	Time between measurement of index test and reference standard: not specified						
2×2 table		Reference standard +	Reference standard -	Total	Reference standard was: FNAB and follow-up		
	Index test +	46	36	82	(>24 months) of 83 benign nodules; follow up by		
	Index test -	3	70	73	FNAB and surgery on 44 malignant and 15		
	Total	49	106	155	benign lesions; surgery alone on five malignant and eight benign lesions.		

Reference	Kim 2002 ¹¹⁴
Statistical	Index text Sonography:
measures	Sensitivity : 93.8% Specificity: 66% PPV: 56.1% NPV: 95.9% Overall accuracy: 74.8%
Source of funding	Not stated
Limitations	Risk of bias: serious risk of bias due to potential bias in patient selection, interpretation of the index test and/or the reference standard Indirectness: none
Comments	

Reference	Kim 2013 ¹¹⁴
Study type	Prospective (review of retrospective data)
Study methodology	Data source: patients biopsied under ultrasound guidance from September 2007 to March 2008 Recruitment: unclear, patients meeting inclusion criteria
Number of patients	n = 686 (713 nodules)
Patient characteristics	Age, mean (range): 49.7
	Gender (male to female ratio): 87:599
	Ethnicity: Not specified
	Setting: Department of radiology, Research Institute of Radiological Science, Yosnei University College of Medicine
	Country: South Korea

Reference	Kim 2013 ¹¹⁴						
	Inclusion criteria: nodules 6-10 mm biopsied under ultrasound guidance that were operated on for nondiagnostic, indeterminate, malignant or suspicious cytological results and that were operated on or showed no interval change for at least 1 year of follow-up for benign cytology. Exclusion criteria: nodules with insufficient cytological results for deciding whether benign or malignant						
		ia: nodules with insufficiel	nt cytological results for o	aeciding whether ber	nign or malignant		
Target condition(s)	Thyroid cancer						
Index test(s)	Index test: Ultrasound (US)						
and reference standard		US images were obtained using 5-12 MHz linear transducers (HDI 5000 and IU-22, respectively). Real-time ultrasound was performed by seven radiologists (four faculty members with 5-13 years of experience and three fellows).					
		all thyroid nodules that un ation, shape and vascular			led according to internal component, echogenicity,		
	Reference stan	dard: UG-FNAB					
			ned to either a 2mL or 20	mL disposable plas	tic syringe. Aspiration was done at least twice in		
		d aspirated material was					
			. 0				
	Time between r	neasurement of index tes	t and reference standard	: not specified			
2×2 table	ΑΤΑ	Reference standard +	Reference standard -	Total			
	Index test +	286	306	592			
	Index test -	10	111	121			
	Total	296	417	713			
Otatiatian	lus el e 4 e 4 1 . 114						
Statistical	Index text: Ultra						
measures	Sensitivity : 96.6% Specificity: 26.6%						
	Specificity: 20.6% PPV: 48.3%						
	NPV: 91.7%						
	AUC:0.616%						
Source of	Not stated						
funding	ווטו זומוכע						
runung	Risk of bias: serious risk of bias due to potential risk in the conduct or interpretation of the index test and/or reference standard						

Reference	Kim 2013 ¹¹⁴
	Indirectness: none
Comments	Diagnostic accuracy of ultrasonographic features of the ATA 2009 guidelines
Reference	Kim 2013 ¹¹⁴
Study type	Retrospective
Study methodology	Data source: patients having undergone US and US-guided FNA between March 2010 and July 2011 Recruitment: unclear
Number of patients	n = 925 (1419 nodules)
Patient characteristics	Age, mean (range): 51.87 (14-85)
	Gender (male to female ratio): 104:821
	Ethnicity: Not specified
	Setting: Department of Surgery, Wonju Christian Hospital
	Country: South Korea
	Inclusion criteria: patients having undergone US and US-guided FNA between March 2010 and July 2011 at the Department of Surgery, Wonju Christian Hospital
	Exclusion criteria: not specified
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound (US) All neck ultrasounds were performed by a surgeon under the supervision of three experienced endocrine surgeons using high frequency linear array transducers 7.5-13 MHz.
	Nodules were classified according to new US guidelines which were established via discussions among experienced physicians who participated in the study. Each nodule was classified by standard US characteristics: suspicious for malignancy, intermediate, probably benign.
	Reference standard: UG-FNAB

Thyroid Disease: DRAFT FOR CONSULTATION Imaging for Fine Needle Aspiration

Reference	Kim 2013 ¹¹⁴				
	Benign cytolog nodule, Hashir undetermined positive for ma	noto thyroiditis, and subac significance, follicular neo	by the Bethesda classifica sute thyroiditis. The intern plasms, and suspicion of	ation system including nediate category includ malignancies. Malign	histopathology consistent with benign follicular ded results consistent with atypical cells of ant category was defined as all histopathology
2×2 table		Reference standard +	Reference standard -	Total	
	Index test +	147	354	501	
	Index test -	0	127	127	
	Total	147	481	628	
2×2 table	New guidelines	Reference standard +	Reference standard -	Total	
	Index test +	142	121	263	
	Index test -	6	676	682	
	Total	148	797	945	
Statistical measures	Sensitivity : 99 Specificity: 62. PPV: 25% NPV: 99.8% Accuracy: 24.1	6% 1% <u>rasound (new guidelines)</u> 7%	<u>5)</u>		
Source of funding	Not stated				
Limitations	Risk of bigs: w	erv serious due to risk of h	ias in nationt selection in	the conduct or intern	retation of the index test, flow and timing
	TISK ULDIAS. VE	ery serious que lo risk or b	as in patient selection, il	r the conduct of interp	relation of the much test, now and timing

Reference	Kim 2013 ¹¹⁴
	Indirectness: none
Comments	Diagnostic accuracy of US features of current and new guidelines
Reference	Koh 2018 ¹¹⁴
Study type	Retrospective
Study	Data source: thyroid nodules with benign or malignant diagnosis confirmed by surgery or US-guided FNA between November 2013 to
methodology	July 2014
	Recruitment: consecutive
Number of	n = 363 (370 nodules)
patients	
Patient	Age, mean (SD; range): 53.1 (13; 19-86)
characteristics	
	Gender (male to female ratio): 65:298
	Ethnicity: Not specified
	Setting: Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yosnei University, College of Medicine
	Country: South Korea
	Country. South Rolea
	Inclusion criteria: nodules ≥10 mm in size, proven to be benign or malignant by surgery or diagnosed as benign or malignant on US-FNA
	wither on initial aspiration or repeat US-FNA after initial non-diagnostic or indeterminate cytology results.
	Exclusion criteria: Symptomatic thyroid cysts that were aspirated for symptom relief
Target	Thyroid cancer
condition(s)	
Index test(s)	Index test: Ultrasound (US)
and reference	Gray-scale US was performed with a 5-12 MHz linear probe by 14 board-certified radiologists with 1-19 years of experience in thyroid
standard	imaging (four staff radiologists, 10 fellows), including four study observers. One radiologist captured transverse and longitudinal images of
	each thyroid nodule from the picture PACS. Four observers with 19, 15, two and one years of experience in thyroid imaging,
	independently reviewed the images and filled out data interpretation forms. All four observers were blind to the clinical information of the patient or cytologic results during the image review.
	After assessing US features, final assessment of nodules was based on the Kim criteria, TI-RADS by Kwak et al, and the 2015 ATA

Imaging for	Thyroid
g for Fine Needle /	yroid Disease:
edle Aspirati	DRAFT I
ation	FOR CON
	CONSULTAT
	NOI.

Reference	Koh 2018 ¹¹⁴				
	guidelines. Test positive: Suspicious malignant for Kim; categories 4 and 5 for TI-RADS; low, intermediate and high suspicion for the 2015 ATA guidelines.				
	Reference standard: UG-FNAB or surgery (n=57) US-fine needle aspiration cytology either on initial aspiration or repeat US-FNA after initial non-diagnostic or indeterminate cytolo results.				
	Time between	measurement of index tes	t and reference standard	1: not specified	
2×2 table	Kim	Reference standard +	Reference standard -	Total	
	Index test +	158	303	461	
	Index test -	54	965	1019	
	Total	212	1268	1480	
2×2 table	K-TIRADS	Reference standard +	Reference standard -	Total	
	Index test +	193	759	952	
	Index test -	19	509	528	
	Total	212	1268	1480	
2×2 table	2015 ATA	Reference standard +	Reference standard -	Total	
	Index test +	197	999	1196	
	Index test -	15	269	284	
	Total	212	1268	1480	
Statistical measures	Index text: Ultr Sensitivity : 74 Specificity: 76. PPV: 34.3% NPV: 94.7% AUC:0.753 Accuracy: 75.9 Index text: Ultr Sensitivity : 91 Specificity: 40. PPV: 20.3%	.5% 1% % <u>asound (Kwak-TIRADS)</u> %			

Reference	Koh 2018 ¹¹⁴
	NPV: 96.4% AUC:0.809 Accuracy: 47.4% Index text: Ultrasound (2015 ATA) Sensitivity : 92.9% Specificity: 21.2% PPV: 16.5 % NPV: 94.7% AUC:0.804 Accuracy: 31.5%
Source of funding	No funding
Limitations	Risk of bias: none Indirectness: none
Comments	Diagnostic accuracy of US using Kim, K-TIRADS, 2015 ATA guidelines

Reference	Koseoglu Atilla 2018 ¹³³
Study type	Retrospective
Study methodology	Data source: patients with thyroid nodules who underwent FNA between 2010 and 2014 in Tepecik Training and Research Hospital
	Recruitment: consecutive
Number of patients	n = 2847 patients; 2614 finally included
Patient characteristics	Age, mean (SD): 51.01 (13.86)
	Gender (male to female ratio): 2263/351
	Ethnicity: not specified
	Setting: Tepecick Training and Research Hospital

Thyroid Disease: DRAFT FOR CONSULTATION Imaging for Fine Needle Aspiration

Reference	Koseoglu Atilla 2018	3 133			
Target condition(s) Index test(s) and reference standard	Country: Turkey Inclusion criteria: consecutive patients with thyroid nodules undergoing FNA between 2010 and 2014; i.e. patients with solid nodules ≥1cm, or with mixed cystic nodules ≥1.5-2cm and songiform nodules ≥2cm and patients with high risk history who had nodules ≥5mm Exclusion criteria: patients with non-diagnostic FNABs Thyroid cancer Index test: Ultrasound US was performed by using high-spatial resolution US machines equipped with a 5.5-12.5 MHz linear probe.				
	Nodules were classified according to the ACR TI-RADS guideline based on composition, echogenicity, shape, and margin charact of the nodules as bening (TR1), not suspicious (TR2), mildly suspicious (TR3), moderately suspicious (TR4) and highly suspicious <u>Reference standard: US-guided FNA</u> FNAB was performed according was performed according to the 2009 ATA guideline. Cytopathological interpretation of FNAB sar was done using the Bethesda System for reporting Thyroid Cytopathology. Time between measurement of index test and reference standard: not specified				ately suspicious (TR4) and highly suspicious (TR5).
2x2 table	ACR TI-RADS	Reference standard +	Reference standard -	Total	Patients with non-diagnostic FNABs
	Index test +	79	880	959	(Bethesda I) were excluded (n=233)
	Index test -	22	1633	1655	
	Total	101	2513	2614	
Statistical measures	Index text Ultrasound Sensitivity : 78.22% Specificity: 65%	<u>(ACR-TIRADS)</u>			
Source of	Not specified				

Reference	Koseoglu Atilla 2018 ¹³³
funding	
Limitations	Risk of bias: none Indirectness: none
Comments	Diagnostic accuracy of US using ACR-TI-RADS

Reference	Lauria Pantano 2018 ¹³⁸
Study type	Retrospective (cross-sectional)
Study methodology	Data source: nodules undergoing FNA from January 2015 to May 2016
	Recruitment: not specified
Number of patients	n = 946 (1169 nodules)
Patient characteristics	Age, mean (SD): 56(13.3)
	Gender (male to female ratio): 199:946
	Ethnicity: not specified
	Setting: Unit of Endocrinology and Diabetes of the Campus Bio-Medico University
	Country: Italy
	Inclusion criteria: All nodules undergoing FNA from January 2015 to May 2016
	Exclusion criteria: nodules with TIR1 (non-diagnostic cytology)
Target condition(s)	Thyroid cancer
Index test(s)	Index test: Ultrasound
and reference standard	US of the thyroid gland and neck area was performed by experienced physicians at a frequency range of 10-12 MHz on a MyLab 50. Nodules were then classified according to the ATA, AACE/ACE/AME US and ACR TI-RADS risk stratification by an automated algorithm.
otunidard	Based on the description retrieved from medical records, a yes or no answer to each of the following features were input for each nodule
	into a Microsoft excel worksheet: purely cystic, more than 50% cystic, eccentric solid area, spongiform, spongiform with internal
	vascularisation, mixed cystic and solid, solid hypoechoic, solid marked (or very hypoechoic), solid isoechoic, hyperechoic,

Reference	Lauria Pantano 2018 ¹³⁸				
	calcifications with sr specified coding dev	nall extrusive soft tissue co	omponent, evidence of ext bove-mentioned guideline	rathyroidal ex s, the softwa	gular margins, taller than wide shape, rim xtension/ suspicious nodes. Then, by using a pre- re combined all the yes or no answers and gory to each nodule
	independent from th specimens were eva (non-diagnostic), TII indeterminate lesion	s performed by experience le study. FNA was perform aluated by expert cytopathe R1C (nondiagnostic cystic) n), TIR4 (suspicious of mali e considered clinically non-	ed by free-hand technique ologists conforming to the , TIR2 (non-malignant/ber gnancy) or TIR 5 (maligna malignant/benign. TIR3b,	e under US g Italian Repor nign), TIR3a (ant). TIR1 noo TIR4 and TIF	d based on an impartial clinical indication, uidance, using a 23- or 25-gauge needle. Cytology rting System for Thyroid Cytology as follows: TIR1 (low-risk indeterminate lesion), TIR3b (high-risk dules were excluded from the study. Nodules with R5 were classified as cytologically high risk of
		TIR2 and TIR3a were consurement of index test and	, , , ,	·	
2×2 table			, , , ,	·	N=54 nodules did not match the ATA
2×2 table	Time between meas	surement of index test and	reference standard: not s	pecified	N=54 nodules did not match the ATA sonographic patterns and were categorised as
2×2 table	Time between meas	surement of index test and Reference standard +	reference standard: not s	pecified Total	
2×2 table	Time between meas ATA Index test +	surement of index test and Reference standard + 87	reference standard: not s Reference standard – 525	Decified Total 612	sonographic patterns and were categorised as
2×2 table 2x2 table	Time between meas ATA Index test + Index test –	surement of index test and Reference standard + 87 17	reference standard: not s Reference standard – 525 394	Decified Total 612 411	sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were
	Time between meas ATA Index test + Index test – Total	Surement of index test and Reference standard + 87 17 104	reference standard: not s Reference standard – 525 394 919	Total 612 411 1023	sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk
	Time between meas ATA Index test + Index test – Total AACE/ACE/AME	Reference standard + 87 17 104 Reference standard +	reference standard: not s Reference standard – 525 394 919 Reference standard –	Total 612 411 1023 Total	sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk N=28 did not match the AACE/ACE/AME
	Time between meas ATA Index test + Index test - Total AACE/ACE/AME Index test +	Reference standard + 87 17 104 Reference standard + 109	reference standard: not s Reference standard – 525 394 919 Reference standard – 786	Total 612 411 1023 Total 895	 sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk N=28 did not match the AACE/ACE/AME categories and were categorised as
	Time between meas ATA Index test + Index test - Total AACE/ACE/AME Index test + Index test + Index test -	Reference standard + 87 17 104 Reference standard + 109 3	reference standard: not s Reference standard – 525 394 919 Reference standard – 786 151	Total 612 411 1023 Total 895 154	 sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk N=28 did not match the AACE/ACE/AME categories and were categorised as 'AACE/ACE/AME unclassified'; of these n=1
2x2 table	Time between meas ATA Index test + Index test - Total AACE/ACE/AME Index test + Index test + Index test - Total	Reference standard + 87 17 104 Reference standard + 109 3 112	reference standard: not s Reference standard – 525 394 919 Reference standard – 786 151 937	Total 612 411 1023 Total 895 154 995	 sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk N=28 did not match the AACE/ACE/AME categories and were categorised as 'AACE/ACE/AME unclassified'; of these n=1
2x2 table	Time between meas ATA Index test + Index test - Total AACE/ACE/AME Index test + Index test + Index test + Index test + Index test - Total AACE/ACE/AME Index test - Total ACR TI-RADS	Reference standard + 87 17 104 Reference standard + 109 3 112 Reference standard +	reference standard: not s Reference standard – 525 394 919 Reference standard – 786 151 937 Reference standard –	Total 612 411 1023 Total 895 154 995 Total	 sonographic patterns and were categorised as 'ATA unclassified', n=9 of those were cytologically high risk N=28 did not match the AACE/ACE/AME categories and were categorised as 'AACE/ACE/AME unclassified'; of these n=1

© National Institute for Health and Care Excellence. 2019 103

Reference	Lauria Pantano 2018 ¹³⁸
Statistical	Index text Ultrasound (ATA)
measures	Sensitivity : 83.7%
	Specificity: 42.9%
	PPV: 14.2%
	NPV: 95.9%
	Index text Ultrasound (AACE/ACE/AME)
	Sensitivity : 97.3%
	Specificity: 16.1%
	PPV: 12.2%
	NPV: 98.1%
	Index text Ultrasound (ACR-TIRADS)
	Sensitivity: 82.3 %
	Specificity: 45.5%
0	NPV: 96.6%
Source of	No funding
funding Limitations	Risk of bias: none
Limitations	Indirectness: none
Comments	Diagnostic accuracy of US using ATA, AACE/ACE/AME, ACR-TI-RADS
Comments	Diagnostic accuracy of US using ATA, AACE/ACE/AME, ACR-11-RADS
Reference	Lim-Dunham 2017 ¹⁵⁰
Study type	Retrospective study
Study	Data source: paediatric patients who underwent US fine-needle aspiration biopsy
methodology	
	Recruitment: consecutive
Number of	n = 33 (39 nodules)
patients	
Patient	Age, median (range): Benign nodules 16 (8-18); malignant 16.5 (9-18)
characteristics	
	Gender (male to female ratio): 5:28

Reference	Lim-Dunham 2017 ¹⁵⁰						
Neierence	Ethnicity: not specified						
	Setting: Department of Radiology, Loyola University Chicago Stritch School of Medicine						
	Country: USA						
	Inclusion criteria: patients ages 18 years and younger who were referred to the radiology department for US-FNAB of one or more thyroid nodules at authors' medical centre between 1996 and 2016						
	aclusion criteria: lack of preliminary US images (n=29), uncertainty in correlating the identity of the nodule on US with pathology (n= 3) and poor US image quality (n=14).)					
Target condition(s)	Thyroid cancer						
Index test(s) and reference standard	Based on US features, each nodule was assigned a level of suspicion of malignancy based on the 2015 ATA management guidelines: benign very low suspicion, low suspicion intermediate suspicion, high suspicion. <u>Reference standard: UG-FNAB or surgery (n=14)</u> Two board-certified paediatric radiologists each with more than 10 years' of experience performed the FNAB procedures in the radiology department by free-hand technique with US guidance using a 25-gauge needle. Nodules less than 5 mm or located adjacent to the common carotid artery or internal jugular vein were not considered for UG-FNAB. Between two and eight samples were taken from the						
	solid component of each nodule. A staff pathologist was present during the procedure to verify diagnostic adequacy of the sample. A decision to proceed with surgical thyroidectomy was made by the endocrine surgeon. If a patient did not undergo surgery, the cytopathology from the UG-FNAB was used to classify nodules. Nodules were classified according to the Bethesda System for reporting Thyroid Cytopathology as follows: Class I, nondiagnostic; C benign; Class III, atypia or follicular lesion of undetermined significance; Class IV, follicular neoplasm/suspicion for a follicular neopla Class V, suspicious for malignancy; and Class VI, malignant. Bethesda Class II and III were considered benign and Class IV, V and were considered malignant.						
2×2 table	Reference standard + Reference standard - Total Notes: 14 nodules were classified based on surgical pathology (n=2 benign, n=12 malignated based on surgical pathology (n=2 benign)	ant)					

Reference	Lim-Dunham 2017 ¹⁵⁰						
	Total	12	21	33	Analysis included each patient's largest nodule observation.		
Statistical measures	Index text Ultrasound Sensitivity : 100% Specificity: 57.1% PPV: 57.1% NPV: 100%						
Source of funding	Not specified						
Limitations	Risk of bias: none Indirectness: none						
Comments	Diagnostic accuracy of US in children using the 2015 ATA guidelines						

Refere	ence	Macedo 2018 ¹¹⁴
Study	type	Prospective
Study metho	odology	Data source: patients with thyroid nodules attending tertiary university-based hospital between July 2014 to August 2015
		Recruitment: consecutive unselected patients
Numb patien		n = 178 (195 nodules)
Patien charac	nt cteristics	Age, median (range): 59 (49-66)
		Gender (male to female ratio): 9:169
		Ethnicity: Not specified
		Setting: Endocrinology Division, Santa Casa de Misericordia de Porto Alegre (tertiary, university-based hospital)
		Country: Brazil (Southern iodine-replete area)
		Inclusion criteria: unselected patients with thyroid nodules attending hospital between July 2014 and August 2015

Reference	Macedo 2018 ¹¹⁴
	Exclusion criteria: Patients with known thyroid cancer and/or purely cystic nodules
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound (US) (using TI-RADS & ATA) Thyroid Ultrasound Conventional B-mode and Doppler images of the neck and thyroid gland were obtained by ultrasound machine (ACUSON S2000, Siemens and ACUSON Antares, Siemens HealthCare, Erlangen, Germany) using a high-frequency probe (12 MHz). A US examinations were performed by the same radiologist (RFI) who has more than 10 years of experience in thyroid ultrasound. All images were examined on real-time two-dimensional gray-scale and Doppler imaging.
	Findings that were considered in favour of malignancy were hypoechoic or markedly hypoechoic in echogenicity; irregular, microlobulated or ill-defined margins; presence of micro calcification; round shape and the presence of lymphadenopathy.
	Prospective evaluation using the modified Russ classification was performed. Each nodule was classified into a TI-RADS category (2, 3, 4 and 5) based on US features. Benign patterns: category 3 or 2; Suspect patterns: category 5 or 4.
	Posteriorly, the same radiologist (RFI), blind about pathological results, scored all evaluated nodules based on new ATA thyroid nodule guideline. Based on the number of features suspicious for malignancy four different sonographic patterns were considered: 'very low suspicion'; 'low suspicion'; 'intermediate' and 'high suspicion'. Benign patterns: low risk and very low risk category; Suspect patterns: high risk and intermediate risk category.
	Reference standard: FNA, cytology, histology All 195 nodules were submitted to FNA performed by using a capillary US-guided technique with a 23-gauge needle attached to a 10 mL disposable plastic syringe. Only one needle pass was made per lesion in most cases. Cytology smears were prepared on four to six slides. One cytopathologist from the institution with vast experience in thyroid pathology interpreted the smears. A thyroid FNA specimen was considered satisfactory if at least 6 groups of follicular cells were present, and each group comprised at leas 10 cells.
	The Bethesda System for Cytological classification of Thyroid Nodules was used to interpret smears as: 1) non-diagnostic or unsatisfactory,2) benign, 3) atypia of undetermined significance, 4) follicular neoplasm or suspicious for a follicular neoplasm, 5) suspicious for malignancy and 6) malignant.
	Histology was_available for 45 cases: Surgery was indicated based on cytopathological results (Bethesda 4,5 and 6), or when the nodule was benign (Bethesda 2) but larger than 2-3 cm and causing compressive symptoms. Anatomopathological examinations of tissue samples obtained at thyroidectomy were carried out according to the World Health organization Guidelines and the pathology reports pertaining to these samples were considered identical to the gold standard for the diagnosis of thyroid cancer.

Reference	Macedo 2018 ¹¹⁴						
	Time between measurement of index test and reference standard: not specified						
2×2 table	TIRADs	Reference standard +	Reference standard -	Total	Notes: Only Bethesda categories 2 and 6 were		
	Index test +	5	51	56	used (n=138) to compare TI-RADS and ATA		
	Index test -	0	82	82	score with cytological results.		
	Total	5	133	138			
2×2 table	ATA	Reference standard +	Reference standard -	Total	Notes: Only Bethesda categories 2 and 6 were		
	Index test +	5	33	38	used (n=138) to compare TI-RADS and ATA		
	Index test –	0	100	100	score with cytological results.		
	Total	5	133	138			
measures Source of	Sensitivity : 100% Specificity: 61.6% NPV: 100% Accuracy: 63% Index text: Ultrasound (ATA) Sensitivity : 100% Specificity: 75 % NPV: 100% Accuracy: 76%						
funding	Not stated						
Limitations	Risk of bias: serious risk of bias due to flow and timing, potential bias in the interpretation of the reference standard Indirectness: none						
Comments	Diagnostic accuracy of ultrasonography using ATA and TI-RADS risk stratification.						
Reference	Maino 2018 ^{114, 170}						
Study type	Prospective						
Study methodology	Data source: patients with nodules submitted to FNAC from November 2016 to June 2017 Recruitment: not specified						

Reference	Maino 2018 ^{114, 170}
Number of patients	n = 340 (432 nodules)
Patient characteristics	Age, mean (SD, range): 57 (14.3, 16-86)
	Gender (male to female ratio): 77:263
	Ethnicity: Not specified
	Setting: Department of Medical, Surgical and Neurological Sciences, University of Sienna
	Country: Italy
	Inclusion criteria: all nodules submitted to FNAC for diagnostic purposes
Torrat	Exclusion criteria: not specified; nodules with non-diagnostic cytology were finally excluded from analysis
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound (US) Neck US was performed by the same experienced endocrinologist of our staff using a high-resolution US color Doppler apparatus with a 7.5 MHz linear transducer. US features of each thyroid nodule were described and recorded in the database by the endocrinologist who performed the examination and nodules were stratified using sonographic patterns as described and published in the 2015 ATA guidelines into: benign, very low suspicion, low suspicion, intermediate suspicion and high suspicion categories and as described in the ETA US risk stratification system into: EU-TIRADS 2 (benign), EU-TIRADS 3 (low risk), EU-TIRADS 4 (intermediate risk) and EU-TIRADS 5 (high risk)
	Reference standard: FNA, cytology, histology US-guided FNAC was performed for at least two separate passes for each thyroid nodule by using a 23/25-gauge needle. Material was air dried, trained with May-Grunwald Giemsa and interpreted by the same experienced cytologist. Cytology reports from US-guided FNAC of thyroid nodules were based on the five categories according to the criteria of the British Thyroid Association (Thy 1: nondiagnostic; Thy2: benign, Thy 3: undetermined significance; Thy 4: suspicious for malignancy; and Thy 5: malignant)
	All patients with Thy4/Thy5 cytologies were send to surgery; in Thy2 only those with compressive symptoms were send to surgery and the remaining were observed by annual follow-up.
	Time between measurement of index test and reference standard: not specified

Time between measurement of index test and reference standard: not specified

Reference	Maino 2018 114	4, 170						
2×2 table	ATA	Reference standard +	Reference standard –	Total	Notes: 381 nodules finally included, excluding			
	Index test +	11	64	75	Thy 1 nodules: nondiagnostic ; 2x2 calculated			
	Index test -	3	272	275	excluding Thy3 nodules with undetermined			
	Total	14	336	350	significance (n=31)			
2×2 table	EU TIRADs	Reference standard +	Reference standard -	Total	Notes: 381 nodules finally included, excluding			
	Index test +	11	66	77	Thy 1 nodules: nondiagnostic; 2x2 calculated			
	Index test -	3	270	273	excluding Thy 3 nodules with undetermined			
	Total	14	336	350	significance (n=31)			
Statistical	Index text: Ultra	asound (ATA)						
measures	-	Sensitivity : 78.6%						
	Specificity: 80.9%							
	Index text: Ultrasound (EU-TI-RADS)							
	Sensitivity : 78.6% Specificity: 80.4%							
	Specificity. 80	.4 /0						
Source of funding	Ministero Italia	no dell'Universita e Ricerc	a					
Limitations	Risk of bias: serious risk due to patient selection, potential bias in the interpretation of index test results, flow and timing Indirectness: none							
Comments	Diagnostic accuracy of ultrasonography using ATA and EU TI-RADS risk stratification.							

...

Martinez-Rios 2018 ¹⁷⁵
Retrospective cohort
Data source: children referred to Hospital for Sick Children, Toronto with US and clinical data from January 1992 to October 2015
Recruitment: not specified, children referred to hospital for the evaluation of thyroid nodules
n = 124 (125 nodules)

Reference	Martinez-Rios 2018 ¹⁷⁵
Patient characteristics	Age, mean (SD, range): 13.6 (3.1, 3.3-17.7)
	Gender (male to female ratio): 40: 84
	Ethnicity: Not specified
	Setting: Hospital of Sick Children, Toronto
	Country: Canada
	Inclusion criteria: patients younger than 18 years; benign or malignant thyroid nodules with confirmed histology and or cytology or no histology available but a minimum 2-year follow-up with clinical sonographic stability of the nodule; thyroid nodules measuring more than 10 mm.
	Exclusion criteria: poor image quality/no US imaging available; previous exposure to irradiation; previous oncological conditions; known family history of RET, DICERI or PTEN gene mutations.
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound (US) (using TI-RADS & ATA) US findings of a combination of gray-scale and colour Doppler US images of the thyroid gland and the bilateral cervical lymph nodes compartments were analysed. Imaging was performed with iU22 and Alpio ultrasound equipment. US examinations were performed according to the standards protocols for thyroid gland/neck protocols of the research department. All examinations were performed with high-frequency linear-array transducers in longitudinal and transverse planes. The entire US examination was reviewed and background echogenicity of the thyroid gland, number of thyroid nodules, nodule location within the gland, and size of nodules in mm.
	US data were reviewed by three radiologists using the ATA and TI-RADS methods. US studies were initially scored by a consensus of two paediatric radiologists (each with 2 years' experience) and then a score by an independent paediatric radiologist (with 37 years' experience) was obtained. Readers were blinded to final diagnoses and clinical data.
	For the purposes of assigning test characteristics, when assessing the ATA method: high and intermediate suspicion classifications were considered as probably malignant; low suspicion, very low suspicion and benign were considered as probably benign. For TI-RADS: categories 4a, 4b, 4c and 5 were considered as probably malignant; categories 2 and 3 were considered as probably benign.
	Reference standard: histopathology/cytology or 2-year follow-up of clinical outcome for non-operative cases The reference standard was surgical histopathology or cytology or at least 2 years' clinical follow-up without evolution of malignant features

Reference	nce Martinez-Rios 2018 ¹⁷⁵				
	Time between	measurement of index tes	t and reference standard	I: not specified	
2×2 table	TIRADs	Reference standard +	Reference standard -	Total	Notes: excluded 1 histologically indeterminate
	Index test +	52	58	110	nodule
	Index test -	0	13	13	
	Total	52	71	123	
2×2 table	ΑΤΑ	Reference standard +	Reference standard -	Total	Notes: excluded 1 histologically indeterminate
	Index test +	45	22	67	nodule
	Index test -	7	49	56	
	Total	52	71	123	
	PPV: 47.3% NPV: 100% Index text: Ultr Sensitivity :86. Specificity: 69% PPV:67.2 % NPV: 87.5%	5 %			
Source of funding	Not stated				
Limitations	Risk of bias: no Indirectness: n				
Comments	Diagnostic acc	uracy of ultrasonography	using ATA and TI-RADS	risk stratification	n.
Reference	Middleton 179				

1

Reference	Middleton ¹⁷⁹
Number of patients	n = 3315 (3822 nodules)
Patient characteristics	Age, mean (SD): 54.4(18-97)
	Gender (male to female ratio): 766:3056
	Ethnicity: not specified
	Setting: Mallinckordt Institute of Radiology, Washington University St Louis; Department of Diagnostic radiology, Mayo Clinic, Rochester; Department of Radiology, The Parelman school of medicine at the University of Pennsylvania; department of Diagnostic imaging, Rhode island hospital, Brown University; Department of Radiology, University of Kentucky College of Medicine; Department of radiology, Stanford University Medical Centre
	Country: USA
	Inclusion criteria: All patients 18 years or older who had undergone diagnostic thyroid ultrasound examinations and US-guided FNA of a focal nodule between August 2006 and May 2010.
	Exclusion criteria: non-diagnostic findings by FNA, surgical histologic analysis or both (n=173), or results that were indeterminate or suspicious for malignancy with no subsequent definitive diagnosis (n=227).
Target condition(s)	Thyroid cancer
Index test(s)	Index test: Ultrasound
and reference standard	Images of the biopsied nodules were obtained using a variety of commercially available ultrasound units, with specific attention prospectively directed to nodule characteristics (e.g. composition, echogenicity, margins, echogenic foci) similar to those used int the ACR lexicon to describe thyroid nodules. The sonographic images and cine clips of thyroid nodules were saved and sent to a central reading site. Nodules were analysed at the central study site by two radiologists who had access to the original ultrasound report but had no knowledge of the findings of cytologic analysis. Points were assigned to each nodule for the separate categories of composition, echogenicity, margins, and echogenic foci on the basis of
	the TIRADS guidelines. Nodule shape (i.e. taller than wide) was included in TIRADS but not in the present analysis. The sum of the points in each category determined the TIRADS level assigned to each nodule, with TR1 indicating 0 points; TR2, 2 points, TR3, 3 points, TR4, 4-6 points; TR5 7 or more points.
	Reference standard: US-guided Fine-needle aspiration
	A total of one to three nodules were biopsied for each patient. The procedure used for specimen procurement was left to the discretion of

Thyroid Disease: DRAFT FOR Imaging for Fine Needle Aspiration

DRAFT FOR CONSULTATION

A total of one to three nodules were biopsied for each patient. The procedure used for specimen procurement was left to the discretion of the physician performing the FNA. The physician was free to perform the number of needle passes deemed appropriate at their institution.

		Middleton ¹⁷⁹				
	Cytopathologic interpretations from each institution were used to distinguish between benign and malignant nodules. The results of the FNA were divided into five categories: malignant, suspicious for malignancy, indeterminate, benign and nondiagnostic. Nodules for which results were suspicious for malignancy, indeterminate or nondiagnostic were excluded from the study unless they were followed by diagnostic FNA or surgical resection that provided histologic confirmation of malignancy or benignancy. Time between measurement of index test and reference standard: not specified					
2×2 table		Reference standard +	Reference standard -	Total	Notes: 303 malignant nodules were diagnosed	
	Index test +	297	1488	1785	on the basis of cytologic analysis, were	
	Index test -	55	1582	1637	resected and had histologically confirmed	
	Total	352	3070	3422	diagnosis.	
measures	Index text Ultrason Sensitivity : 84.4% Specificity: 51.5% PPV: 16.6% NPV: 96.6 %					
Source of funding	Not specified					
	Risk of bias: none Indirectness: none					
Comments	Diagnostic accura	cy of US using TIRADS cl	lassification			

Reference	Moon 2010 ¹⁸⁷
Study type	Retrospective
Study methodology	Data source: patients that underwent US and US-guided FNAB from June 2007 to August 2007 Recruitment: consecutive
Number of	n = 1024 (1083 nodules)

Reference	Moon 2010 ¹⁸⁷
patients	
Patient characteristics	Age, median (range): 50(16-83)
	Gender (male to female ratio): 138:886
	Ethnicity: not specified
	Setting: Severance Hospital (reference centre)
	Country: South Korea
	Inclusion criteria: nodules with benign or malignant results at cytologic evaluation, or with thyroid surgery performed after cytologic results suggestive of papillary thyroid carcinoma, indeterminate results, or with benign or malignant results at cytologic examination or with surgery in case of indeterminate results or inadequate cytologic results.
	Exclusion criteria: not specified
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: gray-scale Ultrasound, elastography All gray-scale and power Doppler US examinations were performed by using a 5-12 MHz linear probe. Power Doppler examinations were performed by using the standard equipment settings for thyroid glands. US examinations were performed by one of five radiologists with 7 to 13 years of experience. US features of all thyroid nodules that underwent US-guided FNA were prospectively recorded according to the internal component, echogenicity, margin, calcifications, shape, and final assessment at the time of FNA by the radiologists who performed the US examination and US-guided FNAB. Vascularity was determined at power Doppler US. Three types of vascularity were identified: type 1, no vascularity; type 2, peripheral vascularity; type 3, intranodular vascularity. Suspicious malignant gray-scale US features were classified by using criteria of marked hypoechogenicity, noncircumscribed margin, microcalcifications and taller than wide shape. When thyroid nodules showed one or more of these suspicious malignant features, they were classified as suspicious. When thyroid nodules showed none of these suspicious features, they were classified as probably benign.
	To compare the diagnostic performance of the combination of only gray-scale US features and the combination of gray-scale and power Doppler US features, six criteria were assigned as follows: criterion 1, any single suspicious gray-scale US-feature; criterion 2, addition of peripheral and intranodular vascularities as one of suspicious features to criterion 1; criterion 3, addition of peripheral vascularity as a suspicious feature to criterion 1; criterion 4, addition of intranodular vascularity as a suspicious feature to criterion 1; criterion 5, addition of no vascularity as a suspicious feature to criterion1; and criterion 6, AACE and AME guidelines-all hypoechoic nodules with at least one of the following additional US features: irregular margins, intranodular vascular spots, taller-than-wide shape, or microcalcifications.
	Reference standard: US-guided Fine-needle bionsy

Reference standard: US-guided Fine-needle biopsy

Reference	Moon 2010 187				
	guided FNAB was features. It was no plastic syringe.	s performed on either thyroid	nodules with suspicious L c nodules. US-guided FN	JS features or the AB was performe	tions, by using a 5-12 MHz linear probe. US- e largest thyroid nodules without suspicious US ed with a 23-gauge needle and a 2-mL disposable
2×2 table	Kim	Reference standard +	Reference standard -	Total	
	Index test +	227	115	342	
	Index test -	42	699	741	
	Total	269	814	1083	
2x2	Kim+USD	Reference standard +	Reference standard -	Total	
	Index test +	245	387	632	
	Index test -	24	427	451	
	Total	269	814	1083	
2x2	AACE/AME	Reference standard +	Reference standard -	Total	
	Index test +	220	168	388	
	Index test -	49	646	695	
	Total	269	814	1083	
Statistical measures	Index text Ultraso Sensitivity : 84.4% Specificity: 85.9% PPV: 66.4% NPV: 94.3 % Index text Ultraso Sensitivity : 91.1% Specificity: 52.5% PPV: 38.8%	<u>und (Kim+ USD)</u>			

Reference	Moon 2010 ¹⁸⁷
	Specificity: 79.4 % PPV: 56.7% NPV: 92.9%
Source of funding	Not specified
Limitations	Risk of bias: serious due to risk of bias in the interpretation of the index test and reference standard test results Indirectness: none
Comments	Diagnostic accuracy of gray-scale US and power Doppler US (USD) using Kim, Kim +USD Rago, AACE/AME classification

Reference	Moon 2012 ¹⁸⁸
Study type	Retrospective
Study methodology	Data source: thyroid nodules imaged at gray-scale US, elastography and US-guided FNA from June to November 2009
	Recruitment: not specified
Number of patients	n = 676 (703 nodules)
Patient characteristics	Age, mean (range): 49.7(18-79)
	Gender (male to female ratio): 120:556
	Ethnicity: not specified
	Setting: Department of Radiology, Yosnei University College of Medicine
	Country: South Korea
	Inclusion criteria: nodules with benign or malignant results at cytologic evaluation, with thyroid surgery performed after obtaining cytologic results suspicious for papillary thyroid carcinoma or indeterminate results, or with benign or malignant results at follow-up US-guided FNA or thyroid surgery after cytologic results of inadequate specimen.

Reference	Moon 2012 188				
					aphy (n=17), nodules suspicious for papillary ion that had not undergone surgery or repeat US-
Target condition(s)	Thyroid cancer				
Index test(s) and reference standard	All gray-scale US ima eight radiologists with prospectively records of FNA by the radiolo Suspicious malignan wide shape. When the thyroid nodules show After gray-scale exa nodules detected at a technique. Elastogra score were classified elastography scores <u>Reference standard:</u> US-guided FNA biop needle and a 2-mL d	h 1 to 15 years of experier ed according to the interna- ogists who performed the l t gray-scale US features in voroid nodules showed on wed no suspicious features mination, elastography was gray-scale US and targete phy images were classifier on a scale from 1 to 5; so were classified on a scale <u>US-guided Fine-needle b</u> sy was performed by the so lisposable plastic syringe was urement of index test and	ing a 6-14 MHz linear arrance. Gray-scale US featur al component, echogenicit US examination and FNA. Included marked hypoecho e or more of these suspicit s, they were assessed as as routinely performed by ed for US-guided FNA by u d according to the scores core of 4 and 4 were class e from 1 to 4; nodules with <u>iopsy</u> same radiologist who perfi- with a freehand technique reference standard: not s	es of thyroid nod y, margin, calcific ogenicity, poorly ious malignant fe probably benign. the same radiolo using the same U by Rago et al an ified as suspiciou score of 3 and 4 ormed gray-scale	gists who performed gray-scale US, in thyroid IS machine and probe, using a free-hand ad Asteria et al. According to Rago elasography us for malignancy. According to Asteria et al were classified as suspicious for malignancy. e US and elastography, by using a 23-gauge
2×2 table	Kim Index test + Index test – Total	Reference standard + 199 18 217	Reference standard – 162 324 486	Total 361 342 703	Surgery performed after FNA in 221 nodules (202 patients); UGFNA for two nodules in 27 patients and one nodule in 649 patients.
2x2	Kim+USE Rago Index test + Index test – Total	Reference standard + 200 17 217	Reference standard – 170 316 486	Total 370 333 703	Surgery performed after FNA in 221 nodules (202 patients); UGFNA for two nodules in 27 patients and one nodule in 649 patients.
2x2	Kim+USE Asteria	Reference standard +	Reference standard -	Total	Surgery performed after FNA in 221

Reference	Moon 2012 188				
	Index test +	205	255	460	nodules (202 patients); UGFNA for two
	Index test -	12	231	243	nodules in 27 patients and one nodule in
	Total	217	486	703	649 patients.
Statistical measures	Sensitivity : 92.2% Specificity: 65% PPV: 54.1% NPV: 94.9% Accuracy: 73.4%	Ind (Kim+ USE Rago	-		
Source of funding	Not specified				
Limitations	Risk of bias: seriou Indirectness: none		in the interpretation of th	e index test and refe	rence standard test results
Comments	Diagnostic accurac	cv of grav-scale US	and elastography (USE)	using Kim Kim +US	E Rago, Kim+USE Asteria classification

Reference	Na 2016 ¹⁹⁰
Study type	Retrospective
Study	Data source: patients with thyroid nodules with final diagnosis who had FNA or core needle biopsy (CNB) at low and high cancer volume
methodology	institutions, from January 2010 to May 2011

Reference	Na 2016 ¹⁹⁰
	Recruitment: consecutive enrolment of predetermined number of 2000 nodules (1000 from each low and high cancer volume institutions)
Number of patients	n = 1802 (2000 nodules)
Patient characteristics	Age, mean (SD): 51.2 (12.2) Gender (male to female ratio): 415:1387 Ethnicity: not specified
	Setting: low and high cancer volume institutions (two primary medical centres, two tertiary hospitals) Country: South Korea
	Inclusion criteria: patients enrolled from low and high cancer volume institutions from January 2010 to May 2011, with thyroid nodules (≥1cm) with final diagnosis, who had undergone FNA or CNB.
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound A high resolution US scan using a 10-12MHz or 5-14MHz linear-array transducer was employed. US images were retrospectively reviewed by one of three experienced radiologists with 19, 16 and 12 years of experience. All reviewers with no knowledge of FNA results or final diagnosis assessed the following US features of thyroid nodules: internal content, echogenicity, margin, shape, calcification, nodule vascularity, spongiform appearance, and comet-tail artefact. Colour Doppler US images were available in 1295 nodules. Risk stratification of nodules was according to K-TIRADS and was based on solidity and echogenicity. Nodules were classified into 5 categories: 1. no nodule, 2. Benign, 3. Low suspicion, 4.intermediate suspicion, 5. High suspicion.
	Reference standard: US-guided Fine-needle aspiration or Core-needle biopsy FNA was performed with a conventional method and at least two samplings were performed for each nodule. CNB was performed using a disposable 18-gauge, single-or-double action spring-activated needle. The interpretation of FNA was based on the Bethesda System for Reporting Thyroid Cytopathology, and CNB results were diagnosed with a six-tier pathology reporting system. In case of a nondiagnostic result from the initial FNA, the results of repeated FNA or CNB were used.
	Final diagnoses were determined by surgical resections in 239/1546 (15.5%) benign nodules, 451/454 (99.3%) malignant nodules and by CNB in three cases (0.7%)

Reference	Na 2016 ¹⁹⁰				
	Time between n	neasurement of index test a	nd reference standard: no	ot specified	
2×2 table		Reference standard +	Reference standard -	Total	Surgery:690 nodules
	Index test +	367	462	829	CNB: 3 nodules
	Index test -	87	1084	1171	Repeated FNA or CNB: 381 nodules
	Total	454	1546	2000	FNA or CNB and follow-up US: 926 nodules
Statistical measures	Index text Ultras Sensitivity : 80.8 Specificity:70.6 PPV: 44.6% NPV: 92.6 % Accuracy: 72.9%	%			
Source of funding	Not specified				
Limitations	Risk of bias: nor Indirectness: no				
Comments	Diagnostic accu	racy of K-TIRADS US class	ification		

Reference	Pandya 2018 ²⁰⁷
Study type	Retrospective
Study methodology	Data source: subjects undergoing first-time FNA of a thyroid nodule between October 2009 and February 2016, identified via the electronic medical record system and Department of Radiology records.
	Recruitment: consecutive
Number of patients	n = 1947
Patient characteristics	Age, mean (range): 56 (26-86)
	Gender (male to female ratio): 475:1472

Reference	Pandya 2018 ²⁰⁷
	Ethnicity: not specified
	Setting: Department of Radiology, University of Michigan Health Systems
	Country: USA
	Inclusion criteria: subjects undergoing first-time FNA of a thyroid nodule between October 2009 and February 2016, identified via the electronic medical record system and Department of Radiology records, for patients that had undergone repeat procedural visits of FNA of a thyroid nodule only the most recent procedure was included
	Exclusion criteria:
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound The diagnostic thyroid ultrasound was performed with electronically focused linear transducers ranging in frequency from 6 to 15 mHz. One radiologist, with 9 years' experience, retrospectively reviewed the diagnostic thyroid ultrasound images on a picture archiving and communication workstation, determined whether each nodule had microcalcifications, assigned each nodule one of 14 morphologic descriptors according to the 2015 ATA guidelines, and placed each nodule into one of five 2015 ATA categories of risk (ATA 1, 2, 3, 4, 5), based on echogenicity, margins, shape, cystic nature and presence of microcalcifications.
	Reference standard: US-guided Fine-needle aspiration US-FNA was performed by a member of the cross-sectional interventional service of the radiology department at the University of Michigan. The diagnostic FNA was performed with electronically focused linear transducers ranging in frequency from 6 to 15 mHz. Aspirations were performed with a series of 25-gauge needles and free-hand technique under direct sonographic visualization. The needle was inserted into the targeted nodules, and aspirations were performed with a capillary method. Varying areas of the nodule were sampled in each pass. A minimum of six passes were performed unless a cytopathologist was present. In these latter cases, cellular adequacy was obtained. The maximum number of passes was 12.
	All thyroid FNAS were interpreted according to the Bethesda System for Reporting Thyroid Cytopathology in the categories as follows. Nondiagnostic, benign, atypia of undetermined significance, suspicious for malignancy and malignancy.
	For subjects whose initial FNA results were inconclusive (i.e. nondiagnostic, atypia or follicular lesion of undetermined significance, or suspicious for neoplasm) the electronic medical record was reviewed to determine whether a subsequent targeted FNA or surgery was performed to enable a more definitive diagnosis within a year of the initial FNA. In such cases that final diagnosis was recorded. In cases where no definitive diagnosis was obtained, the initial cytopathology was considered the final result.

Reference	Pandya 2018 207				
	Time between measurement of index test and reference standard: not specified				
2×2 table		Reference standard +	Reference standard -	Total	Nodules identified as indeterminate by US were
	Index test +	85	546	631	treated as benign
	Index test -	13	706	719	
	Total	98	1252	1350	
Statistical measures	Index text Ultrason Sensitivity : 86.7% Specificity: 56.4%	, p			
Source of funding	Not specified				
Limitations	Risk of bias: none Indirectness: none				
Comments					

Reference	Park 2016 ²¹⁵
Study type	Retrospective
Study methodology	Data source: thyroid nodules assessed by US-guided FNA between August and October 2010 at tertiary referral centre
	Recruitment: not specified
Number of patients	n = 592 (622 nodules)
Patient characteristics	Age, mean (range): 49.8 (14-86)
	Gender (male to female ratio): 119:473

Reference	Park 2016 215							
Reference	Ethnicity: not specified							
	Etimology. Hot spee	Etimoly. Not specified						
	Setting: tertiary referral centre							
	Country: South Ko	rea						
	Inclusion criteria: th	hyroid nodules assessed	by US-guided FNA betwe	en August and Oct	ober 2010 at tertiary referral centre			
	Evolucion oritorio.	nonthy maidal lasions, made	ulas anallar than O Fam. a		eccentelle felleur un en energien			
Target	Thyroid cancer	noninyroidal lesions, nodi	ules smaller than 0.5cm, a	ind nodules with no	acceptable follow-up or operation			
condition(s)								
Index test(s)	Index test: Ultrasou	und						
and reference					adiologists. All radiologists had 1 to 11 years of			
standard					logist who performed the US examination. All			
					ording to the KSThR guidelines. Taking into			
			benign, calcification, snap		of the thyroid nodule, based on the KSThR			
	nouules were class	silled as follows. Frobable	benign, indeterminate or	suspicious maligna	ин.			
	Reference standard: US-guided Fine-needle aspiration							
		US-FNA was performed by one of the seven trained radiologists who conducted the US examinations. US-FNA was performed manually						
		with a 23-gauge needle attached to a 2-mL disposable syringe. On average 1-2 passes were performed for each nodule. One of six cytopathologists interpreted the FNA specimens. All cases were reported using a six-tiered diagnostic system according to the Bethesda						
		System for Reporting Thyroid Cytopathology.						
	System for Report							
	Nodules were cons	Nodules were considered benign if they met at least one of the following conditions: 1. They were pathologically confirmed as benign by						
		thyroidectomy or core needle biopsy; 2. Had US-follow up of at least 2 years with either no interval change or a decrease in size after an						
		initial benign cytology finding; and 3. Had benign cytology in more than two FNAs. Nodules were malignant if they were confirmed as						
	malignant thyroid c	malignant thyroid carcinoma by two serial FNAs or by thyroidectomy.						
	Time between mor	surement of index test of	nd reference standard: no	t specified				
			nu relefence stanuaru. 110	r specified				
2×2 table		Reference standard +	Reference standard -	Total	Nodules identified as indeterminate by US were			
	Index test +	140	16	156	treated as benign			
	Index test -	11	303	314				
	Total	151	319	470				

Reference	Park 2016 ²¹⁵
Statistical	Index text Ultrasound
measures	Sensitivity : 93%
	Specificity: 95%
Source of	Samsung Medical Centre
funding	
—	Disk of bissues where the visk of biss in the intermetation of the index test results
Limitations	Risk of bias: serious due to risk of bias in the interpretation of the index test results
	Indirectness: none
Comments	Diagnostic accuracy of KSThR US classification

Study type Prospective Study Data source: patients referred for US-guided FNA from January to September 2016 methodology Recruitment: consecutive	
methodology	
Recluiment. consecutive	
Number of n = 789 (1100 nodules) patients	
Patient Age, mean (SD): 55 (14) characteristics	
Gender (male to female ratio): 181:608	
Ethnicity: white	
Setting: Regina Apostolorum Thyroid Centre	
Country: Italy	
Inclusion criteria: nodules from patients referred for US-guided FNA at the Regina Apostolorum Thyroid Co clinics from January to September 2016	entre from severn endocrine

Reference	Persichetti 20 [°]	18 ⁻²¹⁸				
					d Cytopathology or an incomplete assessment i.e.	
	-	er the first cytological eval	uation did not repeat a se	econd FNA or wh	o did not undergo surgery and were lost at follow-up	
Target condition(s)	Thyroid cancer					
Index test(s)	Index test: Ultra	<u>isound</u>				
and reference standard	transducer and examiners for the described in the from 9 to 21 year Based on the A Based on the B Based on the A To compare the	All sonographic examinations were performed with two identical state-of-the art US machines equipped with a 5-to 15-MHz linear transducer and with colour Doppler, power Doppler, and elastography software. US images were independently evaluated by four examiners for the assignment of the malignancy risk according to the ATA, BTA, AACE/ACE/AME guidelines on the basis of US features described in their classification systems. The operators had specific experience in endocrine neck US examination for a time that ranged from 9 to 21 years. Based on the ATA, nodules were classified as: benign, low suspicion, intermediate suspicion or high suspicion Based on the BTA, nodules were classified as: U1 Normal, U2 benign, U3 intermediate, U4 suspicious and U5 Malignant. Based on the AACE/ACE/AME, nodules were classified as: low risk, intermediate risk and high risk				
	FNA was perfor six diagnostic ca months after the	ategories according to the e first cytological assessme	ccording to the US proce TBSRTC. To decrease th ent. Confirmed class III cy	ne risk of false-ne	previously, and cytological samples were classified in egative results, patients had a second FNA 6 to 8 vith positive immunocytochemical and clinical features	
		s inding were submitted to	o surgery. Class IV, V and		e committed to surgical treatment.	
		neasurement of index test		d VI nodules wer		
2×2 table		neasurement of index test Reference standard +	and reference standard: Reference standard –	d VI nodules wer not specified Total	e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and	
2×2 table	Time between n	neasurement of index test Reference standard + 141	and reference standard: Reference standard – 304	d VI nodules wer not specified Total 445	e committed to surgical treatment. 987 nodules were included in the analysis;	
2×2 table	Time between n BTA Index test + Index test -	neasurement of index test Reference standard + 141 15	and reference standard: Reference standard – 304 527	d VI nodules wer not specified Total 445 542	e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and n=74 with Bethesda class I were excluded	
2×2 table	Time between n BTA Index test +	neasurement of index test Reference standard + 141	and reference standard: Reference standard – 304	d VI nodules wer not specified Total 445	e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and	
2×2 table 2×2 table	Time between n BTA Index test + Index test -	neasurement of index test Reference standard + 141 15	and reference standard: Reference standard – 304 527	d VI nodules wer not specified Total 445 542	e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and n=74 with Bethesda class I were excluded	
	Time between n BTA Index test + Index test – Total	neasurement of index test Reference standard + 141 15 156 Reference standard	and reference standard: Reference standard – 304 527 831	d VI nodules wer not specified Total 445 542 987	 e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and n=74 with Bethesda class I were excluded U2 as benign, U3/4/5 as malignant 987 nodules were included in the analysis; 	
	Time between n BTA Index test + Index test - Total ATA	neasurement of index test Reference standard + 141 15 156 Reference standard +	and reference standard: Reference standard – 304 527 831 Reference standard –	d VI nodules wer not specified Total 445 542 987 Total	 e committed to surgical treatment. 987 nodules were included in the analysis; n=39 patients with incomplete assessment and n=74 with Bethesda class I were excluded U2 as benign, U3/4/5 as malignant 987 nodules were included in the analysis; n=39 patients with incomplete assessment and 	

Reference	Persichetti 2018	218			
					low suspicion
2×2 table	AACE/ACE/AME	Reference standard +	Reference standard -	Total	987 nodules were included in the analysis; n=39 patients with incomplete assessment an
	Index test +	154	653	807	n=74 with Bethesda class I were excluded
	Index test -	2	178	180	
	Total	156	831	987	High vs low-intermediate risk for AACE/ACE/AME: high/intermediate-risk v low- risk
Statistical measures	Index text Ultrasou Sensitivity : 90% Specificity: 63% Index text Ultrasou Sensitivity : 93% Specificity: 52% Index text Ultrasou Sensitivity : 99% Specificity: 21%				
Source of funding	Not stated				
Limitations	Risk of bias: none Indirectness: none				
Comments	Discussofia assume		ACE/AME US classification		

2		
	Reference	Rahal 2016 231
	Study type	Retrospective
	Study methodology	Data source: patients with thyroid nodules undergoing US scan of thyroid gland and neck area and US-guided FNA from November 2011 to February 2014 Recruitment: prospective; not specified.
	Number of	n = 906 (1000 nodules)

Reference	Rahal 2016 ²³¹					
patients						
Patient characteristics	Age, mean (SD): not specified					
	Gender (male to female ratio): not specified					
	Ethnicity: not specified					
	Setting: Hospital Israelita Albert Einstein					
	Country: Brazil					
	Inclusion criteria: thyroid nodules in patients who underwent sonographic evaluation, followed by fine needle aspiration.					
	Exclusion criteria: not specified; nodules with a non-diagnostic or inadequate Bethesda classification were excluded from analysis					
Target condition(s)	Thyroid cancer					
Index test(s)	Index test: Ultrasound (TI-RADS)					
and reference	US scan of thyroid gland and neck area was performed by experienced physicians, using the ATL HDI 5000, IU 22 Philips, Aplio 500					
standard	Platinum and My Lab 75 and the acquired images stored in the PACS System.					
Standard	Nodules were classified according to TI-RADS system as follows: 1 negative finding, 2 Benign, 3 probably benign, 4A low suspicion, 4B					
	intermediate suspicion, 4C moderate suspicion, 5 High suspicion and 6 known proved malignancy.					
	The US features associated to higher malignancy risks were irregular margins, hipoechogenicity, marked hypoechogenicity, morphology					
	taller than wide and microcalcifications.					
	Reference standard: US-guided FNA					
	FNA was performed by freehand technique under US guidance, using a 23-gauge needle attached to a 20cc syringe. Experienced					
	pathologists evaluated all samples according to Bethesda system: I non-diagnostic or inadequate, II benign, III atypia/follicular lesion of					
	undetermined significance, IV follicular neoplasm or suspicious for follicular neoplasm, V suspicious of malignancy, VI malignant. Nodules					
	classified as IV, V and VI were considered suspicious for malignancy.					
	Time between measurement of index test and reference standard: not specified					
2×2 table	Reference standard + Reference standard - Total There were 976 nodules included, 24 were					
	Index test + 114 274 388 classified as Bethesda I and excluded					
	Index test - 9 579 588					
	Total 123 853 976					

Reference	Rahal 2016 ²³¹
Statistical measures	Index text Ultrasound (TI-RADS) Sensitivity: 92.7% Specificity: 67.9% PPV: 29.4% NPV:98.5 %
Source of funding	Not specified
Limitations	Risk of bias: serious due to risk of bias in patient selection Indirectness: none
Comments	Diagnostic performance of TI-RADS.

Reference	Tae 2007 ²⁷⁶
Study type	Prospective study
Study methodology	Data source: 1170 patients who underwent thyroid ultrasonography between January 2003 and January 2005
	Recruitment: not specified
Number of patients	n = 580 (1255 nodules)
Patient characteristics	Age, mean (SD): 47.8 (13.9)
	Gender (male to female ratio): 77:503
	Ethnicity: not specified
	Setting: St Mary's Hospital, Seoul, Republic of Korea
	Country: South Korea
	Inclusion criteria: patients who underwent thyroid ultrasonography at St Mary's Hospital, Seoul, Republic of Korea between January 2003 and January 2005;

Reference	Tae 2007 276				
				(
	Exclusion criteria: not specified; patients with unsatisfactory specimen (n=38) were excluded from analysis				
Target condition(s)	Thyroid cancer	Thyroid cancer			
Index test(s) and reference standard	Index test: UltrasoundAll thyroid ultrasonography was performed by one radiologist, using an HDI 5000 ultrasound scanner equipped with a 5-12 MHz linear- array transducer. Nodules were classified based on the Kim criteria. If a single feature suggestive of malignancy was present, the nodule was classified as category 3, if the nodule showed no suspicious features it was classified as category 2. Anechoic, cystic lesions were classified as category 1. Category 3 was classified as malignant, categories 1, 2 as benign.Reference standard: FNAB or surgery (n=78 patients) FNAs were performed using 22-gauge needles. Palpable, single or dominant nodules >1cm nodules were aspirated by palpation (n=412). Aspiration was performed by sonographic guidance if the nodule was nonpalpable or cystic with a solid portion (n=168). The results of aspiration cytology were categorised as benign, suspicious of malignancy, malignant, and nondiagnostic. A cytology suspicious of follicular or Hurthle cell neoplasm or uncertain findings that could not rule out malignancy were included in a 'suspicious of malignancy' category.				
	I ime between	measurement of index tes	st and reference standard	i: not specified	
2×2 table		Reference standard +	Reference standard -	Total	Notes: 78 cases diagnosed as malignant by
	Index test + Index test -	60 9	64 409	124 418	ultrasonography received surgical treatment.
	Total	69	409	542	Patients with unsatisfactory specimen
				• • -	(n=38) were excluded from analysis
Statistical measures	Index text Ultrasound Sensitivity: 87% Specificity: 86.5% PPV: 48.4% NPV: 97.8% Accuracy: 86.5%				
Source of funding	Not stated				
Limitations	Risk of bias: se Indirectness: ne	5	s in the interpretation of t	he index test, refer	ence standard results, flow and timing

Reference	Tae 2007 ²⁷⁶
Comments	Diagnostic accuracy of US using the Kim criteria
Reference	Tang 2017 ²⁸¹
Study type	Prospective study
Study	Data source: patients with thyroid nodules consenting to UGFNA
methodology	
	Recruitment: consecutive patients meeting inclusion criteria from March 2015 to May 2016
Number of	n = 199 (206 nodules)
patients	
Patient characteristics	Age, mean (SD): not specified
characteristics	Gender (male to female ratio): 54:157
	Ethnicity: not specified
	Setting: Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine
	Country: USA
	Inclusion criteria: having a dominant or suspicious nodule seen on office US and been recommended for UGFNA.
	Exclusion criteria: patients with known thyroid malignancy or previous benign biopsy and patients who do not meet criteria for biopsy
Target	Thyroid cancer
condition(s)	
Index test(s)	Index test: Ultrasound
and reference	Patients underwent an office US using a high resolution machine. Real-time US was performed by senior author, and nodules were
standard	stratified using sonographic patterns as described and published in the 2015 ATA guidelines. Nodules were classified into the best fit
	category of high, intermediate, low, very low suspicion or benign based on specific sonographic patterns.

Thyroid Disease: DRAFT FOR Imaging for Fine Needle Aspiration

DRAFT FOR CONSULTATION

Reference	Tang 2017 281				
2×2 table	Reference stand UGFNAB was p aspiration techr Cytology results significance/ fol reported by train 64 patients with permanent final 65 nodules were	niques. s were reported based up licular lesion of undeterm ned cytopathologists n cytology deemed malign	nician using three to four on the Bethesda System ined significance, follicul ant, indeterminate or ber he index nodules underg used for analysis.	for Reporting Thyroic ar neoplasm, suspicio nign with large nodule oing US-FNA were as	n a 22-to 25-gauge needle utilizing capillary and d Cytopathology i.e. benign, atypia of undetermined us for malignancy, malignant and non-diagnostic, s underwent surgical excision with subsequent sessed as benign or malignant.
	Index test – Total	1 12	86 116	87 128	
Statistical measures	Index text: Ultra Sensitivity : 91. Specificity: 74.1 PPV: 26.8% NPV: 98.9%	7%			
Source of funding	Not specified				
Limitations	Risk of bias: no Indirectness: no				
		racy of US using the 201			

© National Institute for Health and Care Excellence. 2019 132

Reference	Weiss 2018 ³⁰⁹
Study methodology	Data source: patients with thyroid nodules consenting to UGFNA
	Recruitment: consecutive thyroid FNAs during 18 month period (2016-2017)
Number of patients	n = 1157 (1491 nodules); US in n=57 (61 subnodules <1cm)
Patient characteristics	Age, mean (range): 52 (19-81)
	Gender (male to female ratio): 5:42
	Ethnicity: not specified
	Setting: Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine
	Country: USA
	Inclusion criteria: subcentimeter nodules identified by radiographic information. Ultrasound studies obtained before FNAs included.
	Exclusion criteria: not specified.
	Further population details: Patients with nodules <1 cm identified through radiographic information; biopsied because of: concomitant larger companion nodule (44%); personal history of cancer (19%); family history of cancer (9%) or suspicious sonogram that included calcification and/ or irregular contours (16%); unclear reason (14%). 40% of patients who had subcentimeter nodules were under the care of an endocrine specialist.
Target condition(s)	Thyroid cancer
Index test(s)	Index test: Ultrasound (TI-RADS)
and reference standard	51 ultrasound studies were reviewed by a blinded board-certified radiologist subspecialising in thyroid ultrasonography, with 30 years' experience of performing thyroid ultrasound. High TI-RAD score included TR4 and TR5, intermediate TI-RAD score was TR3; low TI-RAD score included TR1 and TR2.
	Reference standard: FNAB All nodules were interpreted using the TBSRTC criteria.

Reference	Weiss 2018 309	9					
	Time between	Time between measurement of index test and reference standard: not specified					
2×2 table		Reference standard +	Reference standard -	Total	Radiographic information for 61		
	Index test +	5	9	14	subcentimeter nodules from 51 patients		
	Index test -	0	28	28			
	Total	5	37	42	(Ultrasound obtained before FNAB was available for 51 nodules)		
Statistical	Index text Ultra	asound					
measures	Sensitivity : 10						
	Specificity: 75.	7%					
	PPV: 35.7%						
	NPV: 100%						
Source of funding	Not specified	Not specified					
Limitations	Risk of bias: no	one					
		Indirectness: none					
Comments	Risk of maligna	ancy in subcentimeter nod	lules using the ACR TI-R	ADS scoring system			

Reference	Xu 2017 ³²³
Study type	Retrospective (multicentre)
Study methodology	Data source: patient data collected from eight tertiary hospitals from January 6,2014 to December 20,2014
	Recruitment: consecutive
Number of patients	n = 734 (962 nodules)
Patient characteristics	Age, mean (SD): 46.8 (14.09)
	Gender (male to female ratio): 156:578
	Ethnicity: not specified

Reference	Xu 2017 ³²³						
	Setting: eight tertiary hospitals around Jiangsu province						
	Country: China	Country: China					
	within a 1-year i	Inclusion criteria: patients who underwent thyroid surgery regardless of cytologic results, patients who underwent FNAB at least two times within a 1-year interval for benign thyroid lesions, patients who had benign results on cytology and showed no change or decreased size at follow-up US for at least a year.					
			RUS, FNAC or postoperative of the set of the		C I, III, IV; BSRTC II without repeated FNAC or n one year.		
Target condition(s)	Thyroid cancer						
Index test(s) and reference standard	 Index test: Ultrasound (TI-RADS; 2015 ATA) All US images were obtained by using a 4-13 MHz linear array transducer. The scanning protocol in all cases included both transverse and longitudinal real-time imaging of the thyroid nodules. The features used in the analysis of thyroid nodules included size, composition, echogenicity of solid portion, orientation, shape, margin, and calcifications. All US patterns were diagnosed by a radiologist with 10 years of experience in thyroid imaging. 931 patterns were categorised based on the TI-RADS classification (2,3, 4A, 4B, 5) 906 patterns were categorised based on the ATA ultrasound patterns (benign, very low suspicion, low suspicion, intermediate suspicion, high suspicion. Reference standard: Histopathology (surgery, n=703)/ follow-up (n=259) Time between measurement of index test and reference standard: not specified 						
2×2 table	TI-RADS	Reference standard +	Reference standard -	Total	Histopathological confirmation available for 703		
	Index test + Index test -	301 62	156 412	363 568	nodules (375 malignant and 328 benign); 259 nodules regarded as benign due to repeated		
	Total	363	568	93	1 benign cytology or follow-up ultrasound after the first benign cytology		
					31 nodules could not be categorised by TI-RADS		

Reference	Xu 2017 323				
2×2 table	ATA	Reference standard +	Reference standard -	Total	Histopathological confirmation available for 703
	Index test +	336	321	657	nodules (375 malignant and 328 benign); 259
	Index test -	23	226	249	nodules regarded as benign due to repeated
	Total	359	547	906	benign cytology or follow-up ultrasound after the first benign cytology
					56 nodules could not be categorised by ATA
Statistical measures	Sensitivity: 83.2 Specificity: 71.5 AUC: 0.826 <u>Index text Ultras</u> Sensitivity: 94% Specificity: 41%	% sound (2015 ATA)			
Source of funding	Not specified				
Limitations	Risk of bias: nor Indirectness: no				
Comments	Diagnostic perfo	rmance of TI-RADS and	2015 ATA scoring system	ms based on nodule si	ze.

Limi	itations	Risk of bias: none Indirectness: none
Com	nments	Diagnostic performance of TI-RADS and 2015 ATA scoring systems based on nodule size.
Refe	erence	Xu 2018 ³²⁴
Stud	ly type	Retrospective
Stud meth	ly hodology	Data source: 3210 lesions that underwent thyroid US examination and FNA and/or surgery between January 2014 to October 2017
		Recruitment: consecutive
Num	nber of	n = 2031 (2465 nodules)

patients Patient Age, mean (SD): 47.7 (13.38) characteristics

Gender (male to female ratio): 415: 1616

Reference	Xu 2018 ³²⁴
IVELET ELLE	Ethnicity: not specified
	Setting: three tertiary hospitals around JiangSu Province
	Country: China
	Inclusion criteria: nodules with definite histopathology results, nodules with complete Bethesda system for reporting thyroid cytopathology results (BSRTC)
	Exclusion criteria: nodules without postoperative pathology except for BSRTC II cytology results, nodules of BSRTC II cytology whose US follow-up interval less than one year or during which increase in size (defined as more than 50% change in volume or a 20% increase in at least two nodule dimensions with a minimal increase of 2mm in solid nodules or in the solid portion of mixed-cystic solid nodule) or change in US features
Target	Thyroid cancer
condition(s)	
Index test(s)	Index test: Ultrasound (TI-RADS;)
and reference standard	All US images were obtained by using a 4-13 MHz linear array transducer. The scanning protocol in all cases included both transverse and longitudinal real-time imaging of the thyroid nodules. Designated radiologists from three centres were asked to assess the thyroid nodules using one set of standards according to published literature. The features used in the analysis of thyroid nodules included size, composition, echogenicity of solid portion, echotexture, vascularity, shape, margin and calcification. One specialist from each centre extracted US features based on static US patterns and description of features and then input these features into database. One experience radiologist in thyroid imaging did all classifications according to the database.
	All nodules were scored based on patterns and US features of KSThR-TIRADS as followed. Category 2 Benign, category 3 low suspicion, category 4 intermediate suspicion, category 5 high suspicion. All nodules were scored based on ACR-TI-RADS: TR1, TR2, TR3, TR4, TR5
	All nodules were scored based on patterns and US-features of EU-TIRADS as follows: EU-TIRADS 2, 3, 4, 5
	<u>Reference standard: FNA and or surgery</u> <u>Among nodules, 505 benign nodules and 1005 malignant nodules were confirmed by histopathology; the remaining 955 benign lesions were diagnosed based on the benign cytology and follow-up ultrasound.</u>

Time between measurement of index test and reference standard: not specified

Reference	Xu 2018 324				
2×2 table	KSThR- TI- RADS	Reference standard +	Reference standard -	Total	
	Index test +	966	671	1637	
	Index test -	39	789	828	
	Total	1005	1460		2465
2×2 table	ACR-TIRADS	Reference standard +	Reference standard -		Total
	Index test +	971	687		1658
	Index test -	34	773		807
	Total	1005	1460		2465
	EU-TIRADS	Reference standard +	Reference standard -		Total
	Index test +	986	810		1796
	Index test -	19	650		669
	Total	1005	1460		2465
Statistical measures	Sensitivity: 96.1 Specificity: 54% Index text Ultras Sensitivity: 96.6 Specificity: 52.9 Index text Ultras Sensitivity: 98.1 Specificity: 44.5	sound (ACR- TI-RADS) % % sound (EU- TI-RADS) %			
Source of funding	Not specified				
Limitations	Risk of bias: not Indirectness: no				
Comments		ormance of TI-RADS			

Thyroid Disease: DRAFT FOR CONSULTATION Imaging for Fine Needle Aspiration

Reference	Yoon 2017 ³²⁹
Study type	Retrospective
Study methodology	Data source: patient data collected from March 2007 to February 2010
	Recruitment: not specified
Number of patients	n = 4585 (4696 nodules)
Patient characteristics	Age, mean (SD; range): 51 (11.9; 17-94)
	Gender (male to female ratio): 3836:749
	Ethnicity: not specified
	Setting: tertiary referral centre
	Country: Korea
	Inclusion criteria: patients who underwent US-guided FNA for diagnosis of thyroid nodules at a tertiary referral centre from March 2007 to February 2010.
	Exclusion criteria: lack of follow-up after results of initial nondiagnostic results, atypia or follicular lesion of undetermined significance, follicular neoplasm or suspicion of follicular neoplasm, or suspicion of malignancy
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound Real-time US examinations of both thyroid glands and the cervical regions were performed by using a 6-13-MHz or 5-12-MHz linear transducer. Examinations were performed by one of 14 radiologists (four faculty and 10 fellows) with 1-12 years of experience in thyroid imaging. US features of the thyroid nodules that underwent US-guided FNA were prospectively re-corded by each radiologist who had performed the US and /or US-guided FNA according to composition, echogenicity, margin, calcifications and shape. Solid, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, presence of microcalcifications and nonparallel shape were considered to be US features suspicious for malignancy.
	Reference standard: Histopathology: surgery(n=1072), initial UGFNA (n=3443), repeat UGFNA (n=181) US-guided FNA was performed on nodules that showed US features that were suspicious of malignancy or on the largest nodule when none of the multiple thyroid nodules manifested with US features suspicious for malignancy. The decision to perform FNA was at the

discretion of the interpreting radiologist who used the aforementioned criteria. Examinations were performed by one of 14 radiologists

Reference	Yoon 2017 ³²⁹						
	syringe either I least twice and placed in 95% categorised int categories of th Total or near-to extrathyroidal of patients under	by using an aspirator or the l local anaesthesia was no alcohol for Papanicolaou s to: inadequate, benign, inte he Bethesda System have otal thyroidectomy was pe	e freehand technique, de ot routinely applied. Aspir staining. One of eight cyt ermediate suspected of p been used to report resu rformed in patients over t LN) metastasis on either out finding of multiple tur	pending on the performated material was experient opathologists reviewed opathologists reviewed oppillary carcinoma and ults from thyroid cytolo the age of 45 years, while pre-or intraoperative fit ors, extrathyroidal extern	ho had multiple tumors, with the presence of indings. Hemithyroidectomy was performed in		
2×2 table	SRU	Reference standard +	Reference standard -	Total			
z*z table	Index test +	564	921	1485			
	Index test -	480	2731	3211			
	Total	1044	3652	4696			
	TOLAI	1044	3032	4090			
2×2 table	NCCN	Reference standard +	Reference standard -	Total			
	Index test +	973	2200	3173			
	Index test -	71	1452	1523			
	Total	1044	3652	4696			
2×2 table	ΑΤΑ	Reference standard +	Reference standard -	Total			
	Index test +	999	2165	3164			
	Index test -	45	1487	1532			
	Total	1044	3652	4696			
2×2 table	F-TIRADS	Reference standard +	Reference standard -	Total			
	Index test +	994	1754	2748			
	Index test -	50	1898	1948			
	Total	1044	3652	4696			
2×2 table	Kim	Reference standard +	Reference standard -	Total			
	Index test +	908	616	1524			
	Index test -	136	3036	3172			

Reference	Yoon 2017 329							
	Total	1044	3652	4696				
	rotar		0002	1000				
2×2 table	K-TIRADS	Reference standard +	Reference standard -	Total				
	Index test +	1031	2719	3750				
	Index test -	13	933	946				
	Total	1044	3652	4696				
Statistical	Index text Ultras							
measures	Sensitivity: 54%							
	Specificity: 74.8	%						
	PPV: 38%							
	NPV: 85.1%	20/						
	Accuracy: 70.2	2%						
	Index text Ultras							
	Sensitivity: 93.2							
	PPV: 30.7%	Specificity: 39.8%						
	NPV: 95.3%							
	Accuracy: 51.6	5%						
	,							
	Index text Ultras	sound (ATA)						
	Sensitivity: 95.7%							
	Specificity: 40.7	%						
	PPV: 31.6%							
	NPV: 97.1%							
	Accuracy: 52.9	9%						
		ndex text Ultrasound (F-TIRADS)						
		Sensitivity: 95.2%						
		Specificity: 52%						
	NPV: 97.4%	PPV: 36.2%						
	Accuracy: 61.6	5%						
	/ loodidoy. 01.0							
	Index text Ultras	sound (Kim)						

Reference	Yoon 2017 ³²⁹
	Sensitivity: 87.0%
	Specificity: 83.1% PPV: 59.6%
	NPV: 95.7%
	Accuracy: 84%
	Index text Ultrasound (K-TIRADS)
	Sensitivity: 98.8%
	Specificity: 25.6% PPV: 27.5%
	NPV: 98.6%
	Accuracy: 41.8%
Source of funding	Not specified
Limitations	Risk of bias: serious risk due to potential bias in the interpretation of the index test results; flow and timing
	Indirectness: none
Comments	Diagnostic performance of SRU, NCCN, 2015 ATA, F- TI-RADS, Kim, K-TIRADS
Reference	Yoon 2016 ³³¹
Study type	Retrospective
Study	Data source: patient data collected from November 2013 to July 2014 at a tertiary referral centre
methodology	
	Recruitment: not specified
Number of	n = 1241 (1293 nodules)
patients	
Patient	Age, mean (SD; range): 50.8 (13.5; 18-87)
characteristics	
	Gender (male to female ratio): 257:1036
	Ethnicity: not specified
	Setting: tertiary referral centre

Reference	Yoon 2016 331
	Country: Korea
	Inclusion criteria: nodules of patients who underwent US-guided FNA for diagnostic purposes at a tertiary referral centre from November 2013 to July 2014; nodules were included if they had: undergone surgery, definitive diagnostic cytologic findings of benignity or malignancy at US-guided FNA, or inconclusive cytologic findings at initial US-guided FNA but definitive cytologic findings of benignity or malignancy at follow-up US-guided FNA.
	Exclusion criteria: aspiration of cysts for symptom relief of typically benign thyroid cysts or for diagnosis of perithyroidal lesions such as parathyroid cysts, thyroglossal duct cysts, or other cystic masses arising in the cervical region (n=21); maximal diameter less than 10 mm (n=913); non-mass forming lesions (n=6); and inadequate follow-up (n=353) because nodules were lost to follow-up after inconclusive diagnostic cytologic findings.
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound US examinations were performed by using a 6-13-MHz linear array transducer. Real-time US and subsequent US-guided FNA were performed by one of 10 radiologists (four faculty and six fellows) with 1-15 years of experience in thyroid imaging. US features of each thyroid nodule that were described and re-corded by one of the 10 radiologists who performed the examinations according to composition, echogenicity, margin, calcifications and shape. Marked hypoechogenicity, noncircumscribed margins, microcalcifications or mixed calcifications and nonparallel shape were considered to be US features suspicious for malignancy on the basis of published criteria. Nodules were retrospectively classified according to the 2014 ATA guidelines, by one radiologist with 7 years of experience in thyroid imaging, as showing high, intermediate, low, or very low suspicion of malignancy. For TIRADS, nodules were classified on the basis of the number of suspicious US features present as follows: solidity, hypoechogenicity or marked hypoechogenicity, microlobulated to irregular margin, microcalcifications or mixed calcifications, and nonparallel shape. Thyroid nodules without any suspicious features were classified as TIRADS category 3. Nodules showing one, two, three or four, or five suspicious US features were classified as category 4a, 4b, 4c, or 5 respectively.
	Reference standard: UGFNA (n=1051) and surgery (n=242) Ultrasound guided fine needle aspiration was performed in nodules measuring more than 5 mm in maximum diameter, nodules with at least one suspicious US feature, or the largest mass when none of the multiple thyroid nodule detected at US showed any suspicious US features. UGFNA was performed at least twice for each thyroid nodule using a 23-gauge needle attached to a 2-mLsyringe without an aspirator. Local anaesthesia was not routinely applied. Aspirated material was expelled on glass slides, which were immediately placed in 95% alcohol for Papanicolaou staining. Cytopathologists were not present during procedures. One of five cytopathologists interpreted the slides and cytology reports were based on the 6 categories of the Bethesda System for Reporting Thyroid Cytopathology.
	Time between measurement of index test and reference standard: not specified

Reference	Yoon 2016 331					
2×2 table	ATA (2014)	Reference standard +	Reference standard -	Total	Very-low suspicion nodules were considered	
	Index test +	223	663	886	negative and low-to-high suspicion as positive.	
	Index test -	11	396	407		
	Total	234	1059	1293	44 of the 1293 nodules did not meet the criteria for any pattern and were classified as not specified.242 nodules (18.7%) underwent surgery and	
					1051 (81.3%) was diagnosed on the basis of cytologic findings and follow-up US.	
2×2 table	TIRADS	Reference standard +	Reference standard –	Total		
	Index test +	228	749	977	categories 4a to 5 as positive.	
	Index test -	6	310	316		
	Total	234	1059	1293	242 nodules (18.7%) underwent surgery and 1051 (81.3%) was diagnosed on the basis of cytologic findings and follow-up US.	
measures	Sensitivity: 95.3% Specificity: 37.4% PPV: 25.2% NPV: 97.3% Accuracy: 47.9% Index text Ultrasound (TIRADS) Sensitivity: 97.4% Specificity: 29.3% PPV: 23.3% NPV: 98.1% Accuracy: 41.6%					
Source of funding		Not specified				
Limitations	Risk of bias: serious risk of bias due to potential bias in the interpretation of the index test results; flow and timing Indirectness: none					
Comments		formance of 2014 ATA and				

Reference Yoon 2015 ³³²

Reference	Yoon 2015 332
Study type	Retrospective
Study methodology	Data source: data of patients undergoing US-FNA at tertiary referral centre collected from December 2010 to July 2011
	Recruitment: not specified
Number of patients	n = 1257 (1309 nodules)
Patient characteristics	Age, mean (SD; range): 50.1 (12.1; 18-83)
	Gender (male to female ratio): 192: 1065
	Ethnicity: not specified
	Setting: tertiary referral centre
	Country: South Korea
	Inclusion criteria: thyroid nodules with diagnosis confirmed by surgery after inadequate AUS/FLUS, FN or suspicion of malignancy results on cytology, or nodules definitively diagnosed as benign or malignant nodules on US-FNA cytology.
	Exclusion criteria: nodules with inadequate cytology that had not been followed with either US-FNA or US examinations (n=227) and nodules diagnosed as atypia of undetermined significance/follicular lesions of undetermined significance (n=84), follicular neoplasm (n=9) or suspicious for malignancy (n=19) on cytology that had not been followed by US-FNA or surgery.
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound US examinations were performed by using a 5-12-MHz linear array transducer. Real-time US was performed by one of 12 radiologists (four faculty and eight fellows) with 1-15 years of experience in thyroid imaging.
	US features of each thyroid nodule that were prospectively re-corded by one of the radiologists who performed the US examinations and subsequent US-FNA. Each nodule was described according to tumour composition, echogenicity, margin, calcifications and shape. Marked hypoechogenicity, noncircumscribed margins, microcalcifications or mixed calcifications and nonparallel shape were considered to be malignant features based on the Kim criteria. The final assessment was 'probably benign' when none of the aforementioned suspicious US features were present and 'suspicious malignant' when one or more of the malignant features was present in a thyroid nodule.
	Index test: Ultrasound+ vascularity pattern Vascularity was evaluated on 2-D Doppler US images acquired during US examinations. The same US scanner setting and the same 2-D power Doppler colour map were used throughout the study to minimise the effect of machine settings on data acquisition. Vascularity was

power Doppler colour map were used throughout the study to minimise the effect of machine settings on data acquisition. Vascularity was

	Thyroid Disease: DRAFT FOR CONSULTATION
--	---

Reference	Yoon 2015 332				
	classified into three patterns: no vascularity, peripheral vascularity, intra-nodular vascularity			rity	
	Reference standard: UGFNA (n=962) or surgery (n=347) Ultrasound guided fine needle aspiration was performed on nodules with suspicious US features or on the largest mass when none of the multiple thyroid nodule detected had suspicious US features. UGFNA was performed with a freehand technique by the same radiologist who had performed the US examinations; 23-gauge needle attached to a 2-mL disposable plastic syringe without an aspirator were used. Each nodule was aspirated at least twice. Samples obtained were expelled on glass slides, which were smeared and immediately placed in 95% alcohol for Papanicolaou staining. Cytopathologists were not present during the US-FNA procedure. One of five experienced cytopathologists reviewed the slides and cytology reports were based on the 6 categories of the Bethesda System for Reporting Thyroid Cytopathology. Time between measurement of index test and reference standard: not specified				
2×2 table	Kim	Reference standard +	Reference standard -	Total	Surgery (n=347): benign (n=19), malignant
	Index test +	340	238	578	(n=328)
	Index test -	42	689	731	(
	Total	382	927	1309	FNA (n=962): benign (n=910), malignant (n=52)
2×2 table	Kim+USD	Reference standard +	Reference standard -	Total	Surgery (n=347): benign (n=19), malignant
	Index test +	349	351	700	(n=328)
	Index test -	33	576	609	
	Total	382	927	1309	FNA (n=962): benign (n=910), malignant (n=52)
Statistical measures	Index text Ultrasound (Kim) Sensitivity: 89% Specificity: 74.3% PPV: 58.8% NPV: 94.3% AUC: 0.821% Index text Ultrasound (Kim + USD) Sensitivity: 91.4% Specificity: 62.1% PPV: 49.9% NPV: 94.6% Accuracy: 0.766%				
Source of	Not specified				

Reference	Yoon 2015 332
funding	
Limitations	Risk of bias: high due to potential risk of bias in the interpretation of the index test and reference standard results; flow and timing Indirectness: none
Comments	Diagnostic performance of US using the Kim criteria and Kim +USD
Reference	Zhang 2018 353
Study type	Prospective
Study methodology	Data source: patients with thyroid nodules more than 1cm in diameter from July 2011 to October 2017
	Recruitment: not specified.
Number of patients	n = 162 (243 nodules)
Patient	Age, mean (range): 54.7 (21-79)
characteristics	Gender (male to female ratio): 41: 121
	Ethnicity: not specified
	Setting: Nanjing integrated traditional Chinese and western medicine hospital, Nanjing University of Chinese medicine
	Country: China
	Inclusion criteria: Patients with thyroid nodules more than 1cm in largest diameter, patients agreed to surgery if FNAB results are malignant, suspicious for malignancy and indeterminate follicular lesions, patients agreed to initial US-guided FNAB and US follow-up (>12 months after US-guided FNAB) for benign thyroid lesions (except for adenomas); and patients agreed to US-guided FNAB for benign thyroid lesions at least twice within one-year interval.
	Exclusion criteria: not specified
Target condition(s)	Thyroid cancer
Index test(s) and reference standard	Index test: Ultrasound (TI-RADS) Us evaluation was performed by clinically experienced radiologist with 18 years of thyroid US experience or by residents and fellows under his supervision .

Thyroid Disease: DRAFT FOR Imaging for Fine Needle Aspiration

DRAFT FOR CONSULTATION

US findings were classified according to TIRADS system as described by Russ et al. into the following categories: 1= normal thyroid

Reference	Zhang 2018 35	3			
Reference	 Zhang 2018 ³⁵³ tissue without any nodular aspect; 2=simple cyst, spongiform nodules, 'white knight', isolated macrocalficication, nodular hyperplation osigns of high suspicion, isoechoic or hyperechoic, partial in capsulated; 4a= no signs of high suspicion, mildly isoechoic, encapt nodule; 4B= irregular shape, taller than wide, irregular borders, microcalcifications, markedly hypoechoic, high stiffness with elastography: strain ratio >4, 3 to 5 signs and/or lymph node metastasis. TIRADS categories were interpreted as follows: category 1=normal thyroid findings; category 2= constantly benign aspects, catego 3=very probably benign, category 4A= undetermined, 4B=suspicious and 5= highly suspicious. Reference standard: pathological examination or FNAB US-guided FNAB was performed by LQ.H, with 16 years of pathological diagnosis experience, routinely using a 23- gauge needle gauge needle was chosen when a nodule had a large cystic portion and for second-needle passage when the first FNA failed due severe nodule stiffness. Direct smears were made, immediately fixed with alcohol after FNA and stained with Papanicolaou stain. adequacy of the specimens was assessed using visual inspection, classified into two groups: insufficient (fewer than six particles) sufficient (more than 6 visible particles). Additional FNA procedures were performed when the lesion was considered inaccurately in the case of small nodules or when an insufficient specimen was suspected by visual inspection. US-guided FNAB were performed at the hospital. Pathology results were obtained after surgery if FNAB results were malignant, suspicious for malignancy and indeterminate follicular lesions. For malignant nodules the pathological diagnosis was confirmed by 			of high suspicion, mildly isoechoic, encapsulated kedly hypoechoic, high stiffness with elastography, ir borders, microcalcifications, markedly ode metastasis. egory 2= constantly benign aspects, category picious. rience, routinely using a 23- gauge needle. A 21- dle passage when the first FNA failed due to FNA and stained with Papanicolaou stain. The oups: insufficient (fewer than six particles) or en the lesion was considered inaccurately targeted nspection. surgery if FNAB results were malignant,	
	surgery. A final diagnosis of benign nodule was made when one of the following parameters were met: repeated FNA confirmed at le twice; surgical specimen; and benign cytology findings on the FNA in confirmed with a stable size or reduced size during follow-up US (>12 months). If the nodule was surgically resected, the FNAB diagnosis was then compared to the surgical pathology diagnosis to evaluate concordance.				eters were met: repeated FNA confirmed at least table size or reduced size during follow-up US
2×2 table		Reference standard +	Reference standard -	Total	Resection was performed on 82 nodules
	Index test +	64	66	130	•
	Index test -	3	110	113	
	Total	67	176	243	
Statistical measures	Index text Ultra Sensitivity: 92. Specificity: 68. PPV: 52.5% NPV: 96% Accuracy:74.	2%			

Reference	Zhang 2018 353
Source of funding	Not specified
Limitations	Risk of bias: very serious due to high risk of bias in patient selection; index test, reference standard, flow and timing Indirectness: none
Comments	Diagnostic performance of F- TIRADS.
Reference	Zhang 2017 ³⁵⁴
Study type	Retrospective
Study methodology	Data source: patients with thyroid nodules who had received conventional US and CEUS examinations between December 2012 and December 2014
	Recruitment: retrospective; not specified.
Number of patients	n=246 (319 nodules)
Patient characteristics	Age, mean (SD; range): 46.1 (15.2; 19-74) Gender (male to female ratio): 85: 161 Ethnicity: not specified Setting: Department of Ultrasound, The Third Xiangya Hospital, Central South University Country: China Inclusion criteria: Patients who had received conventional US and CEUS examinations and postoperative pathological diagnoses or FNABs between December 2012 and December 2014 Exclusion criteria: not specified
Target	Thuraid cancor
Target condition(s)	Thyroid cancer
Index test(s)	Index test: Ultrasound (TI-RADS; TI-RADS+CEUS)
and reference	Diagnosis was performed with a S2000 colour Doppler US system equipped with an 14L5 transducer for conventional US and equipped

Reference	Zhang 2017 354				
standard	with an 9 L4 trans and classify ever peripheral veins the experience in US by two other experience analyse the nature The 4a, 4b thyroid TI-RADS classified benignity; score 4 to five malignant CEUS classificate enhancement diase <u>Reference stands</u>	y nodule. The CPS techr to establish intravenous a diagnosis and more that erienced radiologists who re of the thyroid nodules. d nodules which were can cation: score 1: normal th 4a: two malignant signs, signs, highly suggestive ion: circular enhancemer agnosed as benign; low e	nique and SonoVue contr access. All examinations n 1 years' experience of p performed blind indepe ategorised by TI-RADS an nyroid; score 2: no maligr possible benignity; score of malignancy. Scores 1	ast agent were used. A were performed by an performing CEUS of the ndent analyses of the and a combination of TI- nant sign, benign lesion 4b: three malignant s 4a diagnosed as benig ual enhancement; low as malignant.	bid was scanned. TI-RADS were used to evaluate A 20-G needle was inserted into the patients' a experienced radiologist with more than 10 years' hyroid nodules. US imaging data were analysed TI-RADS and CEUS images to retrospectively -RADS and CEUS were studied retrospectively. hs; score 3: one malignant sign, high probability of signs, high probability of malignancy; score 5: four gn; scores 4b-5 diagnosed as malignant.
2x2	K TIRADS	Reference standard +	Reference standard -	Total	
	Index test +	75	176	251	
	Index test -	0	68	68	
	Total	75	244	319	
2×2 table	ZhangTI-RADS	Reference standard +	Reference standard -	Total	
	Index test +	65	21	86	
	Index test -	10	223	233	
	Total	75	244	319	
2x2 table	TIRADS+CEUS	Reference standard +	Reference standard -	Total	
	Index test +	73	10	83	
	Index test -	2	234	236	
	Total	75	244	319	

Reference	Zhang 2017 ³⁵⁴
Statistical	Index text Ultrasound (K TI-RADS)
measures	Sensitivity: 96%
	Specificity: 67.6%
	PPV: 47.7%
	NPV: 98.2%
	Accuracy:73.8%
	Index text Ultrasound (Zhang TI-RADS)
	Sensitivity: 86.7%
	Specificity: 91.4%
	PPV: 75.6%
	NPV: 95.7%
	Accuracy:90.3%
	Index text Ultrasound (TI-RADS+CEUS)
	Sensitivity: 97.3%
	Specificity: 95.5%
	PPV: 88%
	NPV: 99.1%
	Accuracy:96.0%
Source of	No funding
funding	
Limitations	Risk of bias: serious risk due to patient selection, index test
	Indirectness: none
Comments	Diagnostic performance of TI-RADS; TI-RADS+ CEUS.
Reference	Zhang 2015 ³⁴⁶
Study type	Prospective
Study methodology	Data source: patients with thyroid nodules from October 2011 to June 2013
	Recruitment: prospective; not specified.
Number of	n = 2921 (3980 nodules)
patients	

Reference	Zhang 2015 ³⁴⁶				
Patient	Age, mean (SD): 51.6 (11.6, 16-78)				
characteristics	Gender (male to female ratio): 951: 1970				
	Ethnicity: not specified				
	Setting: not specified/ Department of Medical Ultrasound, Shanghai Tenth People's Hospital?				
	Country: China				
	Inclusion criteria: Patients with thyroid nodules				
	Exclusion criteria: loss at follow-up, less than 12 month follow-up for benign nodules, no cytology/pathology results with TI-RADS category 4 and 5, increase in size on follow-up US without further cytopathological evaluation.				
	Nodule diameter ranged from 2.0 mm to 70.0 mm; mean (SD) 15.7 (11) mm.				
Target condition(s)	Thyroid cancer				
Index test(s) and reference standard	Index test: Ultrasound (TI-RADS) Us scanning was performed with an S2000 US system, using a 4-9 MHz linear-array transducer and a Logiq E9 US system using a 9-15 MHz linear-array transducer.				
	All the image analysis and TI-RADS classification was performed by two board-certified investigators with consensus who were blind to the final results. TI-RADS category 2 and 3 were regarded as 'test negative'; TI-RADS category 4 and 5 as 'test positive'. Therefore, benign lesions classified as 2 and 3 were regarded as true negative and non-benign lesions classified as 4 or 5 as true positive				
	Reference standard: pathological examination or FNA cytology				
	UGFNA was performed under sterile conditions. Three to four passes were made for each nodule using a 23-gauge needle. On-site accuracy was not performed in this study. Samples were submitted for cytology.				
	Time between measurement of index test and reference standard: not specified				
2×2 table	Reference standard + Reference standard - Total Final diagnosis based on FNA (n-628 nodules);				

Defer		7 home 204 5 346						
Refere	ence	Zhang 2015 346			504			
		Index test +	222	339	561	Surgery (partial or total thyroidectomy)		
		Index test -	6	3413	3419	performed in all nodules with benign or		
		Total	228	3752	398			
						inconclusive cytology and 10 benign nodules.		
						Remaining 737 nodules underwent surgery		
						without FNA. 971 had pathological results.		
Statis		Index text Ultras	<u>ound (TI-RADS)</u>					
measu	ures	Sensitivity: 97%						
		Specificity: 90%						
		PPV: 40%						
		NPV: 99%						
		Accuracy:91%						
Sourc	e of	Shanghai Hospit	al Development Centre;	Shanghai Human Resou	irce and Social secu	rity Bureau; National Natural Science foundation of		
fundir	ng	China	• •	5				
Limita	tions	Risk of bias: seri	ous risk due to flow and	timing.				
		Indirectness: ser	ious due to indirect refe	rence standard for some	cases			
Comm	nents	Diagnostic performance of Kwak's TI-RADS.						
Refere		Zheng 2018 363						
Study		Retrospective						
Study		Data source: pat	ients who had undergon	e sonography and had th	lyroid surgery or FN	A from January 2015 to December 2016		
metho	odology							
		Recruitment: reti	rospective; not specified					
Numb	or of	n = 1162 / 21190	noduloo)					
Numb		n = 1163 (21189	nodules)					
Patien Patien								
	cteristics	Age, mean (SD; range): 45.3 (13; 15-81)						
Citata	clenslics	Gender (male to	female ratio): 308: 725					
		Gender (male to female ratio): 308: 725 Ethnicity: not specified						
		Setting: Department of Ultrasound, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University						
						<u>.</u>		

Reference	Zheng 2018 363					
	Country: China					
	Inclusion criteria: Patients who had undergone sonography and had thyroid surgery or FNA at Rui Jin Hospital from January 2015 to					
	Inclusion criteria: December 2016	Patients who had unde	rgone sonography and h	ad thyroid surge	ery or ⊢	NA at Rui Jin Hospital from January 2015 to
	December 2010					
						ith final histopathological or cytological results but
To see 4		uspicious lesions in US ((n=16); with typically ben	ign US features	(n=6);	inadequate sonographic data acquisition (n=107)
Target condition(s)	Thyroid cancer					
Index test(s)	Index test: Ultrase	ound (TI-RADS)				
and reference	Conventional Us	was performed with a 5				nning, patients lay on the bed in supine position
standard						es were acquired by carefully scanning the thyroid nt, every suspicious one would be focused on.
		Ultrasound examination and image acquisition are performed by radiologists with more than 5 years of experience.				
		Two reviewers with more than 5 years of experience in thyroid US independently performed retrospective analysis of ultrasonic images of				
	the surgical nodules without knowing pathological or cytological results and other clinical information. Discordance was solved by another reviewer with more than 10 years of experience in thyroid US.					
						the e ACR TI-RADS: composition, echogenicity,
						f the points determined by TI-RADS level, with
	TR1 indicating 0 points, TR2, 2 points; TR3, 3 points; TR4 4 to 6 points and TR5, 7 or more points.					
	Reference standard: surgery (n=527) or FNA (n=506)					
	Time between me	easurement of index tes	t and reference standard	: not specified		
OwD takla		Defense standard	Defense standard	Tatal		Nedulae with the inelly begins 100 features at
2×2 table		Reference standard + 307	Reference standard – 410	Total 715		Nodules with typically benign US features and without any suspicious features were excluded
	Index test -	1	315	318		
		308	725		1033	

Reference Statistical measures	Zheng 2018 ³⁶³ Index text Ultrasound (ACR-TIRADS) Sensitivity: 99% Specificity: 43.4% PPV: 42.7% NPV: 99.1% Accuracy:60%
Source of funding	Not specified
Limitations	Risk of bias: serious risk due to high risk of bias in the conduct of the reference standard; flow and timing Indirectness: none
Comments	Diagnostic performance of ACR TIRADS.

Reference	Zhou 2018 ³⁶⁷								
Study type	Prospective								
Study methodology	Data source: patients with thyroid nodules from July to September 2016								
	Recruitment: not specified.								
Number of patients	n = 161 (167 nodules)								
Patient characteristics	Age, mean (SD): 44.14 (12.01)								
	Gender (male to female ratio): 43: 118								
	Ethnicity: not specified								
	Setting: Department of Ultrasound of the Third Xiangya Hospital								
	Country: China								
	Inclusion criteria: Patients with solid or mainly solid thyroid nodules, with at least 1 of the suspicious features (solid component, hypoechogenicity or marked hypoechogenicity, irregular margins, microcalcifications, and a taller than wide shape) on US imaging.								

Reference	Zhou 2018 ³⁶⁷									
	Exclusion criteria: dominantly	Exclusion criteria: dominantly cystic nodules, pregnancy, suspicious thyroid nodules that were eggshell calcified.								
Target condition(s)	Thyroid cancer									
Index test(s) and reference standard	contrast-enhanced US with u (hypo, iso, or hyper level), co US, the transducer was switc software. The Region of Inter thyroid tissues and served as enhanced US performance a perinodule tissue ; 4.time to p compared to perinodule tissu Ultrasound examinations wa performed by trained sonogra	formed with commercially a ltra-wideband nonlinear com mposition (solitary or mixed hed to the contrast-enhance est (ROI) was set in the mo- a control. A time-intensity s follows: 1. Peak intensity; beak- compared to perinodu e. The ratios of nodule and s performed by a single exp aphers, blinded to clinical dated on the TI-RADS classification surgery ine based on the Bethesda	ntrast imaging. The followi d), taller-than- wide shape, ded US mode. Images were ost evident enhanced regio curve and all of the quanti 2.ascend slope-compared le tissue; 5. Time from pe perinodule values were are berienced examiner, and the ation as levels: 3, 4a, 4b a classification system.	ng information w nodule margin a e quantitative and on and the same tative parameters d to perinodule tis ak to one-half- co dopted to evalua he quantitative a ings.	ransducer for both conventional and as gathered with conventional US: echo and calcifications. After conventional alysed with Contrast Imaging QA ROI area was copied in perinodule s were generated to show the contrast- ssue; 3.descent slope- compared to ompared to perinodule tissue; 6. AUC - te the thyroid nodules. nalysis of contrast-enhanced US was a nodules were supposed to be benign.					
2×2 table	TI-RADS Index test +	Reference standard + 91	Reference standard – 15	Total 106	Results for 161 patients with solid thyroid nodules.					
	Index test -	2	53	55						
	Total	03								
	Total	93	68	161						
2×2 table	Total TI-RADS+contrast- enhanced US parameter ratios	93 Reference standard +			Results for 161 patients with solid thyroid nodules.					
2×2 table	TI-RADS+contrast- enhanced US parameter		68	161						
2×2 table	TI-RADS+contrast- enhanced US parameter ratios	Reference standard +	68 Reference standard –	161 Total						

Reference	Zhou 2018 ³⁶⁷
Statistical	Index text Ultrasound (TI-RADS)
measures	Sensitivity: 98% Specificity: 78%
	Index text Ultrasound (TI-RADS+ contrast-enhanced US parameter ratios)
	Sensitivity: 98%
	Specificity: 78%
Source of funding	Not stated
Limitations	Risk of bias: serious due to risk of bias in reference bias and flow and timing Indirectness: none
Comments	Diagnostic performance of TI-RADS and TI-RADS+ contrast-enhanced US parameter ratios

Appendix E: Coupled sensitivity and specificity forest plots and sROC curves

3 E.1 Coupled sensitivity and specificity forest plots

Figure 2: BTA

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Farihah 2018 Persichetti 2018	. –	60 304	-		1.00 [0.74, 1.00] 0.90 [0.85, 0.95]			

Figure 3: Kim

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ahn 2010	303	205	24	866	0.93 [0.89, 0.95]	0.81 [0.78, 0.83]	-	
Alam 2014	22	16	2	60	0.92 [0.73, 0.99]	0.79 [0.68, 0.87]		
Kim 2002	46	36	3	70	0.94 [0.83, 0.99]	0.66 [0.56, 0.75]		
Kim 2013	147	354	0	127	1.00 [0.98, 1.00]	0.26 [0.23, 0.31]	•	-
Koh 2018	158	303	54	965	0.75 [0.68, 0.80]	0.76 [0.74, 0.78]	-	•
Moon 2010	227	115	42	699	0.84 [0.79, 0.89]	0.86 [0.83, 0.88]	-	•
Moon 2012	199	162	18	324	0.92 [0.87, 0.95]	0.67 [0.62, 0.71]	-	
Tae 2007	60	64	9	9	0.87 [0.77, 0.94]	0.12 [0.06, 0.22]		
Yoon 2015	340	238	42	689	0.89 [0.85, 0.92]	0.74 [0.71, 0.77]		•
Yoon 2017	908	616	136	3036	0.87 [0.85, 0.89]	0.83 [0.82, 0.84]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Figure 4: Modified Kim

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Kim 2013	142	121	6	676	0.96 [0.91, 0.98]			0 0.2 0.4 0.6 0.8 1

4

1

2

Figure 5: Kim + Doppler

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Moon 2010	245	387	24	427	0.91 [0.87, 0.94]	0.52 [0.49, 0.56]	-	-
Yoon 2015	349	351	33	576	0.91 [0.88, 0.94]	0.62 [0.59, 0.65]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

5

Figure 6: Kim + USE (Rago)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Moon 2012	200	170	17	316	0.92 [0.88, 0.95]			0 0.2 0.4 0.6 0.8 1

6

Figure 7: Kim + USE (Asteria)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Moon 2012	205	255	12	231	0.94 [0.91, 0.97]	0.48 [0.43, 0.52]	· · · · · · · · · · · · · · · · · · ·	
								0 0.2 0.4 0.6 0.8 1

Figure 8: SRU

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ahn 2010	116	489	211	582	0.35 [0.30, 0.41]	0.54 [0.51, 0.57]	-	-
Hobbs 2014	24	250	5	81	0.83 [0.64, 0.94]	0.24 [0.20, 0.29]		+
Yoon 2017	564	921	480	2731	0.54 [0.51, 0.57]	0.75 [0.73, 0.76]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

1

Figure 9: AACE/ACE/AME

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ahn 2010	259	98	68	973	0.79 [0.74, 0.83]	0.91 [0.89, 0.93]	-	•
Grani 2018	31	296	5	170	0.86 [0.71, 0.95]	0.36 [0.32, 0.41]		•
Lauria Pantano 2018	109	786	3	151	0.97 [0.92, 0.99]	0.16 [0.14, 0.19]	-	•
Moon 2010	220	168	49	646	0.82 [0.77, 0.86]	0.79 [0.76, 0.82]	-	-
Persichetti 2018	154	653	2	178	0.99 [0.95, 1.00]	0.21 [0.19, 0.24]	<u>⊢</u>	
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Figure	10:	ΑΤΑ
--------	-----	-----

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Grani 2018	27	255	9	211	0.75 [0.58, 0.88]	0.45 [0.41, 0.50]		+
Ha 2018	247	202	12	372	0.95 [0.92, 0.98]	0.65 [0.61, 0.69]	-	-
Hoang 2018	13	70	2	15	0.87 [0.60, 0.98]	0.18 [0.10, 0.27]		
Koh 2018	197	999	15	269	0.93 [0.89, 0.96]	0.21 [0.19, 0.24]	-	
Lauria Pantano 2018	87	525	17	394	0.84 [0.75, 0.90]	0.43 [0.40, 0.46]		-
Macedo 2018	5	33	0	100	1.00 [0.48, 1.00]	0.75 [0.67, 0.82]		
Maino 2018	11	64	3	272	0.79 [0.49, 0.95]	0.81 [0.76, 0.85]		
Pandya 2018	85	546	13	706	0.87 [0.78, 0.93]	0.56 [0.54, 0.59]		•
Persichetti 2018	145	399	11	432	0.93 [0.88, 0.96]	0.52 [0.49, 0.55]	-	-
Tang 2017	11	30	1	86	0.92 [0.62, 1.00]	0.74 [0.65, 0.82]		
Xu 2017	336	321	23	226	0.94 [0.91, 0.96]	0.41 [0.37, 0.46]	•	+
Yoon 2016	223	663	11	396	0.95 [0.92, 0.98]	0.37 [0.34, 0.40]	•	•
Yoon 2017	999	2165	45	1487	0.96 [0.94, 0.97]	0.41 [0.39, 0.42]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Figure 11: ATA (subcentimetre)

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Kim 2013	286	306	10	111	0.97 [0.94, 0.98]			0 0.2 0.4 0.6 0.8 1

Figure 12: KSThR

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ha 2018	254	263	12	373	0.95 [0.92, 0.98]	0.59 [0.55, 0.63]	-	-
Park 2016	140	16	11	303	0.93 [0.87, 0.96]	0.95 [0.92, 0.97]	-	-
Xu 2018	966	671	39	789	0.96 [0.95, 0.97]	0.54 [0.51, 0.57]		0 0.2 0.4 0.6 0.8 1
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Figure 13: TIRADS (ACR)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Atilla 2018	79	880	22	1633	0.78 [0.69, 0.86]	0.65 [0.63, 0.67]		•
Chen 2018	385	313	10	384	0.97 [0.95, 0.99]	0.55 [0.51, 0.59]	•	-
Grani 2018	30	204	6	262	0.83 [0.67, 0.94]	0.56 [0.52, 0.61]		-
Ha 2018	255	297	11	339	0.96 [0.93, 0.98]	0.53 [0.49, 0.57]	-	-
Hoang 2018	14	48	1	37	0.93 [0.68, 1.00]	0.44 [0.33, 0.55]		
Lauria Pantano 2018	93	525	20	439	0.82 [0.74, 0.89]	0.46 [0.42, 0.49]		
Middleton 2017	297	1488	55	1582	0.84 [0.80, 0.88]	0.52 [0.50, 0.53]	-	
Weiss 2018	5	9	0	28	1.00 [0.48, 1.00]	0.76 [0.59, 0.88]		
Xu 2018	971	687	34	773	0.97 [0.95, 0.98]	0.53 [0.50, 0.56]		•
Zheng 2018	307	410	1	315	1.00 [0.98, 1.00]	0.43 [0.40, 0.47]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

© National Institute for Health and Care Excellence, 2019

Figure 14: TIRADS (French)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Grani 2018	31	317	5	149	0.86 [0.71, 0.95]	0.32 [0.28, 0.36]		-
Hoang 2018	13	57	2	28	0.87 [0.60, 0.98]	0.33 [0.23, 0.44]	_	
Macedo 2018	5	51	0	82	1.00 [0.48, 1.00]	0.62 [0.53, 0.70]		
Maino 2018	11	66	3	270	0.79 [0.49, 0.95]	0.80 [0.76, 0.84]		+
Xu 2018	986	810	19	650	0.98 [0.97, 0.99]	0.45 [0.42, 0.47]	•	
Yoon 2017	994	1754	50	1898	0.95 [0.94, 0.96]	0.52 [0.50, 0.54]	•	
Zhang 2018	64	66	3	110	0.96 [0.87, 0.99]	0.63 [0.55, 0.70]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

1

Figure 15: TIRADS (Kwak)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Koh 2018	193	759	19	509	0.91 [0.86, 0.95]	0.40 [0.37, 0.43]	-	•
Rahal 2016	114	274	9	579	0.93 [0.87, 0.97]	0.68 [0.65, 0.71]	-	-
Yoon 2016	228	749	6	310	0.97 [0.95, 0.99]	0.29 [0.27, 0.32]	-	
Yoon 2017	1031	2719	13	933	0.99 [0.98, 0.99]	0.26 [0.24, 0.27]	•	
Zhang 2015	222	339	6	3413	0.97 [0.94, 0.99]	0.91 [0.90, 0.92]	-	-
Zhang 2018	75	176	0	68	1.00 [0.95, 1.00]	0.28 [0.22, 0.34]	-	-
Zhou 2018	91	15	2	53	0.98 [0.92, 1.00]	0.78 [0.66, 0.87]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

2

Figure 16: TIRADS (Korean)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Grani 2018	33	383	3	83	0.92 [0.78, 0.98]	0.18 [0.14, 0.22]		•
Ha 2016	254	263	12	373	0.95 [0.92, 0.98]	0.59 [0.55, 0.63]	-	-
Hoang 2018	13	71	2	14	0.87 [0.60, 0.98]	0.16 [0.09, 0.26]		
Na 2016	367	462	87	1084	0.81 [0.77, 0.84]	0.70 [0.68, 0.72]	0 0.2 0.4 0.6 0.8 1	

3

Figure 17: TIRADS (Horvarth)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Horvath 2009	349	360	46	342	0.88 [0.85, 0.91]	0.49 [0.45, 0.52]	•	-
Xu 2017	301	156	62	412	0.83 [0.79, 0.87]			
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

4

Figure 18: TIRADS (Zhang)

Study	ΤР	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Zhang 2018	65	21	10	223	0.87 [0.77, 0.93]			
						l	0 0.2 0.4 0.0 0.0 1	0 0.2 0.4 0.0 0.0 1

5

Figure 19: TIRADS (Zhang + CEUS)

Study	TP I	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Zhang 2018	73	10	2	234	0.97 [0.91, 1.00]	0.96 [0.93, 0.98]		0 0.2 0.4 0.6 0.8 1

Figure 20: TIRADS (Kwak + CEUS)

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Zhou 2018	91	15	2	53	0.98 [0.92, 1.00]		0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Figure 21: NCCN

Study	TP	FP FI	I TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Yoon 2017	973	2200 7	1452	0.93 [0.91, 0.95]	0.40 [0.38, 0.41]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

1

Figure 23: Children - ATA

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Creo 2018	46	63	4	32	0.92 [0.81, 0.98]	0.34 [0.24, 0.44]		
Lim-Dunham 2017	12	9	0	12	1.00 [0.74, 1.00]	0.57 [0.34, 0.78]		—— — —
Martinez-Rios 2018	45	22	7	49	0.87 [0.74, 0.94]			

Figure 24: Children - TIRADS (Kwak)


Study	ΤР	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Martinez-Rios 2018	52	58	0	13	1.00 [0.93, 1.00]	0.18 [0.10, 0.29]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

1

2

Appendix F: Health economic evidence selection

Figure 22: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language TFT; thyroid function test, FNA; fine-needle aspiration, US; ultrasound, RAI; radioactive iodine, ATDs; antithyroid drugs, Mang; management, SCH; Subclinical hypothyroidism, SCT; Subclinical thyrotoxicosis.

Appendix G: Health economic evidence tables

Appendix H: Health economic analysis

None

Appendix I: Excluded studies

2 I.1 Excluded clinical studies

3

1

Table 10: Studies excluded from the clinical review

Reference	Exclusion reason
Abdel-Rahman 2016 ¹	Incorrect population
Afifi 2017 ²	USE not combined with US criteria
Aggarwal 2017 ³	No usable outcomes
Aghaghazvini 2018 ⁴	Incorrect population
Ahn 2018 ⁵	Inappropriate test
Akhavan 2016 ⁷	US no criteria
Al Nofal 2016 ⁸	SR, references checked
Albair Ashamallah 2016 ¹⁰	Incorrect population
Algin 2010 ¹¹	USD not combined with US criteria
Appetecchia 2006 ¹²	No usable outcomes
Asteria 2008 ¹³	Inappropriate test
Azizi 2013 ¹⁴	Inappropriate tests
Bae 2018 ¹⁵	Erratum
Bae 2018 ¹⁶	Inappropriate study design
Bhatia 2011 ¹⁷	Inappropriate test
Bhatia 2012 ¹⁸	No usable outcomes
Bojunga 2010 ¹⁹	SR, references checked
Brito 2014 ²⁰	SR, references checked
Brophy 2016 ²¹	No usable outcomes
Cakal 2015 ²²	USE not combined with US criteria
Cakir 2011 ²³	Inappropriate study design
Cam 2014 ²⁴	No criteria used
Camargo 2007 ²⁵	Inappropriate study design
Cantisani 2014 ²⁶	No usable outcomes
Cantisani 2015 ²⁷	Inappropriate study design
Cappelli 2005 ³⁰	Inappropriate tests
Cappelli 2006 ²⁹	Inappropriate study design
Cappelli 2007 ²⁸	Inappropriate study design
Cavallo 2017 ³¹	Inappropriate tests
Cetin 2015 ³²	Incorrect population
Chandramohan 2016 ³³	Inappropriate study design
Chen 2010 ³⁸	Inappropriate study design
Chen 2014 ³⁹	Inappropriate tests
Chen 2016 ³⁵	SR, references checked
Chen 2016 ³⁷	Inappropriate study design
Chen 2017 ³⁴	Inappropriate tests
Cheng 2013 ⁴⁰	US no criteria

Reference	Exclusion reason
Cheng 2013 ⁴¹	Inappropriate population
Chi 2017 ⁴²	Inappropriate test
Chiu 1998 ⁴³	Inappropriate tests
Chng 2018 ⁴⁴	Surgery only
Choi 2015 ⁴⁵	US no criteria
Choi 2017 ⁴⁶	Inappropriate test
Chong 2013 ⁴⁷	Inappropriate test
Delfim 2017 ⁵⁰	Two gate study design
Deng 2014 ⁵¹	Inappropriate study design
Deng 2017 ⁵³	Inappropriate population
Deng 2018 ⁵²	
	Inappropriate tests, no combination
Diao 2017 ⁵⁵	Inappropriate population
Dighe 2010 ⁵⁶	Inappropriate study design
Dighe 2013 ⁵⁷	Inappropriate tests
Dilli 2012 ⁵⁸	No usable outcomes
Ding 2011 ⁵⁹	Inappropriate study design
Dobruch-Sobczak 201660	No usable outcomes
D'Souza 2010 ⁴⁹	Inappropriate test
Du 2018 ⁶¹	Inappropriate population
Duan 2016 ⁶²	Inappropriate population
Dy 2017 ⁶³	Inappropriate study design
Ebeed 2017 ⁶⁴	Inappropriate population
El-Hariri 2014 ⁶⁵	Inappropriate test
Elsayed 2016 ⁶⁶	Inappropriate test
Fukunari 2004 ⁶⁸	Inappropriate test
Gamme 2017 ⁶⁹	Inappropriate study design
Gannon 2018 ⁷⁰	Inappropriate test
Gao 2018 ⁷¹	Inappropriate population
Garcia-Monco Fernandez 201872	Inappropriate population
Gietka-Czernel 2010 ⁷³	USE no combination
Ginat 2010 ⁷⁴	US no criteria
Giusti 2013 ⁷⁵	Inappropriate population
Glogovsek 2015 ⁷⁶	No usable outcomes
Goldfarb 2011 ⁷⁷	Inappropriate population
Goldfarb 2012 ⁷⁸	Inappropriate population
Gotzberger 2016 ⁷⁹	Inappropriate study design
Gu 2012 ⁸²	
Gu 2018 ⁸¹	Inappropriate study design
Guazzaroni 2014 ⁸³	Inappropriate tests
	Inappropriate tests
Gul 2009 ⁸⁴	Inappropriate tests
Gupta 2011 ⁸⁵	Inappropriate population
Ha 2017 ⁸⁸	No usable outcomes
Ha 2017 ⁸⁹	No usable outcomes
Hamidi 2015 ⁹⁰	Inappropriate tests
He 2016 ⁹¹	Inappropriate study design

 $\ensuremath{\mathbb{C}}$ National Institute for Health and Care Excellence, 2019

Reference	Exclusion reason
Hoang 2018 ⁹³	No usable outcomes
Hong 2009 ⁹⁵	Inappropriate population
Hong 2012 ⁹⁶	Inappropriate population
Hu 2018 ⁹⁸	Inappropriate population
Huan 2014 ⁹⁹	Inappropriate population
Huang 2015 ¹⁰⁰	Inappropriate study design
Hughes 2017 ¹⁰¹	Inappropriate population
lanni 2016 ¹⁰²	Inappropriate study design
Ishigaki 2004 ¹⁰³	Inappropriate study design
Ito 2007 ¹⁰⁴	Inappropriate tests
Jiang 2015 ¹⁰⁵	Inappropriate study design
Jin 2014 ¹⁰⁷	Inappropriate population
Jin 2018 ¹⁰⁶	Inappropriate tests
Kagoya 2010 ¹⁰⁸	Inappropriate tests
Kakkos 2000 ¹⁰⁹	Inappropriate tests
Kamran 2013 ¹¹⁰	Inappropriate tests
Kathuria 2003 ¹¹¹	USD no combination
Khamis 2017 ¹¹²	Inappropriate tests
Kim 2008 ¹²¹	Inappropriate population
Kim 2008 ¹²³	Inappropriate study design
Kim 2010 ¹²⁵	Inappropriate study design
Kim 2012 ¹¹⁸	USE no combination
Kim 2013 ¹¹⁵	USE not validated criteria
Kim 2013 ¹²⁰	Inappropriate tests
Kim 2015 ¹¹³	Inappropriate study design
Kim 2015 ¹¹⁹	Inappropriate population
Kim 2015 ¹²⁶	USE no established criteria
Kim 2016 ¹²⁴	Inappropriate population
Kim 2018 ¹¹⁷	Inappropriate study design
Kizilkaya 2014 ¹²⁷	Inappropriate population
Ko 2012 ¹²⁸	Inappropriate population
Koh 2016 ¹³⁰	Inappropriate tests
Koike 2001 ¹³¹	Inappropriate tests
Koltin 2016 ¹³²	Inappropriate tests
Kunz 2014 ¹³⁴	Inappropriate population
Kwak 2011 ¹³⁵	No usable outcomes
Kwak 2013 ¹³⁶	No usable outcomes
Lai 2016 ¹³⁷	Inappropriate population
Lee 2011 ¹³⁹	Inappropriate tests
Li 2014 ¹⁴⁶	Inappropriate population
Li 2015 ¹⁴¹	Inappropriate population
Li 2015 ¹⁴²	No usable outcomes
Li 2015 ¹⁴⁷	Inappropriate tests
Li 2015 ¹⁴⁸	Inappropriate tests
Li 2016 ¹⁴⁴	Inappropriate population

Reference	Exclusion reason
Li 2017 ¹⁴⁰	Inappropriate tests
Li 2017 ¹⁴⁵	Inappropriate study design
Li 2018 ¹⁴³	Inappropriate tests, no combination
Liang 2018 ¹⁴⁹	Inappropriate population
Lim 2008 ¹⁵¹	Inappropriate tests
Lin 2005 ¹⁵²	Inappropriate tests
Lingam 2013 ¹⁵³	Inappropriate tests
Lippolis 2011 ¹⁵⁴	Inappropriate population
Liu 2011 ¹⁵⁹	Inappropriate tests
Liu 2014 ¹⁵⁶	Inappropriate population
Liu 2017 ¹⁵⁵	USE no combination
Liu 2017 ¹⁵⁸	Inappropriate population
Liu 2018 ¹⁵⁷	Inappropriate population
Lu 1994 ¹⁶⁰	Inappropriate population
Lu 2011 ¹⁶¹	US no criteria
Luo 2011 ¹⁶²	Inappropriate tests
Luo 2012 ¹⁶³	Inappropriate tests
Lyshchik 2005 ¹⁶⁴	Inappropriate tests
Ma 2014 ¹⁶⁵	US no criteria
Maia 2011 ¹⁶⁷	Inappropriate population
Maia 2011 ¹⁶⁸	Inappropriate population
Maimaiti 2016 ¹⁶⁹	Inappropriate population
Majstorov 2015 ¹⁷¹	US no criteria
Mallikarjunappa 2014 ¹⁷²	US no criteria
Mansor 2012 ¹⁷³	USE no combination
Marqusee 2000 ¹⁷⁴	US no criteria
Mehrotra 2013 ¹⁷⁶	No usable outcomes
Memon 2017 ¹⁷⁷	Inappropriate tests
Merino 2011 ¹⁷⁸	US no criteria
Migda 2018 ¹⁸⁰	Inappropriate population
Migda 2018 ¹⁸¹	SR, references checked
Mohamed 2013 ¹⁸²	USE no combination
Mohammadi 2013 ¹⁸³	US no criteria
Mohey 2013 ¹⁸⁴	US no criteria
Moon 2007 ¹⁸⁵	US no criteria
Moon 2008 ¹⁸⁹	Inappropriate test
Moon 2011 ¹⁸⁶	US no criteria
Nam 2016 ¹⁹²	USG no combination
Nachiappan 2018 ¹⁹¹	USE no combination
Nemec 2012 ¹⁹⁴	Inappropriate test
Nixon 2010 ¹⁹⁵	No usable outcomes
Nixon 2013 ¹⁹⁶	No usable outcomes
Nobrega 2007 ¹⁹⁷	Inappropriate population
Noda 2015 ¹⁹⁸	Inappropriate population
Nonchev 2017 ¹⁹⁹	Not in English

© National Institute for Health and Care Excellence, 2019

Reference	Exclusion reason
Okamoto 1994 ²⁰¹	US no criteria
Okamoto 1995 ²⁰⁰	Erratum, not relevant
Okasha 2018 ²⁰²	Inappropriate population
Oliveira 2018 ²⁰³	Inappropriate tests
Ozel 2012 ²⁰⁴	US no criteria
Palaniappan 2016 ²⁰⁵	US no criteria
Pandey 2017 ²⁰⁶	ARFI no combination
Pang 2017 ²⁰⁸	US no criteria
Papini 2002 ²⁰⁹	Inappropriate tests
Park 2009 ²¹²	Derivation of criteria
Park 2009 ²¹³	Inappropriate test
Park 2012 ²¹⁴	No usable outcomes
Park 2012 ²¹⁰	USE no established criteria
Park 2017 ²¹¹	
Pathirana 2016 ²¹⁶	Inappropriate population
Peccin 2002 ²¹⁷	
	Inappropriate test Derivation of criteria
Petrone 2012 ²¹⁹	
Phuttharak 2009 ²²⁰	US no criteria
Pompili 2018 ²²¹	Inappropriate population
Popli 2012 ²²²	No combination with conventional US
Popowicz 2009 ²²³	Inappropriate population
Ragazzoni 2012 ²²⁴	Inappropriate population
Raggiunti 2011 ²²⁵	USE no combination
Raghavendra 2017 ²²⁶	Inappropriate tests
Rago 1998 ²³⁰	USE no combination
Rago 2007 ²²⁷	Inappropriate population
Rago 2007 ²²⁸	Inappropriate tests
Rago 2017 ²²⁹	USE no combination
Ram 2015 ²³²	US no criteria
Rao 2014 ²³³	USD no combination
Razavi 2013 ²³⁴	SR, not PICO
Razek 2008 ²³⁵	Inappropriate population
Refaat 2014 ²³⁶	Inappropriate population
Reginelli 2014 ²³⁷	No usable outcomes
Rios 2016 ²³⁹	Inappropriate tests
Rios 2018 ²³⁸	Not in English
Rivo-Vazquez 2013 ²⁴⁰	Inappropriate tests
Rosario 2015 ²⁴²	USD no combination
Rosario 2018 ²⁴¹	Inappropriate population
Russ 2011 ²⁴³	Abstract only
Russ 2011 ²⁴⁴	Abstract only
Sagazio 2014 ²⁴⁵	Abstract only
Sahbaz 2017 ²⁴⁶	Abstract only
Saito 2015 ²⁴⁷	Abstract only
Sajjadieh 2005 ²⁴⁸	US no criteria
- <u></u>	

 $\ensuremath{\mathbb{C}}$ National Institute for Health and Care Excellence, 2019

Reference	Exclusion reason
Salehi 2014 ²⁴⁹	US no criteria
Salmaslioglu 2008 ²⁵⁰	Inappropriate population
Samulski 2015 ²⁵¹	US no criteria
Sands 2011 ²⁵²	Inappropriate population
Sarabia 2017 ²⁵³	Abstract only
Schenke 2015 ²⁵⁴	Inappropriate study design
Schenke 2019 ²⁵⁵	Inappropriate population
Schueller-Weidekamm 2009 ²⁵⁶	Inappropriate population
Sebag 2010 ²⁵⁷	USE no combination
Seo 2012 ²⁶⁰	US no criteria
Seo 2015 ²⁵⁸	Inappropriate tests
Seo 2017 ²⁵⁹	Inappropriate tests
Shankar 2015 ²⁶¹	Abstract only
Shao 2015 ²⁶²	Inappropriate population
Shi 2013 ²⁶³	Inappropriate population
Shimura 2005 ²⁶⁴	Inappropriate study design
Shrestha 2012 ²⁶⁵	Inappropriate tests
Shuzhen 2012 ²⁶⁶	Inappropriate population
Siderova 2016 ²⁶⁷	Abstract only
Simon 2017 ²⁶⁸	Abstract only
Singaporewalla 2017 ²⁶⁹	Inappropriate tests
Stacul 2007 ²⁷⁰	Inappropriate tests
Stoian 2015 ²⁷¹	Inappropriate population
Sui 2016 ²⁷²	Inappropriate population
Sun 2014 ²⁷³	SR, not matching PICO
Swan 2017 ²⁷⁴	Inappropriate tests
Szczepanek-Parulska 2013 ²⁷⁵	Inappropriate population
Taghipour Zahir 2013 ²⁷⁷	Inappropriate population
Taha Ali 2017 ²⁷⁸	Inappropriate tests
Tahmasebi 2016 ²⁷⁹	US no criteria
Tamsel 2007 ²⁸⁰	Inappropriate tests
Tatar 2013 ²⁸²	USE no criteria
Tatar 2014 ²⁸³	US no criteria
Tezelman 2007 ²⁸⁴	Inappropriate population
Trimboli 2012 ²⁸⁵	RTE not combined with validated
Tugendsam 2018 ²⁸⁶	Inappropriate population
Tunca 2007 ²⁸⁷	Inappropriate population
Tuzun 2016 ²⁸⁸	Inappropriate population
Unluturk 2012 ²⁸⁹	Inappropriate tests
Vargas-Uricoechea 2017 ²⁹⁰	USE no combination
Varverakis 2002 ²⁹¹	USD no combination
Veyrieres 2012 ²⁹²	USE no combination
Vidal-Casariego 2012 ²⁹³	Inappropriate tests
Vorlander 2010 ²⁹⁴	Inappropriate tests
Wang 2006 ³⁰¹	Inappropriate tests

Wang 2012 ²⁹⁹	
J	USE no combination
Wang 2013 ²⁹⁷	USE no combination
Wang 2014 ²⁹⁸	Inappropriate tests
Wang 2014 ³⁰⁴	US no criteria
Wang 2015 ³⁰⁰	US no criteria
Wang 2017 ²⁹⁵	USE no combination
Wang 2017 ³⁰²	Only surgical
Wang 2018 ²⁹⁶	USE no combination
Wang 2018 ³⁰³	Inappropriate population
Watters 1992 ³⁰⁵	Inappropriate tests
Wei 2014 ³⁰⁶	SR, checked for references
Wei 2016 ³⁰⁷	SR, checked for references
Wei 2016 ³⁰⁸	Inappropriate tests
Wharry 2014 ³¹⁰	Only surgical
Witczak 2016 ³¹¹	Inappropriate tests
Wu 2013 ³¹⁵	Inappropriate tests
Wu 2016 ³¹²	Inappropriate population
Wu 2016 ³¹⁴	Inappropriate tests
Wu 2017 ³¹³	Only indetermine on previous USE
Xia 2017 ³¹⁶	Machine learning
Xing 2011 ³¹⁸	Only surgical
Xing 2016 ³¹⁷	ARFI no combination
Xu 2014 ³¹⁹	Inappropriate study design
Xu 2014 ³²¹	ARFI no combination
Xu 2015 ³²²	Only surgical
Xu 2016 ³²⁰	VTI no combination
Xue 2016 ³²⁶	Only surgical/core Bx
Xue 2017 ³²⁵	Only surgical
Yang 2017 ³²⁷	USE no combination
Yerli 2017 ³²⁸	USE no combination
Yoon 2014 ³³³	Inappropriate population
Yoon 2018 ³³⁰	Inappropriate tests
Yu 2017 ³³⁴	Inappropriate tests
Yuan 2012 ³³⁵	Only surgical/core Bx
Yuan 2015 ³³⁶	CEUS no combination
Yunus 2010 ³³⁷	US no criteria
Zayadeen 2016 ³³⁸	No usable outcomes
Zhan 2017 ³³⁹	Inappropriate population
Zhang 2010 ³⁴⁰	No usable outcomes
Zhang 2012 ³⁵⁶	Only surgical
Zhang 2013 ³⁴²	Inappropriate study design
Zhang 2014 ³⁴³	ARFI, no combination with US criteria
Zhang 2014 ³⁴⁵	ARFI no combination
Zhang 2014 ³⁴⁷	Non-systematic review

© National Institute for Health and Care Excellence, 2019

Reference	Exclusion reason
Zhang 2014 ³⁴⁹	Only surgical
Zhang 2014 ³⁵⁵	Only surgical
Zhang 2015 ³⁵¹	Not in English
Zhang 2015 ³⁵⁷	ARFI, no combination with US criteria
Zhang 2015 ³⁵⁸	Only high risk based on US
Zhang 2016 ³⁵²	CEUS no combination
Zhang 2016 ³⁵⁹	No combination with conventional US
Zhang 2017 ³⁴¹	Inappropriate population
Zhang 2017 ³⁴⁴	VTUS, no combination with US criteria
Zhang 2017 ³⁴⁸	Inappropriate population
Zhang 2018 ³⁵⁰	Not in English
Zhao 2018 ³⁶⁰	No combination with conventional US
Zhao 2018 ³⁶¹	Inappropriate population
Zheng 2013 ³⁶²	No combination with conventional US
Zhou 2014 ³⁶⁶	USD, no combination with US criteria
Zhou 2016 ³⁶⁴	Inappropriate population
Zhou 2017 ³⁶⁵	No combination with conventional US
Zhu 2013 ³⁶⁸	Inappropriate tests

1

2 I.2 Excluded health economic studies

3 None